
<html lang="en"     class="pb-page"  data-request-id="b47ea5a8-5c74-49d9-a436-480d98da4799"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.0c00948;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-22"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases" /></meta><meta name="dc.Creator" content="Brian S.  Gerstenberger" /></meta><meta name="dc.Creator" content="Catherine  Ambler" /></meta><meta name="dc.Creator" content="Eric P.  Arnold" /></meta><meta name="dc.Creator" content="Mary-Ellen  Banker" /></meta><meta name="dc.Creator" content="Matthew F.  Brown" /></meta><meta name="dc.Creator" content="James D.  Clark" /></meta><meta name="dc.Creator" content="Alpay  Dermenci" /></meta><meta name="dc.Creator" content="Martin E.  Dowty" /></meta><meta name="dc.Creator" content="Andrew  Fensome" /></meta><meta name="dc.Creator" content="Susan  Fish" /></meta><meta name="dc.Creator" content="Matthew M.  Hayward" /></meta><meta name="dc.Creator" content="Martin  Hegen" /></meta><meta name="dc.Creator" content="Brett D.  Hollingshead" /></meta><meta name="dc.Creator" content="John D.  Knafels" /></meta><meta name="dc.Creator" content="David W.  Lin" /></meta><meta name="dc.Creator" content="Tsung H.  Lin" /></meta><meta name="dc.Creator" content="Dafydd R.  Owen" /></meta><meta name="dc.Creator" content="Eddine  Saiah" /></meta><meta name="dc.Creator" content="Raman  Sharma" /></meta><meta name="dc.Creator" content="Felix F.  Vajdos" /></meta><meta name="dc.Creator" content="Li  Xing" /></meta><meta name="dc.Creator" content="Xiaojing  Yang" /></meta><meta name="dc.Creator" content="Xin  Yang" /></meta><meta name="dc.Creator" content="Stephen W.  Wright" /></meta><meta name="dc.Description" content="Tyrosine kinase 2 (TYK2) is a member of the JAK kinase family that regulates signal transduction downstream of receptors for the IL-23/IL-12 pathways and type I interferon family, where it pairs wi..." /></meta><meta name="Description" content="Tyrosine kinase 2 (TYK2) is a member of the JAK kinase family that regulates signal transduction downstream of receptors for the IL-23/IL-12 pathways and type I interferon family, where it pairs wi..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 5, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00948" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00948" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00948" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00948" /></link>
        
    
    

<title>Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00948" /></meta><meta property="og:title" content="Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0019.jpeg" /></meta><meta property="og:description" content="Tyrosine kinase 2 (TYK2) is a member of the JAK kinase family that regulates signal transduction downstream of receptors for the IL-23/IL-12 pathways and type I interferon family, where it pairs with JAK2 or JAK1, respectively. On the basis of human genetic and emerging clinical data, a selective TYK2 inhibitor provides an opportunity to treat autoimmune diseases delivering a potentially differentiated clinical profile compared to currently approved JAK inhibitors. The discovery of an ATP-competitive pyrazolopyrazinyl series of TYK2 inhibitors was accomplished through computational and structurally enabled design starting from a known kinase hinge binding motif. With understanding of PK/PD relationships, a target profile balancing TYK2 potency and selectivity over off-target JAK2 was established. Lead optimization involved modulating potency, selectivity, and ADME properties which led to the identification of the clinical candidate PF-06826647 (22)." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Tyrosine kinase 2 (TYK2) is a member of the JAK kinase family that regulates signal transduction downstream of receptors for the IL-23/IL-12 pathways and type I interferon family, where it pairs with JAK2 or JAK1, respectively. On the basis of human genetic and emerging clinical data, a selective TYK2 inhibitor provides an opportunity to treat autoimmune diseases delivering a potentially differentiated clinical profile compared to currently approved JAK inhibitors. The discovery of an ATP-competitive pyrazolopyrazinyl series of TYK2 inhibitors was accomplished through computational and structurally enabled design starting from a known kinase hinge binding motif. With understanding of PK/PD relationships, a target profile balancing TYK2 potency and selectivity over off-target JAK2 was established. Lead optimization involved modulating potency, selectivity, and ADME properties which led to the identification of the clinical candidate PF-06826647 (22)." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0019.jpeg" /></meta><meta name="twitter:title" content="Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00948"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00948">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00948&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00948&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00948&amp;href=/doi/10.1021/acs.jmedchem.0c00948" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 13561-13577</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00944" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.0c01170" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Brian S. Gerstenberger</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian S. Gerstenberger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Cambridge, Massachusetts 02139, United States</div></div><span class="conrtib-corresp"><strong>*</strong>B.S.G.: email, <a href="/cdn-cgi/l/email-protection#e1839388808fcf8684939295848f838493868493a19187889b8493cf828e8c"><span class="__cf_email__" data-cfemail="5d3f2f343c33733a382f2e2938333f382f3a382f1d2d3b3427382f733e3230">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian+S.++Gerstenberger">Brian S. Gerstenberger</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6553-1975" title="Orcid link">http://orcid.org/0000-0002-6553-1975</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Catherine Ambler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Catherine Ambler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Catherine++Ambler">Catherine Ambler</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eric P. Arnold</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eric P. Arnold</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eric+P.++Arnold">Eric P. Arnold</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mary-Ellen Banker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mary-Ellen Banker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mary-Ellen++Banker">Mary-Ellen Banker</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthew F. Brown</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew F. Brown</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+F.++Brown">Matthew F. Brown</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James D. Clark</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James D. Clark</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+D.++Clark">James D. Clark</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alpay Dermenci</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alpay Dermenci</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alpay++Dermenci">Alpay Dermenci</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martin E. Dowty</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin E. Dowty</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin+E.++Dowty">Martin E. Dowty</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrew Fensome</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew Fensome</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew++Fensome">Andrew Fensome</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8916-1895" title="Orcid link">http://orcid.org/0000-0001-8916-1895</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Susan Fish</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Susan Fish</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Susan++Fish">Susan Fish</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthew M. Hayward</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew M. Hayward</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+M.++Hayward">Matthew M. Hayward</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martin Hegen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin Hegen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Hegen">Martin Hegen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brett D. Hollingshead</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brett D. Hollingshead</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brett+D.++Hollingshead">Brett D. Hollingshead</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John D. Knafels</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John D. Knafels</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+D.++Knafels">John D. Knafels</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David W. Lin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David W. Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+W.++Lin">David W. Lin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tsung H. Lin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tsung H. Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tsung+H.++Lin">Tsung H. Lin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dafydd R. Owen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dafydd R. Owen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dafydd+R.++Owen">Dafydd R. Owen</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3106-7809" title="Orcid link">http://orcid.org/0000-0003-3106-7809</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eddine Saiah</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eddine Saiah</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eddine++Saiah">Eddine Saiah</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Raman Sharma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Raman Sharma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Raman++Sharma">Raman Sharma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Felix F. Vajdos</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Felix F. Vajdos</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Felix+F.++Vajdos">Felix F. Vajdos</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Li Xing</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Li Xing</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Li++Xing">Li Xing</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaojing Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaojing Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaojing++Yang">Xiaojing Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xin Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xin Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xin++Yang">Xin Yang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Stephen W. Wright</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephen W. Wright</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Inc., Groton, Connecticut 06340, United States</div></div><span class="conrtib-corresp"><strong>*</strong>S.W.W.: email, <a href="/cdn-cgi/l/email-protection#a5d6d1c0d5cdc0cb8bd28bd2d7ccc2cdd1e5d5c3ccdfc0d78bc6cac8"><span class="__cf_email__" data-cfemail="fe8d8a9b8e969b90d089d0898c9799968abe8e9897849b8cd09d9193">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephen+W.++Wright">Stephen W. Wright</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9785-5077" title="Orcid link">http://orcid.org/0000-0002-9785-5077</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00948&amp;href=/doi/10.1021%2Facs.jmedchem.0c00948" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 13561–13577</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 5, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 June 2020</li><li><span class="item_label"><b>Published</b> online</span>5 August 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 November 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00948" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00948</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 <span class="NLM_copyright-holder">American Chemical Society</span></strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D13561%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBrian%2BS.%2BGerstenberger%252C%2BCatherine%2BAmbler%252C%2BEric%2BP.%2BArnold%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D22%26contentID%3Dacs.jmedchem.0c00948%26title%3DDiscovery%2Bof%2BTyrosine%2BKinase%2B2%2B%2528TYK2%2529%2BInhibitor%2B%2528PF-06826647%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BAutoimmune%2BDiseases%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D13577%26publicationDate%3DNovember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00948"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4340</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">10</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00948" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;S. Gerstenberger&quot;},{&quot;first_name&quot;:&quot;Catherine&quot;,&quot;last_name&quot;:&quot;Ambler&quot;},{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;P. Arnold&quot;},{&quot;first_name&quot;:&quot;Mary-Ellen&quot;,&quot;last_name&quot;:&quot;Banker&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;F. Brown&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;D. Clark&quot;},{&quot;first_name&quot;:&quot;Alpay&quot;,&quot;last_name&quot;:&quot;Dermenci&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;E. Dowty&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;Fensome&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;Fish&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;M. Hayward&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Hegen&quot;},{&quot;first_name&quot;:&quot;Brett&quot;,&quot;last_name&quot;:&quot;D. Hollingshead&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;D. Knafels&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;W. Lin&quot;},{&quot;first_name&quot;:&quot;Tsung&quot;,&quot;last_name&quot;:&quot;H. Lin&quot;},{&quot;first_name&quot;:&quot;Dafydd&quot;,&quot;last_name&quot;:&quot;R. Owen&quot;},{&quot;first_name&quot;:&quot;Eddine&quot;,&quot;last_name&quot;:&quot;Saiah&quot;},{&quot;first_name&quot;:&quot;Raman&quot;,&quot;last_name&quot;:&quot;Sharma&quot;},{&quot;first_name&quot;:&quot;Felix&quot;,&quot;last_name&quot;:&quot;F. Vajdos&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Xing&quot;},{&quot;first_name&quot;:&quot;Xiaojing&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Xin&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;W. Wright&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;13561-13577&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00948&quot;},&quot;abstract&quot;:&quot;Tyrosine kinase 2 (TYK2) is a member of the JAK kinase family that regulates signal transduction downstream of receptors for the IL-23/IL-12 pathways and type I interferon family, where it pairs with JAK2 or JAK1, respectively. On the basis of human genetic and emerging clinical data, a selective TYK2 inhibitor provides an opportunity to treat autoimmune diseases delivering a potentially differentiated clinical profile compared to currently approved JAK inhibitors. The discovery of an ATP-competitive pyrazolopyrazinyl series of TYK2 inhibitors was accomplished through computational and structurally enabled design starting from a known kinase hinge binding motif. With understanding of PK/PD relationships, a target profile balancing TYK2 potency and selectivity over off-target JAK2 was established. Lead optimization involved modulating potency, selectivity, and ADME properties which led to the identification of the clinical candidate PF-06826647 (22).&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00948&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00948" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00948&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00948" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00948&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00948" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00948&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00948&amp;href=/doi/10.1021/acs.jmedchem.0c00948" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00948" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00948" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00948%26sid%3Dliteratum%253Aachs%26pmid%3D32787094%26genre%3Darticle%26aulast%3DGerstenberger%26date%3D2020%26atitle%3DDiscovery%2Bof%2BTyrosine%2BKinase%2B2%2B%2528TYK2%2529%2BInhibitor%2B%2528PF-06826647%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BAutoimmune%2BDiseases%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D22%26spage%3D13561%26epage%3D13577%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/22" title="Go to Volume 63, Issue 22"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/jmcmar.2020.63.issue-22/20201125/jmcmar.2020.63.issue-22.largecover.jpg" alt="Go to Volume 63, Issue 22"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Tyrosine kinase 2 (TYK2) is a member of the JAK kinase family that regulates signal transduction downstream of receptors for the IL-23/IL-12 pathways and type I interferon family, where it pairs with JAK2 or JAK1, respectively. On the basis of human genetic and emerging clinical data, a selective TYK2 inhibitor provides an opportunity to treat autoimmune diseases delivering a potentially differentiated clinical profile compared to currently approved JAK inhibitors. The discovery of an ATP-competitive pyrazolopyrazinyl series of TYK2 inhibitors was accomplished through computational and structurally enabled design starting from a known kinase hinge binding motif. With understanding of PK/PD relationships, a target profile balancing TYK2 potency and selectivity over off-target JAK2 was established. Lead optimization involved modulating potency, selectivity, and ADME properties which led to the identification of the clinical candidate PF-06826647 (<b>22</b>).</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77818" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77818" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Intercellular cytokine signaling plays a critical role in immunological regulation and host immune response in health and disease. Excessive cytokine signaling is a significant contributor to the pathogenesis of autoimmune diseases. Targeting cytokine signaling pathways through pharmacological inhibition or modulation has been shown to be a successful strategy for treatment of several autoimmune and inflammatory diseases.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Effective targeting of cytokine signaling pathways via inhibition of Janus kinases (JAK) has been demonstrated as clinically useful in rheumatoid arthritis (RA), psoriatic arthritis, and ulcerative colitis as well as for myeloproliferative disorders and graft-versus-host disease (GvHD).<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> Tyrosine kinase 2 (TYK2) is one of the four members of the JAK non-receptor tyrosine kinase family which also includes JAK1, JAK2, and JAK3. The JAK kinases are important in both the innate and adaptive immune systems through the modulation of cytokine signaling and their influence on the signal transducer and activation of transcription (STAT) pathways.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> TYK2 is associated with the receptors for interleukin-12 (IL-12), IL-23, and type I interferons (IFNs) and regulates the downstream signal transduction pathways.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> These cytokines are critical for the functions of T helper 1 (TH1), TH17, B cells, and myeloid cells that play a key role in a number of autoimmune and chronic inflammatory diseases. JAK kinases function as pairs of homo- or heterodimers in the JAK-STAT pathways. TYK2 pairs with JAK1 to mediate multiple cytokine pathways including type I IFNs, IL-10 and IL-22. TYK2 also pairs with JAK2 to transmit the signals of IL-12 and IL-23.</div><div class="NLM_p">Genome-wide association studies have identified the TYK2 loci associated with several autoimmune diseases including rheumatoid arthritis, psoriasis, systemic lupus erythematosus, Crohn’s disease, and ulcerative colitis.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> A <i>TYK2</i> variant encoding a proline to alanine substitution at amino acid 1104 is expressed but is inactive and has been shown to provide protection from several autoimmune diseases.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> This coding variant has diminished IL-12, IL-23, and type I interferon (IFN) signaling, suggesting that function of TYK2 is critical to the pathogenesis of the above-mentioned autoimmune diseases. Notably, humans homozygous for this inactive variant do not have an increase in malignancy, bacterial, mycobacterial, fungal, or viral infections suggesting that inhibition should be tolerated. Targeting inhibition of IL-12 and IL-23 signaling has been demonstrated in the clinic by ustekinumab (STELARA), a monoclonal antibody against the p40 subunit common to IL-23 and IL-12, which is approved for the treatment of psoriasis (PsO), psoriatic arthritis, Crohn’s disease, and ulcerative colitis.<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9−11)</a> Additionally, antibodies targeting the IL-23-specific p19 subunit guselkumub (TREMFYA), tidrakizumab (ILUMYA), and risankizumab (SKYRIZI) have been approved for the treatment of adults with moderate to severe plaque psoriasis.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> The pharmacological profile of a small molecule selective TYK2 kinase inhibitor provides an opportunity to treat several autoimmune diseases with an oral therapy.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14−16)</a></div><div class="NLM_p">Currently there are four oral FDA approved JAK kinase inhibitors, tofacitinib (XELJANZ) (<b>1</b>), baricitinib (OLUMIANT) (<b>2</b>), ruxolitinib (JAKAFI) (<b>3</b>), and upadacitinib (RINVOQ) (<b>4</b>) along with peficitinib (SMYRAF) (<b>5</b>) approved in Japan (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> All approved JAK kinase inhibitors demonstrate activity against JAK1 without high specificity for TYK2.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> These compounds bind to the ATP site of the catalytically active Janus homology 1 (JH1) domain. BMS-986165 (<b>6</b>)<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> is a TYK2 inhibitor in phase 3 clinical trials for psoriasis that, in contrast to most other JAK inhibitors, binds to the pseudokinase Janus homology 2 regulatory domain (JH2). We have previously disclosed the discovery of a JH1 TYK2/JAK1 dual inhibitor brepocitinib (PF-06700841) (<b>7</b>) which is currently under clinical investigation for a number of autoimmune indications.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Approved JAK kinase inhibitors and disclosed clinical stage TYK2 kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An inhibitor of TYK2 with enhanced selectivity over JAK1, JAK2, and JAK3 could be beneficial based on an orthogonal cytokine inhibition profile driving IL-23, IL-12, and IFNα signaling while simultaneously sparing suppression of other JAK-dependent cytokines, thus potentially avoiding broader immunosuppression. Sufficient selectivity over JAK2 would be desirable to minimize inhibition of erythropoietin (EPO) and thrombopoietin (TPO) signaling, which is mediated via a JAK2 homodimer. Decreased inhibition of EPO and TPO signaling should minimize effects on the production of red blood cells and platelets that may contribute to anemia and thrombocytopenia seen with some JAK inhibitors.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In addition, selectivity over JAK1 and JAK3 would limit inhibition of IL-6 and common γ-chain family cytokines, including anti-inflammatory cytokines IL-2, IL-15, and IL-21. The overall profile of a TYK2 inhibitor, particularly with clear selectivity over JAK1, is hypothesized to offer the potential for differentiation over the currently approved JAK family-based therapies while blocking numerous proinflammatory pathways implicated in psoriasis, inflammatory bowel disease (IBD), and other autoimmune diseases.</div><div class="NLM_p last">This manuscript describes the discovery and preclinical profile of PF-06826647 (<b>22</b>), a potent TYK2 inhibitor binding to the JH1 domain, that is under clinical development for the treatment of psoriasis (PsO), ulcerative colitis (UC), and hidradenitis suppurativa (HS).<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24−26)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Program Objectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67633" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67633" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The objectives for our TYK2 inhibitor program were based on the clinical and preclinical PK:PD relationships previously observed and discussed for tofacitinib (<b>1</b>). Biochemical kinase assays for TYK2, JAK1, JAK2, and JAK3 and human whole blood cytokine assays, to measure pathway inhibition, were utilized as the primary screens for the SAR campaign. Previous analysis supports that efficacy would be driven by average (<i>C</i><sub>av</sub>) IC<sub>80</sub> coverage of IL-12 as the primary cytokine target of combined TYK2 and JAK2 inhibition.<a onclick="showRef(event, 'ref21 ref27'); return false;" href="javascript:void(0);" class="ref ref21 ref27">(21,27)</a> Similar coverage analysis for JAK inhibitors approved for the treatment of RA has been reported. JAK inhibitors for the treatment of RA demonstrate similar profiles of <i>in vitro</i> cytokine receptor inhibition.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> These drugs inhibit JAK1 with limited selectivity against other JAK family members and show about IC<sub>80</sub> coverage of IFNα signaling (mediated by JAK1 and TYK2). JAK2-mediated EPO inhibition (CD34<sup>+</sup> cells spiked into human whole blood) would be limited to <i>C</i><sub>av</sub> ≤ IC<sub>30</sub> to minimize anemia and thrombocytopenia. To enable the analog advancement, a predicted human PK model would be established to calculate target cytokine inhibition levels. For the expedience of regular SAR interpretation, a calculated <i>C</i><sub>av</sub> inhibition or IC<sub>xx</sub>* was used (IC<sub>xx</sub>* = 100 × ((IC<sub>80</sub>IL-12)/(IC<sub>80</sub>IL-12 + IC<sub>50</sub> EPO) to assess functional selectivity.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51786" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51786" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Identification of a selective ATP site inhibitor of TYK2 is challenging due to the high homology across the four JAK isoforms.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Rational design of a TYK2 inhibitor requires a hinge binding motif that allows for the optimal scaffolding of vectors to further drive potency and selectivity. In examining the JH1 ATP site of the four JAK kinases, there is a common methionine gatekeeper; however the back pocket is defined by Ile960 in TYK2 which is a valine in the other three JAK family members. This unique amino acid difference sets the stage for an opportunity to rationally design the hinge group moiety. Overlaying of the pyrrolopyridimidine hinge binding group used in <b>1</b>, <b>2</b>, and <b>3</b> shows a two-point hydrogen bond donor and acceptor interaction with Glu979 and Val981 amino acids (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a). This binding mode places a steric clash against the larger side chain of Ile960 in TYK2 and forces the rotation of the lipophilic side chain toward the polar NH of the pyrrolopyridimidine hinge. This can, in part, rationalize why compounds <b>1</b>, <b>2</b>, and <b>3</b> have ∼30×, 20×, and 5× decreased potency for TYK2 compared to JAK1, respectively.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Two different TYK2 hinge binding modes: modeled <b>2</b> (yellow) superimposed with <b>7</b> TYK2 protein X-ray structures (green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBM">6DBM</a>) with Ile960 highlighted in purple. (b) General scaffolding strategy for a [5,6]-fused ring hinge binder.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Identification of a hinge binding group that does not interact with the carbonyl of Glu969 could resolve the clash with TYK2 Ile960. A [5,6]-fused ring hinge binder with a hydrogen bond acceptor and donor both to Val981 was proposed to allow for improved TYK2 potency. A [5,6]-fused aromatic system would provide (1) a position off the six-membered ring to build into the P-loop region and (2) a second opportunity to building toward the solvent front to manipulate compound physicochemical properties (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b). The combination of the steric bulk of the solvent exposed group and the unsubstituted five-membered ring would prevent the hinge group from flipping the binding mode to use the Glu979 and NH-Val981 positions. Targeting of the Tyr980 and Val981 hinge binding mode was previously exploited in identifying TYK2 active compounds, a strategy that ultimately led to the identification of the TYK2/JAK1 dual inhibitor <b>7</b>.</div><div class="NLM_p">A [5,6]-fused aromatic hinge binding group would require a hydrogen bond acceptor nitrogen atom on the five-membered ring, along with a hydrogen bond donor to project from the six-membered ring as an aryl C–H (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b). Analysis and selection of known kinase hinge binding scaffolds as a starting point were used.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Polarization of the aryl C–H to increase the hydrogen bonding potential was believed to be necessary to bring about sufficient TYK2 activity and two point binding. To that end several [5,6]-fused aromatic systems were designed and synthesized based off previously known hinge motifs. Initial SAR employed a methylpyrazole moiety as a solvent front group in a similar manner to that used in PF-06700841 (<b>7</b>). A substituted trifluoroethylazetidinyl pyrazole group similar to baricitinib to engage the P-loop region was also used. The imidazopyridine <b>8</b> was found to have modest potency against TYK2 (enzyme IC<sub>50</sub> = 290 nM) and showed low electrostatic potential on the C–H, which was utilized as a relative measure of H-bond donor ability (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Addition of a nitrogen into either position of the five-membered ring was calculated to modestly increase the electrostatic C–H potential, and thus both the [1,2,4]triazole[1,5]pyridine <b>9</b> and [1,2,4]triazole[4,3]pyridine <b>10</b> analogs were synthesized. However, compound <b>9</b> was found to be only a moderate TYK2 inhibitor (476 nM) and compound <b>10</b> was inactive against TYK2 with an IC<sub>50</sub> > 10 uM. In both cases there was increased electropositive potential (∼50 kJ/mol) not only on the C7–H but also on the 2- or 3-positions of the five-membered ring. These positions face toward the lipophilic gatekeeper, and the added polarity in this region likely contributed to the reduced TYK2 potency. In addition, the 2-position nitrogen of <b>10</b> could also be clashing with the carbonyl oxygen of Glu979 leading to complete loss of TYK2 activity.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. [5,6] Fused aromatic TYK2 lead structures <b>8</b>–<b>11</b> with electrostatic potential maps calculated in Spartan ’18 with Hartree–Fock 6-31G*.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. TYK2 Biochemical IC<sub>50</sub>, sfLogD, and TYK2 LipE of Compounds [5,6] Fused Aromatic TYK2 Lead Structures <b>8</b>–<b>11</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">compd</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>8</b></th><th class="colsep0 rowsep0" align="center"><b>9</b></th><th class="colsep0 rowsep0" align="center"><b>10</b></th><th class="colsep0 rowsep0" align="center"><b>11</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TYK2<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a>IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">290</td><td class="colsep0 rowsep0" align="left">476</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sfLogD<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TYK2 LipE<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">4.5</td><td class="colsep0 rowsep0" align="left">4.0</td><td class="colsep0 rowsep0" align="left"><3.8</td><td class="colsep0 rowsep0" align="left">5.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Enzyme assay. Compounds were assayed at least twice, and the IC<sub>50</sub> is reported as the geometric mean. ATP concentration = 1 mM.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Shake-flask log <i>D</i> (sfLogD) measured between octanol/water phosphate buffered to pH 7.4.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">LipE = pIC<sub>50</sub> – log <i>D</i>.</p></div></div></div><div class="NLM_p">With these results in hand, we turned to modification of the six-membered ring system to improve potency. A pyrazole[1,5]pyrazine core<a onclick="showRef(event, 'ref32 ref33 ref34 ref35 ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34 ref35 ref36 ref37 ref38">(32−38)</a> was of particular interest due to the calculated increased polarization of the C–H for hydrogen bond donor properties (122 kJ/mol). In contrast to <b>9</b> and <b>10</b>, the most electronegative nitrogen atom was now placed toward the solvent front where it could be better accommodated by bulk water and not clash with the protein (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Gratifyingly the pyrazole[1,5]pyrazine analog <b>11</b> was found to be a potent TYK2 enzyme inhibitor at 10 nM with a lipophilic efficiency (LipE) of 5.5. With the identification of an appropriately potent and efficient hinge binding core, compound <b>11</b> was chosen for further optimization to improve physicochemical properties and JAK selectivity.</div><div class="NLM_p">An X-ray crystal structure of <b>11</b> bound to TYK2 confirmed the expected binding mode with N1 accepting a hydrogen bond from the amide NH of Val981 in the TYK2 hinge region (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a). The proposed polarized C7–H was observed to be 2.4 Å from the carbonyl of Val981, within van der Waals radii. The positioning of the alkyl cyano group was shown to be toward the C-terminal lobe in the active site’s lower lipophilic pocket. This mimicked the positioning of the 4<i>R</i>-methylpiperidine positioning observed with tofacitinib.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The trifluoromethyl azetidine group provided the desired TYK2 kinase potency through engagement of the P-loop, but the moderate LipE of 5.5 reflected the high overall lipophilicity of the molecule. On the basis of the physicochemical properties and high permeability (MDCK-LE = 18 × 10<sup>–6</sup> cm/s) the primary clearance mechanism was predicted to be oxidative metabolism.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Optimization of the azetidine substituent was guided by LipE through increasing potency/lowering log <i>D</i> as well as driving toward improving the modest metabolic stability profile of <b>11</b> as judged by human liver microsome turnover (HLM) of 18 (μL/min/mg protein). In addition, replacement of the trifluoroethylamino group was preferred due to association with testicular toxicity liability for potential metabolites.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The des-fluoroethyl compound <b>12</b> lost approximately 5-fold in TYK2 potency relative to <b>11</b> with no change to the overall JAK selectivity profile (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Interestingly, both compounds showed moderate metabolic profiles (HLM = 18 and 21 (μL/min/mg protein). Attempts to recapitulate the trifluoro group impact using a cyclopropane analog <b>13</b> did not improve potency (TYK2 IC<sub>50</sub> = 40 nM) and were reflected in a loss of LipE (4.8) and increased HLM clearance (30 μL/min/mg protein).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Protein X-ray structure of <b>11</b> bound to TYK2 (green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6X8F">6X8F</a>) at 2.15 Å with crystallographic waters. (b) Overlay of P-loop region of protein X-ray structure of <b>11</b> bound to TYK2 (green) at 2.15 Å with Connolly surface and JAK2 (blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6X8E">6X8E</a>) at 1.75 Å.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of Substituted Azetidines<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">()</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0013.gif" alt="" id="GRAPHIC-d7e861-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0014.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Compounds were assayed at least twice, and the IC<sub>50</sub> is reported as the geometric mean. ATP concentration = 1 mM.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Shake-flask log <i>D</i> (sfLogD) measured between octanol/water phosphate buffered to pH 7.4.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">LipE = pIC<sub>50</sub> – log <i>D</i>.</p></div></div><div></div></div><div class="NLM_p">Further attempts to introduce polarity to lower clearance while retaining TYK2 potency provided by the trifluoro group provided mixed results. Introduction of the azetidine amide in compound <b>14</b> lowered both sfLogD and brought HLM clearance (<8 μL/min/mg protein) into the desired range but also caused a significant loss in potency. This could be due to the amide sp<sup>2</sup> character causing flattening of the azetidine which may not allow the acetyl group to directly engage the P-loop. Appending a hydroxyl to the ethyl group providing compound <b>15</b> again showed a loss of potency, even with the increased flexibility of the azetidine N-substituent. In contrast to alkyl groups, <b>14</b> and <b>15</b> that bear polar groups both had lower permeability as judged by flux in an MDCK-LE cell line (4 × 10<sup>–6</sup> cm/s). Unique within this series, the cyanomethyl group of compound <b>16</b> recapitulated the potency of compound <b>11</b> but also lowered HLM clearance (<8 μL/min/mg protein) and increased LipE to 6.7. Compound <b>16</b> showed good selectivity against JAK3 and JAK1 but only a modest 5-fold selectivity against JAK2.</div><div class="NLM_p">To provide further understanding of JAK2 selectivity, a JAK2 protein X-ray crystal structure of <b>11</b> was acquired to compare to the TYK2 structure (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b). From comparison of the protein structures of JAK2 and TYK2 superimposed, the JAK2 P-loop was slightly raised relative to the TYK2 P-loop. Overlay of the two structures and electron density unsurprisingly showed similar binding modes. Subtle interaction differences with the P-loop have been reported to influence selectivity in other JAK inhibitors.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The only minor difference seen in the overlay was the azetidine ring configuration. In the JAK2 structure at 1.75 Å resolution, the azetidine adopted a “<i>trans</i>-like” configuration placing the terminal −CF<sub>3</sub> group toward the P-loop. In contrast, the TYK2 azetidine configuration adopted a “<i>cis</i>-like” configuration. These observations from the X-ray structures provided the hypothesis that fixing the four-membered ring configuration that could provide the C2-symmetric achiral <i>cis</i> or <i>trans</i> conformations could improve selectivity and replacing the azetidine with a cyclobutane may accomplish this goal.</div><div class="NLM_p">The methoxycyclobutane diastereomers <i>cis</i>-<b>17</b> and <i>trans</i>-<b>18</b> were prepared, and both retained TYK2 potency (16 and 22 nM) while the cyclobutane stereoisomer <i>trans</i>-<b>18</b> showed superior selectivity against JAK1 (68-fold) and JAK2 (10-fold). As expected with the replacement of the azetidine, the methoxycyclobutane analogs showed increased sfLogD and the <i>cis</i>-<b>17</b> had high clearance as judged by HLM (27 μL/min/mg protein). Somewhat unexpectedly, the isolipophilic <i>trans</i>-<b>18</b> had very low HLM clearance (<8 μL/min/mg protein) when compared to the <i>cis</i>-<b>17</b>. The two diastereomeric <i>cis</i>/<i>trans</i> isomers demonstrated a useful divergence in clearance in addition to differences in potency and selectivity.</div><div class="NLM_p">The <i>cis</i>-<b>19</b> and <i>trans</i>-<b>20</b> isomers of 2-cyclobutylacetonitrile were prepared as homologs of azetidine <b>16</b>. The <i>cis-</i><b>19</b> configuration provided a near identical profile to the azetidine <b>16</b>, while the <i>trans</i>-<b>20</b> had a slight loss in potency across all JAK isoforms. The JAK2 selectivity of <i>cis-</i><b>19</b> and <i>trans-</i><b>20</b> were lower than the methoxy analogs <b>17</b> and <b>18</b> with higher <i>in vitro</i> clearances (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). To improve JAK2 selectivity by further removal of flexibility in the P-loop engagement, truncation of the 2-cyclobutylacetonitrile to the cyclobutanecarbonitrile group was proposed. The <i>cis</i>-<b>21</b> cyclobutanecarbonitrile showed excellent TYK2 potency (6 nM) but lacked selectivity against JAK2 (8 nM). In addition, even with the lower measured sfLogD (1.8), significant clearance was still observed (HLM = 17 μL/min/mg protein), in line with the previous results for <i>cis</i>-<b>17</b>. In contrast, the <i>trans</i>-<b>22</b> cyclobutanecarbonitrile (PF-06824467) showed good selectivity against JAK1 and JAK2 with very low HLM clearance (<8 μL/min/mg protein) consistent with <i>trans</i>-<b>20</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Influence of Cyclobutane Substituent on Potency, sfLogD, and Metabolism of Compounds <b>17</b>–<b>22</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0015.gif" alt="" id="GRAPHIC-d7e1089-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0016.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Compounds were assayed at least twice, and the IC<sub>50</sub> is reported as the geometric mean. ATP concentration = 1 mM.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Shake-flask log <i>D</i> (sfLogD) measured between octanol/water phosphate buffered to pH 7.4.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">LipE = pIC<sub>50</sub> – log <i>D</i>.</p></div></div><div></div></div><div class="NLM_p">To better understand the interactions of the cyclobutane analogs with TYK2, a protein X-ray crystal structure of <b>22</b> was acquired. The <i>cis</i> cyclobutanecarbonitrile moiety was positioned below and toward the tip of the P-loop (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a). Simulated waters in the apo structure showed a calculated high energy water molecule (Δ<i>G</i> = 5.3 kcal/mol) in this region.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> The end of the P-loop contains mainly hydrophobic residues and a generally satisfied hydrogen bond network which may contribute to the calculated lability of this modeled water in the apo structure. This predicted high energy water is displaced by the cyclobutanecarbonitrile group of <b>22</b>. The electrostatic mapping of this pocket also showed a positive electrostatic potential which could provide a favorable interaction with the cyano group (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a). The optimized hinge binding group along with the rationally designed interactions with the P-loop combined to give potent TYK2 inhibition.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Protein X-ray structure of <b>22</b> in TYK2 (yellow, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6X8G">6X8G</a>)) at 2.21 Å with electrostatic potential map and modeled APO waters in the P-loop (spheres). (b) Top view of the hinge and solvent exposed region of the protein X-ray structure of <b>22</b> showing two-point interaction with Val981</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of the TYK2 potency, JAK selectivity profile, and low clearance, <b>22</b> was selected to further explore the SAR of the pyrazole group (R<sub>2</sub>) (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The SAR was also explored on the more potent but less JAK1 selective <i>trans</i>-<b>21</b> in order to attempt to improve TYK2 selectivity in a parallel effort. A matrix of pyrazole structural analogs were made in an attempt to further tune the properties. The presumed solvent exposed methyl group on the pyrazole was hypothesized to be of inefficient lipophilicity (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b). Removal of the methyl group from the 4-pyrazole in the <i>cis</i><b>-23</b> and <i>trans</i>-<b>24</b> pair showed an increase in HLM clearance despite reduction in log <i>D</i> and lowered the permeability as measured by MDCK-LE. Neither compound showed improvement from their corresponding methyl analogs with no improvement in JAK1 selectivity from <b>21</b> to <b>23</b> and an erosion of TYK2 potency from <b>22</b> to <b>24</b>. In order to improve the permeability of the NH pyrazole, the 1<i>H</i>-3-pyrazole would allow a tautomer to place the N–H toward the core nitrogen and mask the H-bond donor via an intermolecular hydrogen bond. This strategy was not successful when applied to <i>cis</i>-<b>25</b>, but gratifyingly, the <i>trans</i>-<b>26</b> analog showed improved permeability compared to <b>24</b>. In addition, TYK2 potency was partially regained while retaining low HLM clearance. Finally, the 1-methyl-3-pyrazole analogs were synthesized. In the case of <i>cis</i>-<b>27</b> there was a gain in JAK1 and JAK2 selectivity, but this was still a higher clearance compound based on HLM. Analog <i>trans</i>-<b>28</b> had weaker TYK2 potency compared to <b>22</b> but had similar low clearance and JAK selectivity.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR of the Hinge Pyrazole Region Compounds <b>23</b>–<b>28</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0017.gif" alt="" id="GRAPHIC-d7e1256-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0018.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Compounds were assayed at least twice, and the IC<sub>50</sub> is reported as the geometric mean. ATP concentration = 1 mM.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Shake-flask log <i>D</i> (sfLogD) measured between octanol/water phosphate buffered to pH 7.4.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">LipE = pIC<sub>50</sub> – log <i>D</i>.</p></div></div><div></div></div><div class="NLM_p">A selection of compounds that showed both TYK2 biochemical potency and low <i>in vitro</i> metabolic clearance (HLM < (8 μL/min/mg protein) were selected to advance into profiling in human whole blood (HWB) cytokine assays. These assays were established to identify the desired candidate profile with respect to efficacy and off-target effects. Inhibition of IL-12 stimulated phosphorylation of STAT4 was selected as the efficacy driver, and blockade of EPO-induced phosphoSTAT5 was the key selectivity measurement. The project objective was to achieve potent IL-12 inhibition (IC<sub>50</sub> < 50 nM) with a selectivity profile of IC<sub>xx</sub> < 0.30 on EPO when set to a calculated IC<sub>80</sub> of IL-12 coverage. For all compounds, human plasma protein binding was measured to correct for free-drug potency. The compounds profiled were moderately bound with fraction unbound ranging from 0.2 to 0.5 (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). In addition, <i>in vitro</i> clearance was further profiled using human hepatocytes (HHEP) as a complement to the HLM data (CYP450 metabolism) in order to cover both phase I and II metabolic processes.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. HWB Cytokine and HHEP Profile of Potent TYK2 Compounds <b>18</b>, <b>21</b>, <b>22</b>, <b>26</b>, and <b>28</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="​" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">human plasma protein binding <i>F</i><sub>u</sub><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">TYK2 IC<sub>50</sub> (nM) (TYK2/JAK2 approximate fold selectivity)</th><th class="colsep0 rowsep0" align="center" char="​">IL-12 free IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">EPO free IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">IC<sub>xx</sub> EPO<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">HHEP ((μL/min)/million cells)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="char" char=".">0.30</td><td class="colsep0 rowsep0" align="left">22 (10×)</td><td class="colsep0 rowsep0" align="char" char="​">186</td><td class="colsep0 rowsep0" align="left">1100</td><td class="colsep0 rowsep0" align="left">0.41</td><td class="colsep0 rowsep0" align="char" char=".">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="char" char=".">0.34</td><td class="colsep0 rowsep0" align="left">6 (1×)</td><td class="colsep0 rowsep0" align="char" char="​">9</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">0.63</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="char" char=".">0.38</td><td class="colsep0 rowsep0" align="left">15 (5×)</td><td class="colsep0 rowsep0" align="char" char="​">14<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">148<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">0.28</td><td class="colsep0 rowsep0" align="char" char="."><3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="left">26 (7×)</td><td class="colsep0 rowsep0" align="char" char="​">334</td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="char" char=".">0.20</td><td class="colsep0 rowsep0" align="left">67 (7×)</td><td class="colsep0 rowsep0" align="char" char="​">254</td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char="."><2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Fraction unbound in human plasma.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Compounds were assayed at least twice, and the IC<sub>50</sub> is reported as the geometric mean. Free IC<sub>50</sub> calculated using assumed blood to plasma concentration ratio = 1.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">IC<sub>xx</sub> EPO = 1/((EPO IC<sub>50</sub>/(4 × IL-12 IC<sub>50</sub>) + 1).</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Not determined.</p></div><div class="footnote" id="t5fn5"><sup><sup>e</sup></sup><p class="last">Free IC<sub>50</sub> calculated by whole blood IC<sub>50</sub> × <i>F</i><sub>u</sub>/measured blood to plasma concentration ratio.</p></div></div></div><div class="NLM_p">Of the compounds selected for this more extensive profiling, methoxycyclobutane <b>18</b> showed the largest TYK2/JAK2 selectivity at 10-fold. Unfortunately, even with good TYK2 biochemical potency (22 nM) there was only moderate inhibition in HWB of IL-12 (IC<sub>50,u</sub> = 186 nM). Compound <b>18</b> had a low metabolic clearance (HHEP = 6 (μL/min)/million cells). Both <b>26</b> and <b>28</b> had weaker TYK2 potency and more moderate JAK2 selectivity which translated into weak overall IL-12 inhibition (IC<sub>50,u</sub> of 334 and 254 nM, respectively). Compound <b>21</b> was the most potent compound identified on TYK2 which drove strong potency against IL-12 (IC<sub>50,u</sub> = 9 nM). However insufficient biochemical selectivity against JAK2 meant there was an unacceptably high coverage of EPO (IC<sub>63</sub>). In addition, <b>21</b> showed a moderate but increased clearance profile (HHEP = 12 (μL/min)/million cells). The <i>cis</i>-cyclobutane <b>22</b> showed weaker TYK2 enzyme activity compared to its stereoisomer <b>21</b> but with more selectivity against JAK2. With this profile, <b>22</b> provided the desired level of IL-12 potency (IC<sub>50,u</sub> = 14 nM). Compound <b>22</b> also demonstrated the desired selectivity profile with an IC<sub>28</sub> for EPO coverage at the IL-12 IC<sub>80</sub> and a very low in vitro clearance profile (HHEP < 3 (μL/min)/million cells). Further profiling of <b>22</b> against a panel of 231 kinases at nonphysiologically conditions for each kinase <i>K</i><sub>m</sub> showed 21 non-JAK kinases with >50% at 1 μM dose. However, a kinase biochemical promiscuity panel against 40 kinase targets at physiologically relevant conditions with the 1 mM ATP and under those conditions no kinase target screened in both formats had >50% inhibition. (ThermoFisher kinase profiling, see <a href="/doi/suppl/10.1021/acs.jmedchem.0c00948/suppl_file/jm0c00948_si_002.pdf" class="ext-link">Supplementary Table 1</a>)<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> On the basis of the strong IL-12 potency, acceptable off-target profile, and excellent metabolic clearance profile, <b>22</b> was selected to advance to <i>in vivo</i> profiling.</div><div class="NLM_p">The physical properties of <b>22</b> include a basic p<i>K</i><sub>a</sub> of < 1.7 indicating the compound would be neutral at physiological pH. The measured log <i>D</i> at pH 7.4 was 1.7. Thermodynamic solubility of the crystalline material was low at 0.8 μM (0.3 μg/mL) at pH 7.4, and a salt formation strategy to improve solubility could not be pursued due to the lack of ionizable groups. A spray dried dispersion (SDD) formulation improved experimental intestinal solubility to approximately 160–180 μM (60–70 μg/mL). Compound <b>22</b> showed high passive permeability in MDCK-LE cells (mean <i>P</i><sub>app</sub> = 16.7 × 10<sup>–6</sup> cm/s) but is a substrate for MDR1 (efflux ratio > 6) and BCRP (efflux ratio > 2) efflux transport.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><div class="NLM_p">The pharmacokinetics of <b>22</b> were studied in Sprague-Dawley rats. Following a 1 mg/kg intravenous dose, the systemic clearance was 12 (mL/min)/kg, the steady state volume of distribution (<i>V</i><sub>ss</sub>) was 1.1 L/kg, and the AUC<sub>inf</sub> was 1380 ng·h/mL. Following oral administration of the crystalline (non-SDD) material at 3 and 30 mg/kg in 0.5% methylcellulose, oral bioavailability was 15 and 8% respectively. Oral bioavailability significantly improved to 58 and 63% at 3 and 30 mg/kg, respectively, when dosed in a SDD at 25% drug load, indicating an improved fraction absorbed of >75%. At 3 and 30 mg/kg in SDD, the respective <i>C</i><sub>max</sub> was 369 and 2780 ng/mL and the respective AUC<sub>inf</sub> was 2390 and 25 900 ng·h/mL. Plasma protein binding was 18% in rat and 38% in human without significant blood to plasma distribution (1.4 in human).</div><div class="NLM_p">The <i>in vitro</i> metabolism of <b>22</b> was studied in human liver microsomes (<8 (μL/min)/mg protein) and hepatocytes (1.8 (μL/min)/million cells), both of which indicated low metabolic turnover (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Oxidative metabolites of <b>22</b> accounted for the primary routes of biotransformation in rat, monkey, and human <i>in vitro</i> hepatic systems consistent with CYP450 metabolism. Primary metabolic pathways included N-demethylation of the pyrazole, hydroxylation of the pyrazole, and addition of oxygen and loss of the nitrile groups. Renal (1.3%) and bile (0.9%) excretion was low in the rat. Considering the importance of CYP450 metabolism, human clearance predictions were made using both human liver microsomes and hepatocyte scaling (well-stirred model) indicating a blood clearance of 2.3 and 1.5 (mL/min)/kg, respectively. The <i>V</i><sub>ss</sub> was predicted to be 1.2 L/kg using SimCYP PBPK modeling, consistent with the neutral properties of the compound. Oral bioavailability was expected to be dose-dependent based on low solubility characteristics and the need for a solubility enabling formulation.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Summary of Predicted Human Blood Pharmacokinetics of <b>22</b> from <i>in Vivo</i> and <i>in Vitro</i> Systems<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">human prediction</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">method</th><th class="colsep0 rowsep0" align="center">CL<sub>b</sub> ((mL/min)/kg)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub> (L/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human liver microsomes</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human relay hepatocytes</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat single species</td><td class="colsep0 rowsep0" align="left">5.2</td><td class="colsep0 rowsep0" align="left">2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SimCYP PBPK modeling</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">CL<sub>b</sub>, blood clearance; <i>V</i><sub>ss</sub>, volume of distribution at steady state; PBPK, physiologically based pharmacokinetics. Human clearance predictions from <i>in vitro</i> systems were scaled based on the well-stirred model or single species scaling from allometry.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a></p></div></div></div><div class="NLM_p">The overall cytokine inhibition profile (IC<sub>xx</sub>) was calculated for <b>22</b> based upon the modeled daily <i>C</i><sub>av</sub> exposure (i.e., AUC/dosing interval = 56 nM unbound) to cover the calculated IC<sub>80</sub> of IL-12 (unbound IC<sub>50</sub> 14 nM × 4 = 56 nM). Relative average daily cytokine inhibition representing different JAK signaling pairs is shown in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a> and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Human Whole Blood Potencies for <b>22</b> with Different Cytokine Stimuli and IC<sub>xx</sub> Calculated from Predicted <i>C</i><sub>av</sub> Exposure To Cover IL-12 IC<sub>80</sub></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">human whole blood</th><th class="colsep0 rowsep0" align="center">JAK signaling complex</th><th class="colsep0 rowsep0" align="center">uncorrected IC<sub>50</sub> (nM), mean ± SD<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">IC<sub>xx</sub><a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-12-induced pSTAT4 IC<sub>50</sub> (lymphocytes)</td><td class="colsep0 rowsep0" align="left">TYK2/JAK2</td><td class="colsep0 rowsep0" align="left">53 ± 16</td><td class="colsep0 rowsep0" align="left">0.80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-23-induced pSTAT3 IC<sub>50</sub> (lymphocytes)</td><td class="colsep0 rowsep0" align="left">TYK2/JAK2</td><td class="colsep0 rowsep0" align="left">112 ± 18</td><td class="colsep0 rowsep0" align="left">0.65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IFNα-induced pSTAT3 IC<sub>50</sub> (lymphocytes)</td><td class="colsep0 rowsep0" align="left">TYK2/JAK1</td><td class="colsep0 rowsep0" align="left">66 ± 21</td><td class="colsep0 rowsep0" align="left">0.76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-10-induced pSTAT3 IC<sub>50</sub> (lymphocytes)</td><td class="colsep0 rowsep0" align="left">TYK2/JAK1</td><td class="colsep0 rowsep0" align="left">427 ± 157</td><td class="colsep0 rowsep0" align="left">0.33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-27-induced pSTAT3 IC<sub>50</sub> (lymphocytes)</td><td class="colsep0 rowsep0" align="left">TYK2/JAK1/JAK2</td><td class="colsep0 rowsep0" align="left">201 ± 25</td><td class="colsep0 rowsep0" align="left">0.51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-6-induced pSTAT1 IC<sub>50</sub> (CD3<sup>+</sup> cells)</td><td class="colsep0 rowsep0" align="left">TYK2/JAK1/JAK2</td><td class="colsep0 rowsep0" align="left">566 ± 283</td><td class="colsep0 rowsep0" align="left">0.27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-6-induced pSTAT3 IC<sub>50</sub> (CD3<sup>+</sup> cells)</td><td class="colsep0 rowsep0" align="left">TYK2/JAK1/JAK2</td><td class="colsep0 rowsep0" align="left">4370 ± 1260</td><td class="colsep0 rowsep0" align="left">0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-21-induced pSTAT3 IC<sub>50</sub> (lymphocytes)</td><td class="colsep0 rowsep0" align="left">JAK1/JAK3</td><td class="colsep0 rowsep0" align="left">4890 ± 2550</td><td class="colsep0 rowsep0" align="left">0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-15-induced pSTAT5 IC<sub>50</sub> (lymphocytes)</td><td class="colsep0 rowsep0" align="left">JAK1/JAK3</td><td class="colsep0 rowsep0" align="left">4840 ± 2260</td><td class="colsep0 rowsep0" align="left">0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-2-induced pSTAT5 IC<sub>50</sub> (lymphocytes)</td><td class="colsep0 rowsep0" align="left">JAK1/JAK3</td><td class="colsep0 rowsep0" align="left">3740 ± 270</td><td class="colsep0 rowsep0" align="left">0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IFNγ-induced pSTAT1 IC<sub>50</sub> (CD14<sup>+</sup>)</td><td class="colsep0 rowsep0" align="left">JAK1/JAK2</td><td class="colsep0 rowsep0" align="left">2220 ± 750</td><td class="colsep0 rowsep0" align="left">0.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EPO-induced pSTAT5 (spiked CD34<sup>+</sup> progenitor cells)</td><td class="colsep0 rowsep0" align="left">JAK2/JAK2</td><td class="colsep0 rowsep0" align="left">547 ± 195</td><td class="colsep0 rowsep0" align="left">0.28</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Compound <b>22</b> was assayed at least three times in each assay, and the IC<sub>50</sub> is reported as the geometric mean. SD = standard deviation.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>xx</sub> cytokine = 1/((whole blood IC<sub>50</sub>/(4 × IL-12 IC<sub>50</sub>) + 1).</p></div></div></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Radial plot of cytokine inhibition IC<sub>xx</sub> relative to the IL-12 IC<sub>80</sub> for compound <b>22</b>, derived from potency in human whole blood assays and predicted average daily human plasma drug concentration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Efficacy of <b>22</b> was evaluated in the mouse imiquimod-induced skin inflammation model employing a therapeutic dosing paradigm previous used to profile <b>1</b> of an anti-p40 antibody.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> In this mouse skin inflammation model, the subjects are challenged with topically applied imiquimod (Toll-like receptor 7 and 8 agonist) on the ear to induce inflammation followed by oral dosing of <b>22</b>. In this mouse model, the murine TYK2 gene was modified by introducing a humanizing point mutation in order to change amino acid 980 of murine TYK2 protein from valine to isoleucine. This was done in order to compensate for an observed species potency shift driven by this amino acid difference between human and preclinical species.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Oral treatment with <b>22</b> at 30, 10, and 3 mg/kg, once per day (QD) reduced clinical end points associated with skin inflammation in this model (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). The measured average unbound daily concentrations (<i>C</i><sub>av,u</sub>, nM) of 1, 3, 10, and 30 mg/kg were 14.5, 45.7, 225, and 668 nM, respectively, resulting in average IL-12 inhibition of 51, 77, 94, and 98%. No significant effect on ear thickness was seen at 1 mg/kg compared to control animals at the end of the 5-day study.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>22</b> dosed at 30, 10, 3, and 1 mg/kg, po, QD inhibited ear swelling in the imiquimod-induced skin inflammation model. Compound <b>22</b> significantly inhibited ear swelling when compared to the vehicle-treated mice (<i>n</i> = 12) (30 mg/kg, 46.2%, <i>p</i> = 0.0004, 10 mg/kg, 34%, <i>p</i> = 0.0145, and 3 mg/kg, 31.3% (0.0198). The effect of the 1 mg/kg dose was not statistically significant (ns) when compared to the vehicle-treated mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20222" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20222" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Synthesis of the [5,6]-fused heterocycle structures <b>8</b>, <b>9</b>, and <b>10</b> was accomplished as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Conjugate addition of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (<b>29</b>) with <i>tert</i>-butyl 3-(cyanomethylene)azetidine-1-carboxylate (<b>30</b>)<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> gave the elaborated pyrazole boronate <b>31</b>, which underwent Suzuki–Miyaura coupling independently with <b>32</b> and <b>33</b> to provide <b>35</b> and <b>34</b>, respectively (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c00948/suppl_file/jm0c00948_si_002.pdf" class="ext-link">Supporting Information</a>). A second Suzuki–Miyaura coupling of 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole with <b>34</b> and <b>35</b> afforded <b>36</b> and <b>37</b>, respectively. The syntheses were completed by BOC deprotection and azetidine alkylation with 2,2,2-trifluoroethyl triflate to provide <b>8</b> from <b>36</b> and <b>9</b> from <b>37</b>. The alkylation of the deprotected azetidines required neutralization of the acid addition salts obtained by BOC deprotection and elimination of chloride or trifluoroacetate counterions prior to exposure to 2,2,2-trifluoroethyl triflate. The presence of chloride was found to result in the formation of unreactive 2,2,2-trifluoroethyl chloride, while the presence of trifluoroacetate ion was found to result in the formation of 2,2,2-trifluoroethyl trifluoroacetate, which in turn afforded the azetidine trifluoroacetamides as a serious competing reaction. Similarly, compound <b>38</b> (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c00948/suppl_file/jm0c00948_si_002.pdf" class="ext-link">Supporting Information</a>) underwent Suzuki–Miyaura coupling with (1-(<i>tert</i>-butoxycarbonyl)-1<i>H</i>-pyrazol-4-yl)boronic acid to provide <b>39</b> after BOC deprotection <i>in situ</i>. Conjugate addition of <b>39</b> with <b>30</b> gave the <i>N</i>-BOC azetidine <b>40</b>. BOC deprotection followed by azetidine alkylation with 2,2,2-trifluoroethyl triflate completed the synthesis of <b>10</b>.</div><figure id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>8</b>, <b>9</b>, and <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>30</b>, DBU, MeCN, 50–90 °C, 4–18 h; (b) K<sub>2</sub>CO<sub>3</sub> or Cs<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, 1,4-dioxane, H<sub>2</sub>O, 95–100 °C, 16–48 h; (c) 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, K<sub>2</sub>CO<sub>3</sub> or CsF, Pd(dppf)Cl<sub>2</sub>, 1,4-dioxane or Et(Me)<sub>2</sub>COH, 70–100 °C, 18–48 h; (d) (1) MsOH or HCl, MeCN or dioxane, 20–30 °C, 16–20 h; (2) CF<sub>3</sub>CH<sub>2</sub>OTf, DIEA, DMF or MeCN, 0–20 °C, 2–24 h; (e) (1-(<i>tert</i>-butoxycarbonyl)-1<i>H</i>-pyrazol-4-yl)boronic acid, Cs<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, 1,4-dioxane, H<sub>2</sub>O, 95 °C, 16 h; (f) <b>30</b>, DBU, MeCN, 30 °C, 16 h.</p></p></figure><div class="NLM_p">The pyrazolo[1,5-<i>a</i>]pyrazine analogues (<b>11</b>–<b>22</b>) required a longer synthetic sequence to allow the selective installation of the differentially functionalized pyrazole substituents at the 4- and 6-positions of the pyrazolo[1,5-<i>a</i>]pyrazine ring. Initially, the <i>N</i>-methylpyrazole at the 6-position was introduced at the beginning of the synthesis so that its placement in the pyrazolo[1,5-<i>a</i>]pyrazine ring system would be unambiguous following construction of the pyrazine ring (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Reaction of the α-bromoketone <b>41</b> (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c00948/suppl_file/jm0c00948_si_002.pdf" class="ext-link">Supporting Information</a>)<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> with diethyl 1<i>H</i>-pyrazole-3,5-dicarboxylate <b>42</b> provided <b>43</b>. This route was selected to avoid regioselectivity issues associated with attempts to alkylate ethyl pyrazole-3-carboxylate.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Ketone <b>43</b> was cyclized to the pyrazolo[1,5-<i>a</i>]pyrazine <b>44</b> by condensation with ammonium acetate.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Saponification to <b>45</b> followed by thermal decarboxylationgave the pyrazolo[1,5-<i>a</i>]pyrazin-4(5<i>H</i>)-one <b>46</b>, which was treated with phosphoryl chloride to provide the key chloro pyrazolo[1,5-<i>a</i>]pyrazine intermediate <b>47</b>.</div><figure id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>47</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>42</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 20 °C, 18 h; (b) NH<sub>4</sub>OAc, EtOH, 130 °C, 24 h; (c) NaOH, MeOH, H<sub>2</sub>O, 20 °C, 18 h; (d) sulfolane, 280 °C, 2 h; (e) POCl<sub>3</sub>, MeCN, 85 °C, 48 h.</p></p></figure><div class="NLM_p">The compounds <b>23</b>–<b>28</b> shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> required the previously unknown 4,6-dichloropyrazolo[1,5-<i>a</i>]pyrazine intermediate <b>52</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Alkylation of ethyl pyrazole-3-carboxylate (<b>48</b>) with ClCH<sub>2</sub>CN yielded predominantly the desired proximal regioisomer <b>49</b>. The regiochemical outcome of this alkylation was opposite with the results obtained using α-halocarbonyl electrophiles in similar alkylations. Nitrile hydrolysis with H<sub>2</sub>SO<sub>4</sub> in TFA gave the primary amide <b>50</b>. Base-mediated cyclization of <b>50</b> followed by neutralization with HCl to the pyrazolo[1,5-<i>a</i>]pyrazine-4,6-dione <b>51</b>, which was carried forward to chlorination with phosphoryl chloride, provided <b>52</b>. Sequential diversification of <b>52</b> via Suzuki–Miyaura, Stille, and Negishi coupling methodologies could be accomplished under mild conditions with excellent functional group tolerance.</div><figure id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Dichloropyrazolopyrazine <b>52</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ClCH<sub>2</sub>CN, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 25 °C, 16 h; (b) H<sub>2</sub>SO<sub>4</sub>, TFA, 25 °C, 16 h; (c) NaO<i>t-</i>Bu, EtOH, THF, 70 °C, 16 h; (d) POCl<sub>3</sub>, PyHCl, 120 °C, 18 h.</p></p></figure><div class="NLM_p">The syntheses of the necessary cyclobutyl-substituted pyrazole boronates (<b>59</b>–<b>64</b>) were accomplished as shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Substituted cyclobutanones <b>53</b>–<b>55</b> (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c00948/suppl_file/jm0c00948_si_002.pdf" class="ext-link">Supporting Information</a>) were subjected to Horner–Wadsworth–Emmons reaction with diethyl (cyanomethyl)phosphonate<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> to provide substituted 2-cyclobutylideneacetonitriles <b>56</b>–<b>58</b>. Conjugate addition of <b>29</b> with <b>56</b>–<b>58</b> in the presence of DBU was followed by separation of the resulting <i>trans</i> (<b>59</b>–<b>61</b>) and <i>cis</i> (<b>62</b>–<b>64</b>) cyclobutane isomers. The conjugate addition reactions of <b>56</b>–<b>58</b> proceeded with good overall conversion and a generally clean reaction profile. The <i>trans</i> or <i>cis</i> relationships between the pyrazole ring and the distal cyclobutane substituents (CH<sub>2</sub>CN, OCH<sub>3</sub>, or CN) were readily established by NOE experiments.</div><figure id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Syntheses of <i>trans</i> and <i>cis</i> Cyclobutyl-Substituted Pyrazole Boronates <b>59</b>–<b>64</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NCCH<sub>2</sub>P(O)(OEt)<sub>2</sub>, LiBr, Et<sub>3</sub>N, THF, 10–25 °C, 16–20 h. (b) For <b>59</b>, <b>60</b>, <b>62</b>, <b>63</b>: <b>29</b>, DBU, MeCN, 20–25 °C, 16–18 h. (c) For <b>61</b>, <b>64</b>: 4-bromo-1<i>H</i>-pyrazole, DBU, MeCN, 25 °C, 18 h; (d) B<sub>2</sub>Pin<sub>2</sub>, KOAc, XPhos Pd G3, 1,4-dioxane, 65 °C, 2 h.</p></p></figure><div class="NLM_p">With pyrazole boronates <b>31</b> and <b>59</b>–<b>64</b> in hand, the syntheses were completed as shown in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. Suzuki–Miyaura coupling of either <b>47</b> or <b>52</b> with the pyrazole boronates <b>31</b> and <b>59</b>–<b>64</b> installed the pyrazine 4-substituent. In the case of coupling reactions with <b>52</b>, coupling mediated by Pd(<i>t-</i>Bu<sub>3</sub>P)<sub>2</sub> at ambient temperature proceeded with very high regioselectivity for coupling at the desired pyrazolo[1,5-<i>a</i>]pyrazine 4-position. The regiochemical outcome of this Suzuki–Miyaura reaction sequence was established by the sequential Suzuki–Miyaura coupling of <b>52</b> with <b>62</b> (<i>cis</i> isomer) followed by Suzuki–Miyaura coupling with1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole. This reaction sequence afforded a sample of <b>21</b> which was identical in all respects with the <b>21</b> prepared previously from compound <b>47</b>. Reversal of the order of Suzuki–Miyaura coupling steps (Suzuki–Miyaura coupling of <b>52</b> with 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, followed by Suzuki–Miyaura coupling with <b>62</b>) afforded a product that was clearly distinguished from <b>21</b>. In the cases of <b>67</b> and <b>68</b>, a second Suzuki–Miyaura coupling with the appropriate pyrazole boronate<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> mediated by palladium with X-Phos as supporting ligand installed the necessary substituents at the pyrazolo[1,5-<i>a</i>]pyrazine 6-position and was followed by deprotection (if required) to yield <b>23</b>–<b>28</b>. The azetidine analogs <b>11</b>–<b>16</b> were prepared by BOC deprotection of <b>65</b>, followed by appropriate functionalization of the azetidine NH of <b>66</b> by reductive amination (<b>12</b>, <b>13</b>), acylation (<b>14</b>), or alkylation (<b>11</b>, <b>15</b>, <b>16</b>).</div><figure id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Test Compounds <b>11</b>—<b>28</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>31</b>, K<sub>3</sub>PO<sub>4</sub>, XPhos Pd G2, 1,4-dioxane, H<sub>2</sub>O, 60 °C, 5 h; (b) (1) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 20 °C, 90 min; (2) PS-carbonate; (c) CF<sub>3</sub>CH<sub>2</sub>OTf, DIEA, DMF, 20 °C, 18 h; (d) CH<sub>3</sub>CHO, NaOAc, NaBH(OAc)<sub>3</sub>, MeOH, 25 °C, 16 h; (e) <i>c-</i>PrCHO, NaOAc, NaBH(OAc)<sub>3</sub>, MeOH, 25 °C, 16 h; (f) Ac<sub>2</sub>O, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 25 °C, 2 h; (g) BrCH<sub>2</sub>CH<sub>2</sub>OH, K<sub>2</sub>CO<sub>3</sub>, MeCN, 50 °C, 64 h; (h) BrCH<sub>2</sub>CN, DIEA, DMF, 20 °C, 22 h; (i) <b>59</b>–<b>64</b>, K<sub>3</sub>PO<sub>4</sub>, XPhos Pd G3, 1,4-dioxane, H<sub>2</sub>O, 40–55 °C, 1–18 h; (j) <b>59</b> or <b>62</b>, K<sub>3</sub>PO<sub>4</sub>, Pd(<i>t-</i>Bu<sub>3</sub>P)<sub>2</sub>, 1,4-dioxane, H<sub>2</sub>O, 25 °C, 2 h; (k) pyrazole boronate,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> K<sub>3</sub>PO<sub>4</sub>, XPhos Pd G3, 1,4-dioxane, H<sub>2</sub>O, 60 °C, 1 h; (l) TFA, TFAA, 25 °C, 0.5–2 h.</p></p></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37153" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37153" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The discovery of a small molecular inhibitor of IL-12 and IL-23 with cellular and <i>in vivo</i> activity has been accomplished through the identification and optimization of a potent series of TYK2 inhibitors binding to the ATP site in the JH1 domain. Structure-based design and electrostatic modeling led to identification of a kinase hinge core that provided TYK2 potency and an encouraging preclinical <i>in vitro</i> selectivity profile against the other JAK-family members from the onset. Further optimization via design of cyclobutane analogs which engaged the P-loop to further increase TYK2 selectivity over JAK1 and JAK2 as well as balancing physicochemical properties secured high permeability and low metabolic clearance in the series. The balanced level of JAK2 selectivity was identified through screening in human whole blood assays, directly measuring cytokine signaling, and uncovered the complex heterodimer partnership of JAK2 and TYK2. Balanced inhibition of TYK2 and JAK2 drove desired inhibition of IL-12 and IL-23 while maintaining EPO inhibition within program objectives. This effort led to the identification of compound <b>22</b> (PF-06826647) which has completed a phase 1 clinical trial in healthy subjects and subjects with plaque psoriasis patients (NCT03210961) and is currently in phase 2 studies in multiple inflammatory disease indications.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01548" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01548" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All activities involving laboratory animals were carried out in accordance with federal, state, local, and institutional guidelines governing the use of laboratory animals in research and were reviewed and approved by Pfizer (or other) Institutional Animal Care and Use Committee. Pfizer animal care facilities that supported this work are fully accredited by AAALAC International.</div><div class="NLM_p">All biochemical assays for human Janus kinase (JAK) activity have been previously reported.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The microfluidic assay monitored phosphorylation of a synthetic peptide by the recombinant human kinase domain (JAK1, JAK2, JAK3, and TYK2). Reaction mixtures contained 1 mM ATP utilizing mobility shift technology (PerkinElmer LabChip EZ Reader).</div><div class="NLM_p">Human blood samples were collected from healthy donors via vein puncture in accordance with Pfizer protocols (Protocol No. GOHW RDP-01) approved by the Shulman Institutional Review Board. Inhibition of cytokine-induced phosphorylation of STATs by JAK inhibitors in human whole blood has been previously reported.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">Imiquimod-induced skin inflammation model in mutant strain of mouse designated as TYK2 Val980Ile was carried out as previously published.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> The TYK2 Val980Ile mice were orally administered PF-06826647 or vehicle, followed by topical application of imiquimod on the shaved ear to develop inflammation.</div><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> X-ray Crystallography</h3><div class="NLM_p last">Protein production and purification on the JH1 domain of TYK2 and JAK2 were as previously reported.<a onclick="showRef(event, 'ref21 ref43'); return false;" href="javascript:void(0);" class="ref ref21 ref43">(21,43)</a> See <a href="/doi/suppl/10.1021/acs.jmedchem.0c00948/suppl_file/jm0c00948_si_002.pdf" class="ext-link">Supporting Information</a> for further details.</div></div><div id="sec6_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Synthesis. Chemistry General Methods and Compound Characterization</h3><div class="NLM_p">Reagents and solvents were obtained from Aldrich and/or Alfa and were used without further purification. Solvents were commercial anhydrous grades and were used as received. All reactions were conducted with continuous magnetic stirring under an atmosphere of dry nitrogen unless otherwise specified. Chromatographic purifications were affected by medium pressure (“flash”) chromatography on silica gel unless noted otherwise.</div><div class="NLM_p">All new compounds were characterized by proton (<sup>1</sup>H) NMR spectra using Bruker spectrometers and are reported in parts per million (ppm) relative to the residual resonances of the deuterated solvent. Carbon (<sup>13</sup>C) and fluorine (<sup>19</sup>F) NMR spectra were recorded similarly. All <sup>13</sup>C NMR and <sup>19</sup>F NMR spectra were proton decoupled. Melting points were obtained on a Thomas-Hoover Mel-Temp capillary melting point apparatus and are uncorrected. Elemental analyses were performed by Intertek, 291 Rte. 22 East, P.O. Box 470, Whitehouse, NJ 08888.</div><div class="NLM_p">Low-resolution mass spectrometry analyses were conducted on Waters Acquity UPLC and SQ systems. Signal acquisition conditions included the following: Waters Acquity HSS T3 C18 2.1 50 mm column at 60 °C with 0.1% formic acid in water (v/v) as the mobile phase A; 0.1% formic acid in CH<sub>3</sub>CN (v/v) as the mobile phase B; 1.25 mL/min as the flow rate and ESCI (ESI±, APCI±), 100–2000 <i>m</i>/<i>z</i> scan, 0.4 s scan time, Centroid as the MS method. High-resolution mass spectrometry analyses were conducted on an Agilent 6220 TOF mass spectrometer in positive or negative electrospray mode. The system was calibrated to greater than 1 ppm accuracy across the mass range prior to analyses. The samples were separated using UPLC on an Agilent 1200 system prior to mass spectrometric analysis.</div><div class="NLM_p last">Purity of test compounds was assessed by elemental analysis for C, H, and N or by reversed-phase HPLC with UV detection at 210 nm. Analytical reversed-phase HPLC was carried out on a Waters Acquity HSS T3 2.1 mm × 100 mm (1.8 μm) column at 45 °C eluting with 5% (v/v) CH<sub>3</sub>CN in water containing 0.1% CH<sub>3</sub>SO<sub>3</sub>H (v/v) to 100% CH<sub>3</sub>CN over 8.2 min; then holding at 100% CH<sub>3</sub>CN for 0.5 min, then returning to 5% (v/v) CH<sub>3</sub>CN in water containing 0.1% CH<sub>3</sub>SO<sub>3</sub>H (v/v) and hold for 1.5 min at a flow rate of 0.4 mL per min. Compounds <b>12</b>–<b>14</b> were analyzed using a BCUltimate Xbridge C18 3.0 mm × 50 mm (3.0 μm) column at 40 °C eluting with 1% to 5% (v/v) CH<sub>3</sub>CN in water containing 0.1% TFA (v/v) over 1 min; then from 5% (v/v) CH<sub>3</sub>CN in water containing 0.1% TFA (v/v) to 100% CH<sub>3</sub>CN containing 0.1% TFA (v/v) over 5 min; then holding at 100% CH<sub>3</sub>CN containing 0.1% TFA (v/v) for 2 min, then returning to 1.0% (v/v) CH<sub>3</sub>CN in water containing 0.1% TFA (v/v) and hold for 2 min at a flow rate of 1.2 mL per min. All tested compounds returned combustion analyses within 0.4% of theoretical values or demonstrated HPLC purity of >95%, unless otherwise noted.</div></div><div id="sec6_2_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Diethyl 1-(2-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-2-oxoethyl)-1<i>H</i>-pyrazole-3,5-dicarboxylate (<b>43</b>)</h3><div class="NLM_p last">Two reactions were carried out in parallel as follows: A solution of <b>41</b> (500 g, 2.46 mol) and diethyl 1<i>H</i>-pyrazole-3,5-dicarboxylate (<b>42</b>, 580 g, 2.73 mol) in DMF (8 L) was treated with Cs<sub>2</sub>CO<sub>3</sub> (1050 g, 3.23 mol). The mixtures were stirred at 20 °C for 18 h. The two reaction mixtures were then combined, diluted with water (10 L), and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 10 L). The combined extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), concentrated, and purified by chromatography to give <b>43</b> (1.53 kg, 93%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.93 (s, 1H), 7.93 (s, 1H), 7.43 (s, 1H), 5.83 (s, 2H), 4.42 (q, <i>J</i> = 7.03 Hz, 2H), 4.28 (q, <i>J</i> = 7.03 Hz, 2H), 3.96 (s, 3H), 1.40 (t, <i>J</i> = 7.03 Hz, 3H), 1.32 (t, <i>J</i> = 7.03 Hz, 3H). LC–MS: 335 (MH<sup>+</sup>).</div></div><div id="sec6_2_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Ethyl 4-Hydroxy-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrazolo[1,5-<i>a</i>]pyrazine-2-carboxylate (<b>44</b>)</h3><div class="NLM_p last">Three reactions were carried out in parallel as follows: To a solution of <b>43</b> (510 g, 1.52 mol) in ethanol (6 L) was added NH<sub>4</sub>OAc (352 g, 4.57 mol). The reaction mixtures were heated at 130 °C in an autoclave for 24 h. The reaction mixtures were cooled to 50 °C, combined, and filtered. The precipitate was washed with EtOH and dried under vacuum to provide <b>44</b> (1090 g, 83%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 11.70 (br s, 1H), 8.30 (s, 1H), 8.20 (s, 1H), 8.04 (s, 1H), 7.37 (s, 1H), 4.33 (q, <i>J</i> = 7.03 Hz, 2H), 1.32 (t, <i>J</i> = 7.28 Hz, 3H). LC–MS: 310 (MNa<sup>+</sup>).</div></div><div id="sec6_2_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 6-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-4-oxo-4,5-dihydropyrazolo[1,5-<i>a</i>]pyrazine-2-carboxylic Acid (<b>45</b>)</h3><div class="NLM_p last">Two reactions were carried out in parallel as follows: A solution of <b>44</b> (545 g, 1.9 mol) in MeOH (10 L) was treated with 1.0 M NaOH (5.75 L) at 20 °C for 18 h. The mixtures were acidified with 12 M HCl, combined, and concentrated to remove most of the MeOH. The precipitate was filtered, washed with water, and dried to give <b>45</b> (1040 g, 100%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.20 (br s, 1H), 11.65 (s, 1H), 8.30 (s, 1H), 8.15 (s, 1H), 8.05 (s, 1H), 7.32 (s, 1H). LC–MS: 260 (MH<sup>+</sup>).</div></div><div id="sec6_2_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 6-(1-Methyl-1<i>H</i>-pyrazol-4-yl)pyrazolo[1,5-<i>a</i>]pyrazin-4(5<i>H</i>)-one (<b>46</b>)</h3><div class="NLM_p last">Five reactions were carried out in parallel as follows: Sulfolane (800 mL) was heated to 280 °C, after which <b>45</b> (85 g, 0.328 mol) was added in portions. The five reaction mixtures were stirred at 280 °C for 2 h, cooled to 25 °C, and stirred for 18 h. The reaction mixtures were combined, and the mixture was purified by chromatography eluting with petroleum ether–EtOAc (10:1 to 0:1), followed by CH<sub>2</sub>Cl<sub>2</sub>–MeOH (10:1) to give <b>46</b> (490 g, 75%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 11.44 (br s, 1H), 8.27 (s, 1H), 8.09 (s, 1H), 8.03 (s, 1H), 7.88 (d, <i>J</i> = 2.01 Hz, 1H), 6.99 (d, <i>J</i> = 1.51 Hz, 1H), 3.87 (s, 3H). LC–MS: 216 (MH<sup>+</sup>).</div></div><div id="sec6_2_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 4-Chloro-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrazolo[1,5-<i>a</i>]pyrazine (<b>47</b>)</h3><div class="NLM_p last">Two reactions were carried out in parallel as follows: A suspension of <b>46</b> (307 g, 1.43 mol) in MeCN (7.5 L) was treated with POCl<sub>3</sub> (2006 g, 13 mol) at 25 °C, then heated at 85 °C for 48 h. The reaction mixtures were combined and filtered. The precipitate was washed with EtOAc and dried under vacuum. The dried precipitate was purified by chromatography to afford a yellow solid which was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (15 L) and washed with 1 M aq NaHCO<sub>3</sub> (5 L). The CH<sub>2</sub>Cl<sub>2</sub> was concentrated to remove about 13 L of solvent, and the residue was diluted with MTBE (2 L) and petroleum ether (2 L). The mixture was filtered, and the precipitate was dried to afford <b>47</b> (385 g, 58%). <sup>1</sup>H NMR (500 MHz, DMSO) δ = 9.15 (s, 1H), 8.22 (s, 1H), 8.16 (d, <i>J</i> = 2.2 Hz, 1H), 8.00 (s, 1H), 6.96 (d, <i>J</i> = 2.0 Hz, 1H), 3.88 (s, 3H). <sup>13</sup>C (<sup>1</sup>H) NMR (126 MHz, DMSO) δ 142.5, 142.3, 136.3, 132.6, 132.2, 129.1, 118.3, 116.0, 99.8, 38.7. LC–MS: 234 (MH<sup>+</sup>, <sup>35</sup>Cl isotope). HRMS (ESI/QTOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>10</sub>H<sub>8</sub>ClN<sub>5</sub> 234.054; found 234.0538. Analysis Calcd for C<sub>10</sub>H<sub>8</sub>ClN<sub>5</sub>: C, 51.40; H, 3.45; N, 29.97; Cl, 15.17%. Found: C, 51.16; H, 3.35; N, 30.35; Cl, 15.20%.</div></div><div id="sec6_2_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 3-(Cyanomethylene)cyclobutane-1-carbonitrile (<b>56</b>)</h3><div class="NLM_p last">A solution of 3-oxocyclobutane-1-carbonitrile<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> (<b>53</b>, 14.5 g, 152 mmol) in THF (250 mL) was added to a mixture of (EtO)<sub>2</sub>P(O)CH<sub>2</sub>CN (31.1 g, 175 mmol), LiBr (19.9 g, 229 mmol), and Et<sub>3</sub>N (30.9 g, 305 mmol) in THF (300 mL) at 25 °C. After 16 h, the mixture was filtered, and the filtrate was concentrated. The residue was purified by chromatography to afford <b>56</b> (16.01 g, 89%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) δ: 5.38 (s, 1 H), 3.30–3.43 (m, 2 H), 3.16–3.30 (m, 3 H). LC–MS: 119 (MH<sup>+</sup>).</div></div><div id="sec6_2_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (1<i>s</i>,3<i>s</i>)-3-(Cyanomethyl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl)cyclobutane-1-carbonitrile (<i>cis</i> Isomer, <b>62</b>) and (1<i>r</i>,3<i>r</i>)-3-(Cyanomethyl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl)cyclobutane-1-carbonitrile (<i>trans</i> Isomer, <b>59</b>)</h3><div class="NLM_p last">To a solution of <b>29</b> (1.3 kg, 6.67 mol) in MeCN (43 L) were added <b>56</b> (953 g, 8 mol) and DBU (3.06 kg, 20.1 mol) at 20 °C. Stirring was continued at 20 °C for 16 h. The mixture was poured into 1 M aqueous KH<sub>2</sub>PO<sub>4</sub> (10 L) and extracted with EtOAc (5 × 5 L). The combined EtOAc extracts were concentrated and the residue was purified by chromatography to afford <b>59</b> (<i>trans</i> isomer, 610 g, 30%) and <b>62</b> (<i>cis</i> isomer, 250 g, 12%). <b>59</b> (<i>trans</i> isomer): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.90 (s, 1 H), 7.88 (s, 1 H), 3.21–3.28 (m, 3 H), 3.19 (s, 2 H), 2.86–2.94 (m, 2 H), 1.33 (s, 12 H). <sup>13</sup>C(<sup>1</sup>H) NMR (101 MHz, CD<sub>3</sub>OD) δ: 147.5, 136.5, 122.5, 117.1, 85.0, 61.9, 37.5, 30.5, 25.3, 25.2, 17.2. LC–MS: 313 (MH<sup>+</sup>). Melting point 137–140 °C. <b>62</b> (<i>cis</i> isomer): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.86 (s, 2 H), 3.24–3.31 (m, 1 H), 3.13–3.21 (m, 2 H), 3.07 (s, 2 H), 2.96–3.04 (m, 2 H), 1.34 (s, 12 H). <sup>13</sup>C (<sup>1</sup>H) NMR (101 MHz, CD<sub>3</sub>OD) δ: 147.4, 135.9, 121.9, 117.4, 85.0, 76.0, 60.1, 38.0, 28.4, 25.3, 16.2. LC–MS: 313 (MH<sup>+</sup>). Melting point 95–98 °C.</div></div><div id="sec6_2_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (1<i>r</i>,3<i>r</i>)-3-(Cyanomethyl)-3-(4-(6-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrazolo[1,5-<i>a</i>]pyrazin-4-yl)-1<i>H</i>-pyrazol-1-yl)cyclobutane-1-carbonitrile (<i>trans</i> Isomer, <b>22</b>)</h3><div class="NLM_p last">To a solution of <b>59</b> (3.38 g, 10.8 mmol) and <b>47</b> (2.20 g, 9.4 mmol) in 1,4-dioxane (47.1 mL) was added 2 M aqueous K<sub>3</sub>PO<sub>4</sub> (14.1 mL). Nitrogen was bubbled through the mixture for 5 min at 25 °C, after which XPhos Pd G2 (37.0 mg, 0.047 mmol) was added. The mixture was heated at 40 °C for 18 h and then was heated to 80 °C to dissolve the precipitated product. The aqueous layer was removed while maintaining the temperature at 80 °C, and then the warm 1,4-dioxane phase was added to EtOH (471 mL, previously preheated to 50 °C). The mixture was stirred for 10 min at 50 °C before being removed from heat. Stirring at 25 °C was continued for 6 h. The precipitated solid was filtered and washed with EtOH (2 × 25 mL), water (2 × 50 mL), and EtOH (2 × 25 mL). The precipitate was dried under vacuum to afford <b>22</b> (3.61 g, 74%). A sample of <b>22</b> (500 mg, 1.30 mmol) was heated in 1,4-dioxane (6.5 mL) at 80 °C until all of the material was dissolved. 1,2-Bis(diphenylphosphino)ethane (7.8 mg, 0.019 mmol) was added, and heating at 80 °C was continued for 4 h, and then the 1,4-dioxane phase was added to EtOH (58.7 mL, previously preheated to 50 °C). An additional 6.5 mL of preheated EtOH was used to rinse the reaction vessel. The mixture was removed from heat. Stirring at 25 °C was continued for 18 h. The solid was filtered and washed with EtOH (2 × 5 mL), water (5 mL), and then EtOH (3 × 5 mL). The precipitate was dried under vacuum to afford <b>22</b> (450 mg, 90%). <sup>1</sup>H NMR (400 MHz, DMSO) δ: 9.02 (s, 1 H), 8.92 (s, 1 H), 8.52 (s, 1 H), 8.37 (s, 1 H), 8.19 (s, 1 H), 8.16 (s, 1 H), 7.45 (s, 1 H), 3.91 (s, 3 H), 3.55 - 3.65 (m, 1 H), 3.52 (s, 2 H), 3.22–3.38 (m, 2 H), 2.85–3.00 (m, 2 H). <sup>13</sup>C (<sup>1</sup>H) NMR (126 MHz, DMSO) δ: 145.2, 142.5, 140.2, 137.1, 133.8, 131.4, 129.8, 129.5, 122.3, 121.1, 120.3, 117.3, 114.5, 99.9, 61.5, 39.3, 36.3, 29.7, 16.1. LC–MS: 384 (MH<sup>+</sup>). HRMS (ESI/QTOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>17</sub>N<sub>9</sub> 384.1679; found 384.1674. HPLC purity: 99.39%. Melting point 213–215 °C.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00948" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50744" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50744" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00948?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00948</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00948/suppl_file/jm0c00948_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Synthesis of <b>8</b>–<b>10</b>, <b>17</b>–<b>20</b>, and <b>23</b>–<b>28</b>; (2) kinase profiling for compound <b>22</b> at 1 μM; (3) X-ray crystallography methods; (4) <sup>1</sup>H and <sup>13</sup>C NMR spectra and HPLC traces of compounds <b>8</b>–<b>28</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00948/suppl_file/jm0c00948_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00948/suppl_file/jm0c00948_si_001.csv">jm0c00948_si_001.csv (1.91 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00948/suppl_file/jm0c00948_si_002.pdf">jm0c00948_si_002.pdf (4.03 MB)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for the X-ray structure of compound <b>11</b> in TYK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6X8F">6X8F</a>) and JAK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6X8E">6X8E</a>) and compound <b>22</b> in TYK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6X8G">6X8G</a>) are available from the RCSB Protein Data Bank (<a href="http://www.rcsb.org" class="extLink">www.rcsb.org</a>).</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c00948" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82761" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82761" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian S. Gerstenberger</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6553-1975" title="Orcid link">http://orcid.org/0000-0002-6553-1975</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1b7969727a75357c7e69686f7e75797e697c7e695b6b7d72617e6935787476"><span class="__cf_email__" data-cfemail="b3d1c1dad2dd9dd4d6c1c0c7d6ddd1d6c1d4d6c1f3c3d5dac9d6c19dd0dcde">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen W. Wright</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Groton, Connecticut 06340, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9785-5077" title="Orcid link">http://orcid.org/0000-0002-9785-5077</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#72010617021a171c5c055c05001b151a063202141b0817005c111d1f"><span class="__cf_email__" data-cfemail="4d3e39283d252823633a633a3f242a25390d3d2b2437283f632e2220">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Catherine Ambler</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric P. Arnold</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary-Ellen Banker</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew F. Brown</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James D. Clark</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alpay Dermenci</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin E. Dowty</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew Fensome</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8916-1895" title="Orcid link">http://orcid.org/0000-0001-8916-1895</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan Fish</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew M. Hayward</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Hegen</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brett D. Hollingshead</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John D. Knafels</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David W. Lin</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tsung H. Lin</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dafydd R. Owen</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3106-7809" title="Orcid link">http://orcid.org/0000-0003-3106-7809</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eddine Saiah</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Raman Sharma</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Felix F. Vajdos</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Xing</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaojing Yang</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xin Yang</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Inc., Groton, Connecticut 06340, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88512" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88512" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Chao Li for assistance with determinations of purity by HPLC. The authors thank Chaoyan Li, Sheng Tan, Konghua Jing, Guagnyin Zhang, and Xuejyuan Li from WuXi AppTec for assistance with synthesis of compound <b>12</b>–<b>15</b>, <b>27</b>, and <b>28</b>.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">B<sub>2</sub>Pin<sub>2</sub></td><td class="NLM_def"><p class="first last">bis(pinacolato)diboron</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>av</sub></td><td class="NLM_def"><p class="first last">average concentration</p></td></tr><tr><td class="NLM_term">CL<sub>b</sub></td><td class="NLM_def"><p class="first last">blood clearance</p></td></tr><tr><td class="NLM_term">c-Pr</td><td class="NLM_def"><p class="first last">cyclopropyl</p></td></tr><tr><td class="NLM_term">CYP450</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">dppf</td><td class="NLM_def"><p class="first last">1,1′-bis(diphenylphosphino)ferrocene</p></td></tr><tr><td class="NLM_term">EPO</td><td class="NLM_def"><p class="first last">erythropoietin</p></td></tr><tr><td class="NLM_term">GvHD</td><td class="NLM_def"><p class="first last">graft-versus-host disease</p></td></tr><tr><td class="NLM_term">HHEP</td><td class="NLM_def"><p class="first last">human hepatocyte</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">HS</td><td class="NLM_def"><p class="first last">hidradenitis suppurativa</p></td></tr><tr><td class="NLM_term">HWB</td><td class="NLM_def"><p class="first last">human whole blood</p></td></tr><tr><td class="NLM_term">IBD</td><td class="NLM_def"><p class="first last">inflammatory bowel disease</p></td></tr><tr><td class="NLM_term">IC<sub>xx</sub></td><td class="NLM_def"><p class="first last">% average daily inhibition</p></td></tr><tr><td class="NLM_term">IFN</td><td class="NLM_def"><p class="first last">interferon</p></td></tr><tr><td class="NLM_term">IL</td><td class="NLM_def"><p class="first last">interleukin</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">JAK1</td><td class="NLM_def"><p class="first last">Janus kinase 1</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">Janus kinase 2</p></td></tr><tr><td class="NLM_term">JAK3</td><td class="NLM_def"><p class="first last">Janus kinase 3</p></td></tr><tr><td class="NLM_term">JH1</td><td class="NLM_def"><p class="first last">Janus homology 1</p></td></tr><tr><td class="NLM_term">JH2</td><td class="NLM_def"><p class="first last">Janus homology 2</p></td></tr><tr><td class="NLM_term">LipE</td><td class="NLM_def"><p class="first last">lipophilic efficiency</p></td></tr><tr><td class="NLM_term">MDCK-LE</td><td class="NLM_def"><p class="first last">Madin–Darby canine kidney cell line low efflux permeability assay</p></td></tr><tr><td class="NLM_term">nM</td><td class="NLM_def"><p class="first last">nanomolar</p></td></tr><tr><td class="NLM_term">PBPK</td><td class="NLM_def"><p class="first last">physiologically based pharmacokinetics</p></td></tr><tr><td class="NLM_term">P-loop</td><td class="NLM_def"><p class="first last">fingerprint ATP binding motif Gly-X-X-Gly-X-Gly-Lys-Thr/Ser</p></td></tr><tr><td class="NLM_term">PS-carbonate</td><td class="NLM_def"><p class="first last">polystyrene supported (benzyltriethyl)ammonium carbonate</p></td></tr><tr><td class="NLM_term">PsO</td><td class="NLM_def"><p class="first last">psoriasis</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">SDD</td><td class="NLM_def"><p class="first last">spray dried dispersion</p></td></tr><tr><td class="NLM_term">sfLogD</td><td class="NLM_def"><p class="first last">shake-flask log <i>D</i></p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">TPO</td><td class="NLM_def"><p class="first last">thrombopoietin</p></td></tr><tr><td class="NLM_term">TYK2</td><td class="NLM_def"><p class="first last">tyrosine kinase 2</p></td></tr><tr><td class="NLM_term">UC</td><td class="NLM_def"><p class="first last">ulcerative colitis</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">steady state volume of distribution</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76845" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76845" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 56 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazaniga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furumoto, Y.</span></span> <span> </span><span class="NLM_article-title">Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases</span>. <i>J. Autoimmun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/j.jaut.2017.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1016%2Fj.jaut.2017.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=28676205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFantL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2017&pages=20-31&author=M.+Gadinaauthor=N.+Gazanigaauthor=L.+Vianauthor=Y.+Furumoto&title=Small+molecules+to+the+rescue%3A+Inhibition+of+cytokine+signaling+in+immune-mediated+diseases&doi=10.1016%2Fj.jaut.2017.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases</span></div><div class="casAuthors">Gadina, Massimo; Gazaniga, Nathalia; Vian, Laura; Furumoto, Yasuko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Autoimmunity</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20-31</span>CODEN:
                <span class="NLM_cas:coden">JOAUEP</span>;
        ISSN:<span class="NLM_cas:issn">0896-8411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cytokines are small, secreted proteins assocd. with the maintenance of immune homeostasis but also implicated with the pathogenesis of several autoimmune and inflammatory diseases.  Biol. agents blocking cytokines or their receptors have revolutionized the treatment of such pathologies.  Nonetheless, some patients fail to respond to these drugs or do not achieve complete remission.  The signal transduction originating from membrane-bound cytokine receptors is an intricate network of events that lead to gene expression and ultimately regulate cellular functionality.  Our understanding of the intracellular actions that mols. such as interleukins, interferons (IFNs) and tumor necrosis factor (TNF) set into motion has greatly increased in the past few years, making it possible to interfere with cytokines' signaling cascades.  The Janus kinase (JAK)/signal transducer and activator of transcription (STAT), the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), the mitogen activated protein kinase (MAPK) and the Phosphatidylinositol-3'-kinases (PI3K) pathways have all been intensively studied and key steps as well as mols. have been identified.  These research efforts have led to the development of a new generation of small mol. inhibitors.  Drugs capable of blocking JAK enzymic activity or interfering with the proteasome-mediated degrdn. of intermediates in the NF-kB pathway have already entered the clin. arena confirming the validity of this approach.  In this review, we have recapitulated the biochem. events downstream of cytokine receptors and discussed some of the drugs which have already been successfully utilized in the clinic.  Moreover, we have highlighted some of the new mols. that are currently being developed for the treatment of immune-mediated pathologies and malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDTXRNMB9IorVg90H21EOLACvtfcHk0li8KAAeRqfXmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFantL3J&md5=42c5e58da4a9d0b1e39e08bcc6875af4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.jaut.2017.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaut.2017.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DGazaniga%26aufirst%3DN.%26aulast%3DVian%26aufirst%3DL.%26aulast%3DFurumoto%26aufirst%3DY.%26atitle%3DSmall%2520molecules%2520to%2520the%2520rescue%253A%2520Inhibition%2520of%2520cytokine%2520signaling%2520in%2520immune-mediated%2520diseases%26jtitle%3DJ.%2520Autoimmun.%26date%3D2017%26volume%3D85%26spage%3D20%26epage%3D31%26doi%3D10.1016%2Fj.jaut.2017.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">843</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1038%2Fnrd.2017.201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=29104284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=843&author=D.+M.+Schwartzauthor=Y.+Kannoauthor=A.+Villarinoauthor=M.+Wardauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=JAK+inhibition+as+a+therapeutic+strategy+for+immune+and+inflammatory+diseases&doi=10.1038%2Fnrd.2017.201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Kanno, Yuka; Villarino, Alejandro; Ward, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">843-862</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts to target their assocd. signalling pathways.  Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines, and small-mol. inhibitors of JAKs (jakinibs) have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.  Building on the clin. success of first-generation jakinibs, second-generation compds. that claim to be more selective are currently undergoing development and proceeding to clin. trials.  However, important questions remain about the advantages and limitations of improved JAK selectivity, optimal routes and dosing regimens and how best to identify patients who will benefit from jakinibs.  This Review discusses the biol. of jakinibs from a translational perspective, focusing on recent insights from clin. trials, the development of novel agents and the use of jakinibs in a spectrum of immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TNpGT01l8rVg90H21EOLACvtfcHk0lg3HLfAF5JJ-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO&md5=4607422f83f94c0c7194935d6d460c31</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.201%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DVillarino%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJAK%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520for%2520immune%2520and%2520inflammatory%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D843%26doi%3D10.1038%2Fnrd.2017.201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solimani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreschi, K.</span></span> <span> </span><span class="NLM_article-title">Emerging topical and systemic JAK inhibitors in dermatology</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2847</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2019.02847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.3389%2Ffimmu.2019.02847" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=31849996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVeqtbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=2847&author=F.+Solimaniauthor=K.+Meierauthor=K.+Ghoreschi&title=Emerging+topical+and+systemic+JAK+inhibitors+in+dermatology&doi=10.3389%2Ffimmu.2019.02847"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging topical and systemic JAK inhibitors in dermatology</span></div><div class="casAuthors">Solimani, Farzan; Meier, Katharina; Ghoreschi, Kamran</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2847</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Accumulating data on cellular and mol. pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity.  Examples are psoriasis and atopic dermatitis, two clin. and immunol. well-defined disorders.  Here, the elucidation of key pathogenic factors such as IL-17A/IL-23 on the one hand and IL-4/IL-13 on the other hand profoundly changed our therapeutic practice.  The knowledge on intracellular pathways and governing factors is shifting our attention to new druggable mols.  Multiple cytokine receptors signal through Janus kinases (JAKs) and assocd. signal transducer and activators of transcription (STATs).  Inhibition of JAKs can simultaneously block the function of multiple cytokines.  Therefore, JAK inhibitors (JAKi) are emerging as a new class of drugs, which in dermatol. can either be used systemically as oral drugs or locally in topical formulations.  Inhibition of JAKs has been shown to be effective in various skin disorders.  The first oral JAKi have been recently approved for the treatment of rheumatoid arthritis and psoriatic arthritis.  Currently, multiple inhibitors of the JAK/STAT pathway are being investigated for skin diseases like alopecia areata, atopic dermatitis, dermatomyositis, graft-vs.-host-disease, hidradenitis suppurativa, lichen planus, lupus erythematosus, psoriasis, and vitiligo.  Here, we aim to discuss the immunol. basis and current stage of development of JAKi in dermatol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2BP8439dq-7Vg90H21EOLACvtfcHk0lg3HLfAF5JJ-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVeqtbfE&md5=fb32839b61c2d3d61d5deb80d5098b72</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2019.02847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2019.02847%26sid%3Dliteratum%253Aachs%26aulast%3DSolimani%26aufirst%3DF.%26aulast%3DMeier%26aufirst%3DK.%26aulast%3DGhoreschi%26aufirst%3DK.%26atitle%3DEmerging%2520topical%2520and%2520systemic%2520JAK%2520inhibitors%2520in%2520dermatology%26jtitle%3DFront.%2520Immunol.%26date%3D2019%26volume%3D10%26spage%3D2847%26doi%3D10.3389%2Ffimmu.2019.02847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jesson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katkade, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span> <span> </span><span class="NLM_article-title">Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition</span>. <i>Pharmacol. Res. Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e00537</span> <span class="refDoi"> DOI: 10.1002/prp2.537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1002%2Fprp2.537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=31832202" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&author=M.+E.+Dowtyauthor=T.+H.+Linauthor=M.+I.+Jessonauthor=M.+Hegenauthor=D.+A.+Martinauthor=V.+Katkadeauthor=S.+Menonauthor=J.-B.+Telliez&title=Janus+kinase+inhibitors+for+the+treatment+of+rheumatoid+arthritis+demonstrate+similar+profiles+of+in+vitro+cytokine+receptor+inhibition&doi=10.1002%2Fprp2.537"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fprp2.537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.537%26sid%3Dliteratum%253Aachs%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DD.%2BA.%26aulast%3DKatkade%26aufirst%3DV.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DJanus%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%2520demonstrate%2520similar%2520profiles%2520of%2520in%2520vitro%2520cytokine%2520receptor%2520inhibition%26jtitle%3DPharmacol.%2520Res.%2520Perspect.%26date%3D2019%26volume%3D7%26doi%3D10.1002%2Fprp2.537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferdinand, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Jak/STAT signaling in immunity and disease</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1401867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.4049%2Fjimmunol.1401867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=25527793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWls7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2015&pages=21-27&author=A.+V.+Villarinoauthor=Y.+Kannoauthor=J.+R.+Ferdinandauthor=J.+J.+O%E2%80%99Shea&title=Mechanisms+of+Jak%2FSTAT+signaling+in+immunity+and+disease&doi=10.4049%2Fjimmunol.1401867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Jak/STAT Signaling in Immunity and Disease</span></div><div class="casAuthors">Villarino, Alejandro V.; Kanno, Yuka; Ferdinand, John R.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-27</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">A review.  More than two decades ago, expts. on the antiviral mechanisms of IFNs led to the discovery of JAKs and their downstream effectors, the STAT proteins.  This pathway has since become a paradigm for membrane-to-nucleus signaling and explains how a broad range of sol. factors, including cytokines and hormones, mediate their diverse functions.  Jak/STAT research has not only impacted basic science, particularly in the context of intercellular communication and cell-extrinsic control of gene expression, it also has become a prototype for transition from bench to bedside, culminating in the development and clin. implementation of pathway-specific therapeutics.  This brief review synthesizes our current understanding of Jak/STAT biol. while taking stock of the lessons learned and the challenges that lie ahead.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotOsFFpF-ChLVg90H21EOLACvtfcHk0lg3HLfAF5JJ-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWls7rF&md5=777f0f64db038ca8a7f17554931e0655</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1401867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1401867%26sid%3Dliteratum%253Aachs%26aulast%3DVillarino%26aufirst%3DA.%2BV.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DFerdinand%26aufirst%3DJ.%2BR.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DMechanisms%2520of%2520Jak%252FSTAT%2520signaling%2520in%2520immunity%2520and%2520disease%26jtitle%3DJ.%2520Immunol.%26date%3D2015%26volume%3D194%26spage%3D21%26epage%3D27%26doi%3D10.4049%2Fjimmunol.1401867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macleod, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulagowski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin-Koh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span> <span> </span><span class="NLM_article-title">A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">2205</span>– <span class="NLM_lpage">2216</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1202859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.4049%2Fjimmunol.1202859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=23894201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=2205-2216&author=S.+J.+Sohnauthor=K.+Barrettauthor=A.+Van+Abbemaauthor=C.+Changauthor=P.+B.+Kohliauthor=H.+Kandaauthor=J.+Smithauthor=Y.+Laiauthor=A.+Zhouauthor=B.+Zhangauthor=W.+Yangauthor=K.+Williamsauthor=C.+Macleodauthor=C.+A.+Hurleyauthor=J.+J.+Kulagowskiauthor=N.+Lewin-Kohauthor=H.+S.+Denglerauthor=A.+R.+Johnsonauthor=N.+Ghilardiauthor=M.+Zakauthor=J.+Liangauthor=W.+S.+Blairauthor=S.+Magnusonauthor=L.+C.+Wu&title=A+restricted+role+for+TYK2+catalytic+activity+in+human+cytokine+responses+revealed+by+novel+TYK2-selective+inhibitors&doi=10.4049%2Fjimmunol.1202859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors</span></div><div class="casAuthors">Sohn, Sue J.; Barrett, Kathy; Van Abbema, Anne; Chang, Christine; Kohli, Pawan Bir; Kanda, Hidenobu; Smith, Janice; Lai, Yingjie; Zhou, Aihe; Zhang, Birong; Yang, Wenqian; Williams, Karen; MacLeod, Calum; Hurley, Christopher A.; Kulagowski, Janusz J.; Lewin-Koh, Nicholas; Dengler, Hart S.; Johnson, Adam R.; Ghilardi, Nico; Zak, Mark; Liang, Jun; Blair, Wade S.; Magnuson, Steven; Wu, Lawren C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2205-2216</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">TYK2 is a JAK family protein tyrosine kinase activated in response to multiple cytokines, including type I IFNs, IL-6, IL-10, IL-12, and IL-23.  Extensive studies of mice that lack TYK2 expression indicate that the IFN-α, IL-12, and IL-23 pathways, but not the IL-6 or IL-10 pathways, are compromised.  In contrast, there have been few studies of the role of TYK2 in primary human cells.  A genetic mutation at the tyk2 locus that results in a lack of TYK2 protein in a single human patient has been linked to defects in the IFN-α, IL-6, IL-10, IL-12, and IL-23 pathways, suggesting a broad role for TYK2 protein in human cytokine responses.  In this article, we have used a panel of novel potent TYK2 small-mol. inhibitors with varying degrees of selectivity against other JAK kinases to address the requirement for TYK2 catalytic activity in cytokine pathways in primary human cells.  Our results indicate that the biol. processes that require TYK2 catalytic function in humans are restricted to the IL-12 and IL-23 pathways, and suggest that inhibition of TYK2 catalytic activity may be an efficacious approach for the treatment of select autoimmune diseases without broad immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgACYZYW8b07Vg90H21EOLACvtfcHk0lh3GY6z0oXfBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtL%252FP&md5=527289e055e91fe2dfb15d3de7faa894</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1202859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1202859%26sid%3Dliteratum%253Aachs%26aulast%3DSohn%26aufirst%3DS.%2BJ.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DKanda%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DMacleod%26aufirst%3DC.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DLewin-Koh%26aufirst%3DN.%26aulast%3DDengler%26aufirst%3DH.%2BS.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DMagnuson%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DL.%2BC.%26atitle%3DA%2520restricted%2520role%2520for%2520TYK2%2520catalytic%2520activity%2520in%2520human%2520cytokine%2520responses%2520revealed%2520by%2520novel%2520TYK2-selective%2520inhibitors%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D2205%26epage%3D2216%26doi%3D10.4049%2Fjimmunol.1202859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dendrou, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attfield, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jostins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuttikkatte, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faergeman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheeseman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neville, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawcer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVean, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fugger, L.</span></span> <span> </span><span class="NLM_article-title">Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">363ra149</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aag1974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1126%2Fscitranslmed.aag1974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=27807284" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=363ra149&author=C.+A.+Dendrouauthor=A.+Cortesauthor=L.+Shipmanauthor=H.+G.+Evansauthor=K.+E.+Attfieldauthor=L.+Jostinsauthor=T.+Barberauthor=G.+Kaurauthor=S.+B.+Kuttikkatteauthor=O.+A.+Leachauthor=C.+Deselauthor=S.+L.+Faergemanauthor=J.+Cheesemanauthor=M.+J.+Nevilleauthor=S.+Sawcerauthor=A.+Compstonauthor=A.+R.+Johnsonauthor=C.+Everettauthor=J.+I.+Bellauthor=F.+Karpeauthor=M.+Ultschauthor=C.+Eigenbrotauthor=G.+McVeanauthor=L.+Fugger&title=Resolving+TYK2+locus+genotype-to-phenotype+differences+in+autoimmunity&doi=10.1126%2Fscitranslmed.aag1974"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aag1974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aag1974%26sid%3Dliteratum%253Aachs%26aulast%3DDendrou%26aufirst%3DC.%2BA.%26aulast%3DCortes%26aufirst%3DA.%26aulast%3DShipman%26aufirst%3DL.%26aulast%3DEvans%26aufirst%3DH.%2BG.%26aulast%3DAttfield%26aufirst%3DK.%2BE.%26aulast%3DJostins%26aufirst%3DL.%26aulast%3DBarber%26aufirst%3DT.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DKuttikkatte%26aufirst%3DS.%2BB.%26aulast%3DLeach%26aufirst%3DO.%2BA.%26aulast%3DDesel%26aufirst%3DC.%26aulast%3DFaergeman%26aufirst%3DS.%2BL.%26aulast%3DCheeseman%26aufirst%3DJ.%26aulast%3DNeville%26aufirst%3DM.%2BJ.%26aulast%3DSawcer%26aufirst%3DS.%26aulast%3DCompston%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DBell%26aufirst%3DJ.%2BI.%26aulast%3DKarpe%26aufirst%3DF.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DMcVean%26aufirst%3DG.%26aulast%3DFugger%26aufirst%3DL.%26atitle%3DResolving%2520TYK2%2520locus%2520genotype-to-phenotype%2520differences%2520in%2520autoimmunity%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26spage%3D363ra149%26doi%3D10.1126%2Fscitranslmed.aag1974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hundhausen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinsman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkatkar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allenspach, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clough, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eken, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oukka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerosaletti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckner, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlings, D. J.</span></span> <span> </span><span class="NLM_article-title">The TYK2-P1104A autoimmune protective variant limits coordinate signals required to generate specialized T cell subsets</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">44</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2019.00044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.3389%2Ffimmu.2019.00044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=30740104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlWktLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=44&author=J.+A.+Gormanauthor=C.+Hundhausenauthor=M.+Kinsmanauthor=T.+Arkatkarauthor=E.+J.+Allenspachauthor=C.+Cloughauthor=S.+E.+Westauthor=K.+Thomasauthor=A.+Ekenauthor=S.+Khimauthor=M.+Haleauthor=M.+Oukkaauthor=S.+W.+Jacksonauthor=K.+Cerosalettiauthor=J.+H.+Bucknerauthor=D.+J.+Rawlings&title=The+TYK2-P1104A+autoimmune+protective+variant+limits+coordinate+signals+required+to+generate+specialized+T+cell+subsets&doi=10.3389%2Ffimmu.2019.00044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The TYK2-P1104A autoimmune protective variant limits coordinate signals required to generate specialized T cell subsets</span></div><div class="casAuthors">Gorman, Jacquelyn A.; Hundhausen, Christian; Kinsman, Mackenzie; Arkatkar, Tanvi; Allenspach, Eric J.; Clough, Courtnee; West, Samuel E.; Thomas, Kerri; Eken, Ahmet; Khim, Socheath; Hale, Malika; Oukka, Mohamed; Jackson, Shaun W.; Cerosaletti, Karen; Buckner, Jane H.; Rawlings, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">44</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">TYK2 is a JAK family member that functions downstream of multiple cytokine receptors.  Genome wide assocn. studies have linked a SNP (rs34536443) within TYK2 encoding a Proline to Alanine substitution at amino acid 1104, to protection from multiple autoimmune diseases including systemic lupus erythematosus (SLE) and multiple sclerosis (MS).  The protective role of this SNP in autoimmune pathogenesis, however, remains incompletely understood.  Here we found that T follicular helper (Tfh) cells, switched memory B cells, and IFNAR signaling were decreased in healthy individuals that expressed the protective variant TYK2A1104 (TYK2P).  To study this variant in vivo, we developed a knock-in murine model of this allele.  Murine Tyk2P expressing T cells homozygous for the protective allele, but not cells heterozygous for this change, manifest decreased IL-12 receptor signaling, important for Tfh lineage commitment.  Further, homozygous Tyk2P T cells exhibited diminished in vitro Th1 skewing.  Surprisingly, despite these signaling changes, in vivo formation of Tfh and GC B cells was unaffected in two models of T cell dependent immune responses and in two alternative SLE models.  TYK2 is also activated downstream of IL-23 receptor engagement.  Here, we found that Tyk2P expressing T cells had reduced IL-23 dependent signaling as well as a diminished ability to skew toward Th17 in vitro.  Consistent with these findings, homozygous, but not heterozygous, Tyk2P mice were fully protected in a murine model of MS.  Homozygous Tyk2P mice had fewer infiltrating CD4+ T cells within the CNS.  Most strikingly, homozygous mice had a decreased proportion of IL-17+/IFNg+, double pos., pathogenic CD4+ T cells in both the draining lymph nodes (LN) and CNS.  Thus, in an autoimmunemodel, such as EAE, impacted by both altered Th1 and Th17 signaling, the Tyk2P allele can effectively shield animals from disease.  Taken together, our findings suggest that TYK2P diminishes IL-12, IL-23, and IFN I signaling and that its protective effect is most likely manifest in the setting of autoimmune triggers that concurrently dysregulate at least two of these important signaling cascades.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNTbSApKHwTrVg90H21EOLACvtfcHk0lh3GY6z0oXfBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlWktLnK&md5=ec37d6c20f9eac5eba980e5078da862a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2019.00044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2019.00044%26sid%3Dliteratum%253Aachs%26aulast%3DGorman%26aufirst%3DJ.%2BA.%26aulast%3DHundhausen%26aufirst%3DC.%26aulast%3DKinsman%26aufirst%3DM.%26aulast%3DArkatkar%26aufirst%3DT.%26aulast%3DAllenspach%26aufirst%3DE.%2BJ.%26aulast%3DClough%26aufirst%3DC.%26aulast%3DWest%26aufirst%3DS.%2BE.%26aulast%3DThomas%26aufirst%3DK.%26aulast%3DEken%26aufirst%3DA.%26aulast%3DKhim%26aufirst%3DS.%26aulast%3DHale%26aufirst%3DM.%26aulast%3DOukka%26aufirst%3DM.%26aulast%3DJackson%26aufirst%3DS.%2BW.%26aulast%3DCerosaletti%26aufirst%3DK.%26aulast%3DBuckner%26aufirst%3DJ.%2BH.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520TYK2-P1104A%2520autoimmune%2520protective%2520variant%2520limits%2520coordinate%2520signals%2520required%2520to%2520generate%2520specialized%2520T%2520cell%2520subsets%26jtitle%3DFront.%2520Immunol.%26date%3D2019%26volume%3D10%26spage%3D44%26doi%3D10.3389%2Ffimmu.2019.00044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaghi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callis, K. D.</span></span> <span> </span><span class="NLM_article-title">Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis</span>. <i>J. Drugs Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">160</span>– <span class="NLM_lpage">167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=22270196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVGisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=160-167&author=D.+Zaghiauthor=G.+G.+Kruegerauthor=K.+D.+Callis&title=Ustekinumab%3A+a+review+in+the+treatment+of+plaque+psoriasis+and+psoriatic+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis</span></div><div class="casAuthors">Zaghi, Daniel; Krueger, Gerald G.; Duffin, Kristina Callis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drugs in Dermatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">160-167</span>CODEN:
                <span class="NLM_cas:coden">JDDOBA</span>;
        ISSN:<span class="NLM_cas:issn">1545-9616</span>.
    
            (<span class="NLM_cas:orgname">Journal of Drugs in Dermatology</span>)
        </div><div class="casAbstract">A review.  Psoriasis is a complex, multigenic immune/inflammatory-mediated disorder that variably affects the skin, nails, and joints.  In Sept. 2009, ustekinumab (Stelara), a monoclonal antibody that targets interleukin 12 (IL-12) and 23 (IL-23), was approved in the United States for treatment of moderate-to-severe plaque psoriasis.  The drug's mechanism of action is derived from extensive immunol. and genomic research identifying IL-12 and IL-23 of the Th1 and Th17 inflammatory pathways, resp., as key mediators of psoriasis.  Ustekinumab is a completely human monoclonal antibody to the shared p40 subunit of IL-12 and IL-23.  The drug has demonstrated efficacy, short-term safety, and convenience of use in the treatment of plaque psoriasis and psoriatic arthritis.  Though long-term safety concerns remain, ustekinumab adds to the current treatment armamentarium and holds promise to improve quality of life.  This is a concise and current review of ustekinumab in the treatment of plaque psoriasis and psoriatic arthritis, with focus on data from the seven published clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryI6jNhNzbaLVg90H21EOLACvtfcHk0lgKDR1MELZuUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVGisb4%253D&md5=0a7bc928380d0ef2ce2d0340e6d9a86f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZaghi%26aufirst%3DD.%26aulast%3DKrueger%26aufirst%3DG.%2BG.%26aulast%3DCallis%26aufirst%3DK.%2BD.%26atitle%3DUstekinumab%253A%2520a%2520review%2520in%2520the%2520treatment%2520of%2520plaque%2520psoriasis%2520and%2520psoriatic%2520arthritis%26jtitle%3DJ.%2520Drugs%2520Dermatol.%26date%3D2012%26volume%3D11%26spage%3D160%26epage%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, S. T.</span></span> <span> </span><span class="NLM_article-title">Ustekinumab: A review in moderate to severe Crohn’s disease</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1105</span>– <span class="NLM_lpage">1114</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0765-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1007%2Fs40265-017-0765-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=28528528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVOktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1105-1114&author=Y.+N.+Lambauthor=S.+T.+Duggan&title=Ustekinumab%3A+A+review+in+moderate+to+severe+Crohn%E2%80%99s+disease&doi=10.1007%2Fs40265-017-0765-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Ustekinumab: A Review in Moderate to Severe Crohn's Disease</span></div><div class="casAuthors">Lamb, Yvette N.; Duggan, Sean T.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1105-1114</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Ustekinumab (Stelara) has been recently approved in the EU and the USA as i.v. induction and s.c. maintenance therapy for adult patients with moderately to severely active Crohn's disease who have failed or were intolerant to treatment with immunomodulators, corticosteroids or at least one tumor necrosis factor (TNF) antagonist.  Ustekinumab, a monoclonal antibody to the shared p40 subunit of the proinflammatory interleukin (IL)-12 and IL-23 cytokines, has a unique mechanism of action distinct from that of TNF antagonists.  In pivotal phase III trials, compared with placebo, ustekinumab induction therapy improved clin. response and remission rates in patients who had previously failed or were intolerant to conventional therapies or at least one TNF antagonist.  When administered as s.c. maintenance therapy, ustekinumab continued to offer benefits over placebo for clin. response and remission in patients who had clin. responded to the induction therapy.  Ustekinumab was generally well tolerated as both induction and maintenance therapy; serious infections and malignancies were rare.  Thus, ustekinumab presents a promising alternative treatment option in patients with moderately to severely active Crohn's disease who have failed or are intolerant to treatment with conventional therapies or TNF antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4ftg-dQNuBbVg90H21EOLACvtfcHk0lgKDR1MELZuUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVOktb8%253D&md5=eb377509b791b9b9e182a73d2a85f395</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0765-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0765-6%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DY.%2BN.%26aulast%3DDuggan%26aufirst%3DS.%2BT.%26atitle%3DUstekinumab%253A%2520A%2520review%2520in%2520moderate%2520to%2520severe%2520Crohn%25E2%2580%2599s%2520disease%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1105%26epage%3D1114%26doi%3D10.1007%2Fs40265-017-0765-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sands, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandborn, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panaccione, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johanns, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adedokun, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyrin-Biroulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Assche, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danese, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Targan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abreu, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hisamatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szapary, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marano, C.</span></span> <span> </span><span class="NLM_article-title">Ustekinumab as induction and maintenance therapy for ulcerative colitis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>381</i></span>,  <span class="NLM_fpage">1201</span>– <span class="NLM_lpage">1214</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1900750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1056%2FNEJMoa1900750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=31553833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFWnsbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2019&pages=1201-1214&author=B.+E.+Sandsauthor=W.+J.+Sandbornauthor=R.+Panaccioneauthor=C.+D.+O%E2%80%99Brienauthor=H.+Zhangauthor=J.+Johannsauthor=O.+J.+Adedokunauthor=K.+Liauthor=L.+Peyrin-Birouletauthor=G.+Van+Asscheauthor=S.+Daneseauthor=S.+Targanauthor=M.+T.+Abreuauthor=T.+Hisamatsuauthor=P.+Szaparyauthor=C.+Marano&title=Ustekinumab+as+induction+and+maintenance+therapy+for+ulcerative+colitis&doi=10.1056%2FNEJMoa1900750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Ustekinumab as induction and maintenance therapy for ulcerative colitis</span></div><div class="casAuthors">Sands, B. E.; Sandborn, W. J.; Panaccione, R.; O'Brien, C. D.; Zhang, H.; Johanns, J.; Adedokun, O. J.; Li, K.; Peyrin-Biroulet, L.; Van Assche, G.; Danese, S.; Targan, S.; Abreu, M. T.; Hisamatsu, T.; Szapary, P.; Marano, C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1201-1214</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The efficacy of ustekinumab, an antagonist of the p40 subunit of interleukin-12 and interleukin-23, as induction and maintenance therapy in patients with ulcerative colitis is unknown.  We evaluated ustekinumab as 8-wk induction therapy and 44-wk maintenance therapy in patients with moderate-to-severe ulcerative colitis.  A total of 961 patients were randomly assigned to receive an i.v. induction dose of ustekinumab (either 130 mg [320 patients] or a wt.-range-based dose that approximated 6 mg per kg of body wt. [322]) or placebo (319).  Patients who had a response to induction therapy 8 wk after administration of i.v. ustekinumab were randomly assigned again to receive s.c. maintenance injections of 90 mg of ustekinumab (either every 12 wk [172 patients] or every 8 wk [176]) or placebo (175).  The primary end point in the induction trial (week 8) and the maintenance trial (week 44) was clin. remission (defined as a total score of ≤2 on the Mayo scale [range, 0 to 12, with higher scores indicating more severe disease] and no subscore >1 [range, 0 to 3] on any of the four Mayo scale components).  The percentage of patients who had clin. remission at week 8 among patients who received i.v. ustekinumab at a dose of 130 mg (15.6%) or 6 mg per kg (15.5%) was significantly higher than that among patients who received placebo (5.3%) (P lesser than 0.001 for both comparisons).  Among patients who had a response to induction therapy with ustekinumab and underwent a second randomization, the percentage of patients who had clin. remission at week 44 was significantly higher among patients assigned to 90 mg of s.c. ustekinumab every 12 wk (38.4%) or every 8 wk (43.8%) than among those assigned to placebo (24.0%) (P = 0.002 and P lesser than 0.001, resp.).  The incidence of serious adverse events with ustekinumab was similar to that with placebo.  Through 52 wk of exposure, there were two deaths (one each from acute respiratory distress syndrome and hemorrhage from esophageal varices) and seven cases of cancer (one each of prostate, colon, renal papillary, and rectal cancer and three nonmelanoma skin cancers) among 825 patients who received ustekinumab and no deaths and one case of cancer (testicular cancer) among 319 patients who received placebo.  Ustekinumab was more effective than placebo for inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzZGJKBq2nqbVg90H21EOLACvtfcHk0lgKDR1MELZuUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFWnsbbE&md5=389d274cfa9d808851957367c4900db2</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1900750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1900750%26sid%3Dliteratum%253Aachs%26aulast%3DSands%26aufirst%3DB.%2BE.%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DPanaccione%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%2BD.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DJohanns%26aufirst%3DJ.%26aulast%3DAdedokun%26aufirst%3DO.%2BJ.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DPeyrin-Biroulet%26aufirst%3DL.%26aulast%3DVan%2BAssche%26aufirst%3DG.%26aulast%3DDanese%26aufirst%3DS.%26aulast%3DTargan%26aufirst%3DS.%26aulast%3DAbreu%26aufirst%3DM.%2BT.%26aulast%3DHisamatsu%26aufirst%3DT.%26aulast%3DSzapary%26aufirst%3DP.%26aulast%3DMarano%26aufirst%3DC.%26atitle%3DUstekinumab%2520as%2520induction%2520and%2520maintenance%2520therapy%2520for%2520ulcerative%2520colitis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D381%26spage%3D1201%26epage%3D1214%26doi%3D10.1056%2FNEJMoa1900750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhutani, T.</span></span> <span> </span><span class="NLM_article-title">Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1993</span>– <span class="NLM_lpage">2000</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S137588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.2147%2FDDDT.S137588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=31354244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVykurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=1993-2000&author=E.+J.+Yangauthor=M.+P.+Smithauthor=K.+Lyauthor=T.+Bhutani&title=Evaluating+guselkumab%3A+an+anti-IL-23+antibody+for+the+treatment+of+plaque+psoriasis&doi=10.2147%2FDDDT.S137588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis</span></div><div class="casAuthors">Yang, Eric J.; Smith, Mary Patricia; Ly, Karen; Bhutani, Tina</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1993-2000</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">The approval of guselkumab marks the entry of the IL-23 inhibitor class into the therapeutic armamentarium for patients with moderate-to-severe plaque psoriasis.  This class specifically targets the upstream portion of the type 17 helper T (Th17) axis, which has been implicated as a key driver of the abnormal inflammatory state obsd. in psoriasis.  Guselkumab is highly efficacious, with over 85% of the patients achieving ≥ 75% redn. in Psoriasis Area and Severity Index from baseline (PASI 75) and over 70% of the patients achieving PASI 90 response in its Phase III clin. trials.  Addnl., this medication is well-tolerated, with non-serious infections such as nasopharyngitis and upper respiratory infections (URIs) being the most common adverse events (AEs) reported in its clin. trials.  Guselkumab offers yet another effective treatment option in the rapidly growing list of available biol. therapies for moderate-to-severe plaque psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor83KSz_qbTLVg90H21EOLACvtfcHk0ljcsvjjoMx50Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVykurk%253D&md5=48634c9b116dfd58ba54e8d290e1054a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S137588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S137588%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DE.%2BJ.%26aulast%3DSmith%26aufirst%3DM.%2BP.%26aulast%3DLy%26aufirst%3DK.%26aulast%3DBhutani%26aufirst%3DT.%26atitle%3DEvaluating%2520guselkumab%253A%2520an%2520anti-IL-23%2520antibody%2520for%2520the%2520treatment%2520of%2520plaque%2520psoriasis%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2019%26volume%3D13%26spage%3D1993%26epage%3D2000%26doi%3D10.2147%2FDDDT.S137588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blauvelt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukhalo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooderham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacour, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philipp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyring, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berner, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visvanathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pamulapati, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flack, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padula, S. J.</span></span> <span> </span><span class="NLM_article-title">Risankizumab versus Ustekinumab for moderate-to-severe plaque psoriasis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">1551</span>– <span class="NLM_lpage">1560</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1607017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1056%2FNEJMoa1607017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=28423301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOnsb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2017&pages=1551-1560&author=K.+A.+Pappauthor=A.+Blauveltauthor=M.+Bukhaloauthor=M.+Gooderhamauthor=J.+G.+Kruegerauthor=J.-P.+Lacourauthor=A.+Menterauthor=S.+Philippauthor=H.+Sofenauthor=S.+Tyringauthor=B.+R.+Bernerauthor=S.+Visvanathanauthor=C.+Pamulapatiauthor=N.+Bennettauthor=M.+Flackauthor=P.+Schollauthor=S.+J.+Padula&title=Risankizumab+versus+Ustekinumab+for+moderate-to-severe+plaque+psoriasis&doi=10.1056%2FNEJMoa1607017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis</span></div><div class="casAuthors">Papp, Kim A.; Blauvelt, Andrew; Bukhalo, Michael; Gooderham, Melinda; Krueger, James; Lacour, Jean-Philippe; Menter, Alan; Philipp, Sandra; Sofen, Howard; Tyring, Stephen; Berner, Beate R.; Visvanathan, Sudha; Pamulapati, Chandrasena; Bennett, Nathan; Flack, Mary; Scholl, Paul; Padula, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1551-1560</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Interleukin-23 is thought to be crit. to the pathogenesis of psoriasis.  We compared risankizumab (BI 655066), a humanized IgG1 monoclonal antibody that inhibits interleukin-23 by specifically targeting the p19 subunit and thus prevents interleukin-23 signaling, and ustekinumab, an interleukin-12 and interleukin-23 inhibitor, in patients with moderate-to-severe plaque psoriasis.  METHODS We randomly assigned a total of 166 patients to receive s.c. injections of risankizumab (a single 18-mg dose at week 0 or 90-mg or 180-mg doses at weeks 0, 4, and 16) or ustekinumab (45 or 90 mg, according to body wt., at weeks 0, 4, and 16).  The primary end point was a 90% or greater redn. from baseline in the Psoriasis Area and Severity Index (PASI) score at week 12.  RESULTS At week 12, the percentage of patients with a 90% or greater redn. in the PASI score was 77% (64 of 83 patients) for risankizumab (90-mg and 180-mg groups, pooled), as compared with 40% (16 of 40 patients) for ustekinumab (P<0.001); the percentage of patients with a 100% redn. in the PASI score was 45% in the pooled 90-mg and 180-mg risankizumab groups, as compared with 18% in the ustekinumab group.  Efficacy was generally maintained up to 20 wk after the final dose of 90 or 180 mg of risankizumab.  In the 18-mg and 90-mg risankizumab groups and the ustekinumab group, 5 patients (12%), 6 patients (15%), and 3 patients (8%), resp., had serious adverse events, including two basal-cell carcinomas and one major cardiovascular adverse event; there were no serious adverse events in the 180-mg risankizumab group.  CONCLUSIONS In this phase 2 trial, selective blockade of interleukin-23 with risankizumab was assocd. with clin. responses superior to those assocd. with ustekinumab.  This trial was not large enough or of long enough duration to draw conclusions about safety. (Funded by Boehringer Ingelheim; ClinicalTrials.gov no., NCT02054481).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9P87OIwFs5rVg90H21EOLACvtfcHk0ljcsvjjoMx50Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOnsb%252FI&md5=fa36a543b578ddc52d8c9ac7983f996c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1607017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1607017%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DBlauvelt%26aufirst%3DA.%26aulast%3DBukhalo%26aufirst%3DM.%26aulast%3DGooderham%26aufirst%3DM.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26aulast%3DLacour%26aufirst%3DJ.-P.%26aulast%3DMenter%26aufirst%3DA.%26aulast%3DPhilipp%26aufirst%3DS.%26aulast%3DSofen%26aufirst%3DH.%26aulast%3DTyring%26aufirst%3DS.%26aulast%3DBerner%26aufirst%3DB.%2BR.%26aulast%3DVisvanathan%26aufirst%3DS.%26aulast%3DPamulapati%26aufirst%3DC.%26aulast%3DBennett%26aufirst%3DN.%26aulast%3DFlack%26aufirst%3DM.%26aulast%3DScholl%26aufirst%3DP.%26aulast%3DPadula%26aufirst%3DS.%2BJ.%26atitle%3DRisankizumab%2520versus%2520Ustekinumab%2520for%2520moderate-to-severe%2520plaque%2520psoriasis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D376%26spage%3D1551%26epage%3D1560%26doi%3D10.1056%2FNEJMoa1607017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X.-Y.</span></span> <span> </span><span class="NLM_article-title">Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1080/13543776.2019.1567713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1080%2F13543776.2019.1567713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=30621465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2kuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=137-149&author=X.+Heauthor=X.+Chenauthor=H.+Zhangauthor=T.+Xieauthor=X.-Y.+Ye&title=Selective+Tyk2+inhibitors+as+potential+therapeutic+agents%3A+a+patent+review+%282015%E2%80%932018%29&doi=10.1080%2F13543776.2019.1567713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018)</span></div><div class="casAuthors">He, Xingrui; Chen, Xiabin; Zhang, Hancheng; Xie, Tian; Ye, Xiang-Yang</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-149</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Tyrosine kinase 2 (Tyk2) is a non-receptor tyrosine-protein kinase, an enzyme that in humans is encoded by the TYK2 gene.  Tyk2, together with three other family subtypes, namely, Jak1, Jak2, and Jak3, belong to the JAK family.  Before 2014, far more publications and patents appeared in public domain attributing to the development of selective Jak2 and Jak3 inhibitors than those for selective Tyk2 and Jak1 inhibitors.  This review sought to give an overview of patents related to small mol. selective Tyk2 inhibitors published from 2015 to 2018.  The article also covers clin. activities of small mol. selective Tyk2 inhibitors in recent years.  As a key component of the JAK-STAT signaling pathway, Tyk2 regulates INFα, IL12, and IL23.  Selective inhibition of Tyk2 can provide pharmacol. benefits in the treatment of many diseases such as psoriasis, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), cancer, and diabetes.  The selectivity against other Jak family subtypes (such as Jak2) is crucial in order to minimize the potential side effects and to maximize the desired pharmacol. effects.  In this context, this review of recent selective Tyk2 inhibitor patents may prove valid, interesting, and promising within the therapeutic paradigm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrer4xPnKRtvrVg90H21EOLACvtfcHk0ljcsvjjoMx50Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2kuro%253D&md5=cf7fa5e5f7a92eb951886f7951f7da4b</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1080%2F13543776.2019.1567713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2019.1567713%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DYe%26aufirst%3DX.-Y.%26atitle%3DSelective%2520Tyk2%2520inhibitors%2520as%2520potential%2520therapeutic%2520agents%253A%2520a%2520patent%2520review%2520%25282015%25E2%2580%25932018%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2019%26volume%3D29%26spage%3D137%26epage%3D149%26doi%3D10.1080%2F13543776.2019.1567713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thaçi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooderham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girgis, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span> <span> </span><span class="NLM_article-title">Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">1313</span>– <span class="NLM_lpage">1321</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1806382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1056%2FNEJMoa1806382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=30205746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFWlsrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=1313-1321&author=K.+Pappauthor=K.+Gordonauthor=D.+Tha%C3%A7iauthor=A.+Moritaauthor=M.+Gooderhamauthor=P.+Foleyauthor=I.+G.+Girgisauthor=S.+Kunduauthor=S.+Banerjee&title=Phase+2+trial+of+selective+tyrosine+kinase+2+inhibition+in+psoriasis&doi=10.1056%2FNEJMoa1806382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis</span></div><div class="casAuthors">Papp, Kim; Gordon, Kenneth; Thaci, Diamant; Morita, Akimichi; Gooderham, Melinda; Foley, Peter; Girgis, Ihab G.; Kundu, Sudeep; Banerjee, Subhashis</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1313-1321</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Tyrosine kinase 2 (TYK2) signaling pathways, which mediate cytokine signaling, are implicated in the pathophysiol. of psoriasis.  Selective inhibitors of TYK2 may be effective in treating psoriasis. methods We conducted a phase 2, double-blind trial of a TYK2 inhibitor, BMS-986165, in adults with moderate-to-severe psoriasis, excluding patients with a previous lack of response to agents targeting cytokine signaling through the same tyrosine kinase pathway.  Patients were randomly assigned to receive the drug orally at a dose of 3 mg every other day, 3 mg daily, 3 mg twice daily, 6 mg twice daily, or 12 mg daily or to receive placebo.  The primary end point was a 75% or greater redn. from baseline in the Psoriasis Area and Severity Index (PASI) score at week 12 (higher scores indicate greater severity of psoriasis). results A total of 267 patients received at least one dose in an intervention group of the trial.  At week 12, the percentage of patients with a 75% or greater redn. in the PASI score was 7% (3 of 45 patients) with placebo, 9% (4 of 44 patients) with 3 mg of BMS-986165 every other day (P = 0.49 vs. placebo), 39% (17 of 44 patients) with 3 mg daily (P<0.001 vs. placebo), 69% (31 of 45 patients) with 3 mg twice daily (P<0.001 vs. placebo), 67% (30 of 45 patients) with 6 mg twice daily (P<0.001 vs. placebo), and 75% (33 of 44 patients) with 12 mg daily (P<0.001 vs. placebo).  There were three serious adverse events in patients receiving the active drug, as well as one case of malignant melanoma 96 days after the start of treatment. conclusions Selective inhibition of TYK2 with the oral agent BMS-986165 at doses of 3 mg daily and higher resulted in greater clearing of psoriasis than did placebo over a period of 12 wk.  Larger and longer-duration trials of this drug are required to det. its safety and durability of effect in patients with psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhqWANKhDdt7Vg90H21EOLACvtfcHk0lhhc5GO0fcxBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFWlsrbE&md5=ededd5d925dd557cceacc472839a966a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1806382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1806382%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%26aulast%3DGordon%26aufirst%3DK.%26aulast%3DTha%25C3%25A7i%26aufirst%3DD.%26aulast%3DMorita%26aufirst%3DA.%26aulast%3DGooderham%26aufirst%3DM.%26aulast%3DFoley%26aufirst%3DP.%26aulast%3DGirgis%26aufirst%3DI.%2BG.%26aulast%3DKundu%26aufirst%3DS.%26aulast%3DBanerjee%26aufirst%3DS.%26atitle%3DPhase%25202%2520trial%2520of%2520selective%2520tyrosine%2520kinase%25202%2520inhibition%2520in%2520psoriasis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D1313%26epage%3D1321%26doi%3D10.1056%2FNEJMoa1806382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catlett, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimalakonda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L. M.</span></span> <span> </span><span class="NLM_article-title">Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">eaaw1736</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aaw1736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1126%2Fscitranslmed.aaw1736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=31341059" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&author=J.+R.+Burkeauthor=L.+Chengauthor=K.+M.+Gilloolyauthor=J.+Strnadauthor=A.+Zupa-Fernandezauthor=I.+M.+Catlettauthor=Y.+Zhangauthor=E.+M.+Heimrichauthor=K.+W.+McIntyreauthor=M.+D.+Cunninghamauthor=J.+A.+Carmanauthor=X.+Zhouauthor=D.+Banasauthor=C.+Chaudhryauthor=S.+Liauthor=C.+D%E2%80%99Arienzoauthor=A.+Chimalakondaauthor=X.+Yangauthor=J.+H.+Xieauthor=J.+Pangauthor=Q.+Zhaoauthor=S.+M.+Roseauthor=J.+Huangauthor=R.+M.+Moslinauthor=S.+T.+Wrobleskiauthor=D.+S.+Weinsteinauthor=L.+M.+Salter-Cid&title=Autoimmune+pathways+in+mice+and+humans+are+blocked+by+pharmacological+stabilization+of+the+TYK2+pseudokinase+domain&doi=10.1126%2Fscitranslmed.aaw1736"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaw1736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaw1736%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCatlett%26aufirst%3DI.%2BM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%2BM.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DCunningham%26aufirst%3DM.%2BD.%26aulast%3DCarman%26aufirst%3DJ.%2BA.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DBanas%26aufirst%3DD.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DJ.%2BH.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DRose%26aufirst%3DS.%2BM.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DMoslin%26aufirst%3DR.%2BM.%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26aulast%3DSalter-Cid%26aufirst%3DL.%2BM.%26atitle%3DAutoimmune%2520pathways%2520in%2520mice%2520and%2520humans%2520are%2520blocked%2520by%2520pharmacological%2520stabilization%2520of%2520the%2520TYK2%2520pseudokinase%2520domain%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26doi%3D10.1126%2Fscitranslmed.aaw1736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span> <span> </span><span class="NLM_article-title">Selective Janus kinase inhibitors come of age</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1038/s41584-018-0155-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1038%2Fs41584-018-0155-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=30622297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A280%3ADC%252BB3cnptlegtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=74-75&author=J.+J.+O%E2%80%99Sheaauthor=M.+Gadina&title=Selective+Janus+kinase+inhibitors+come+of+age&doi=10.1038%2Fs41584-018-0155-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Janus kinase inhibitors come of age</span></div><div class="casAuthors">O'Shea John J; Gadina Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Rheumatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">74-75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQ5b1SiSXp96_dlEzl_fBafW6udTcc2eYjtYjK3ilQe7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnptlegtg%253D%253D&md5=3bd9525750aa0109f8eaafd4adfe34dc</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fs41584-018-0155-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41584-018-0155-9%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DGadina%26aufirst%3DM.%26atitle%3DSelective%2520Janus%2520kinase%2520inhibitors%2520come%2520of%2520age%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2019%26volume%3D15%26spage%3D74%26epage%3D75%26doi%3D10.1038%2Fs41584-018-0155-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hosseini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharibi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marofi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javadian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babaloo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baradaran, B.</span></span> <span> </span><span class="NLM_article-title">Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>235</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">5903</span>– <span class="NLM_lpage">5924</span>, <span class="refDoi"> DOI: 10.1002/jcp.29593</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1002%2Fjcp.29593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=32072644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtF2nsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=2020&pages=5903-5924&issue=9&author=A.+Hosseiniauthor=T.+Gharibiauthor=F.+Marofiauthor=M.+Javadianauthor=Z.+Babalooauthor=B.+Baradaran&title=Janus+kinase+inhibitors%3A+A+therapeutic+strategy+for+cancer+and+autoimmune+diseases&doi=10.1002%2Fjcp.29593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases</span></div><div class="casAuthors">Hosseini, Arezoo; Gharibi, Tohid; Marofi, Faroogh; Javadian, Mahsa; Babaloo, Zohreh; Baradaran, Behzad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">235</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5903-5924</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Many cytokines are crucial drivers of cancers and autoimmune conditions.  These proteins bind to receptors and signal their responses through Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways.  Genetic variations in the JAK-STAT pathway are correlated with the increased risk of cancers, autoimmunity as well as inflammatory diseases.  Targeting JAKs and STATs can be a safe and efficacious strategy for treating these diseases.  Tofacitinib, as the first JAK inhibitor, is approved for rheumatoid arthritis therapy.  Also, many other JAK inhibitors have been proven or are in various phases of clin. trials for various diseases.  At present, small-mol. JAK inhibitors are considered as a novel category of drugs in the treatment of cancer and immune-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAwlkagGvd-rVg90H21EOLACvtfcHk0lgYHb-OlyA-bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtF2nsbg%253D&md5=8b4a5345f83894bc751e5e1d5d4b317f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fjcp.29593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.29593%26sid%3Dliteratum%253Aachs%26aulast%3DHosseini%26aufirst%3DA.%26aulast%3DGharibi%26aufirst%3DT.%26aulast%3DMarofi%26aufirst%3DF.%26aulast%3DJavadian%26aufirst%3DM.%26aulast%3DBabaloo%26aufirst%3DZ.%26aulast%3DBaradaran%26aufirst%3DB.%26atitle%3DJanus%2520kinase%2520inhibitors%253A%2520A%2520therapeutic%2520strategy%2520for%2520cancer%2520and%2520autoimmune%2520diseases%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2020%26volume%3D235%26issue%3D9%26spage%3D5903%26epage%3D5924%26doi%3D10.1002%2Fjcp.29593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimalakonda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune siseases: Discovery of the allosteric inhibitor BMS-986165</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8973</span>– <span class="NLM_lpage">8995</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00444</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00444" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlyht7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8973-8995&author=S.+T.+Wrobleskiauthor=R.+Moslinauthor=S.+Linauthor=Y.+Zhangauthor=S.+Spergelauthor=J.+Kempsonauthor=J.+S.+Tokarskiauthor=J.+Strnadauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=D.+Shusterauthor=K.+Gilloolyauthor=X.+Yangauthor=E.+Heimrichauthor=K.+W.+McIntyreauthor=C.+Chaudhryauthor=J.+Khanauthor=M.+Ruzanovauthor=J.+Tredupauthor=D.+Mulliganauthor=D.+Xieauthor=H.+Sunauthor=C.+Huangauthor=C.+D%E2%80%99Arienzoauthor=N.+Aranibarauthor=M.+Chineyauthor=A.+Chimalakondaauthor=W.+J.+Pittsauthor=L.+Lombardoauthor=P.+H.+Carterauthor=J.+R.+Burkeauthor=D.+S.+Weinstein&title=Highly+selective+inhibition+of+tyrosine+kinase+2+%28TYK2%29+for+the+treatment+of+autoimmune+siseases%3A+Discovery+of+the+allosteric+inhibitor+BMS-986165&doi=10.1021%2Facs.jmedchem.9b00444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165</span></div><div class="casAuthors">Wrobleski, Stephen T.; Moslin, Ryan; Lin, Shuqun; Zhang, Yanlei; Spergel, Steven; Kempson, James; Tokarski, John S.; Strnad, Joann; Zupa-Fernandez, Adriana; Cheng, Lihong; Shuster, David; Gillooly, Kathleen; Yang, Xiaoxia; Heimrich, Elizabeth; McIntyre, Kim W.; Chaudhry, Charu; Khan, Javed; Ruzanov, Max; Tredup, Jeffrey; Mulligan, Dawn; Xie, Dianlin; Sun, Huadong; Huang, Christine; D'Arienzo, Celia; Aranibar, Nelly; Chiney, Manoj; Chimalakonda, Anjaneya; Pitts, William J.; Lombardo, Louis; Carter, Percy H.; Burke, James R.; Weinstein, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8973-8995</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases.  The discovery of isoform selective JAK inhibitors that traditionally target the catalytically active site of this kinase family has been a formidable challenge.  Our strategy to achieve high selectivity for TYK2 relies on targeting the TYK2 pseudokinase (JH2) domain.  Herein we report the late stage optimization efforts including a structure-guided design and water displacement strategy that led to the discovery of BMS-986165 (11, I) as a high affinity JH2 ligand and potent allosteric inhibitor of TYK2.  In addn. to unprecedented JAK isoform and kinome selectivity, I shows excellent pharmacokinetic properties with minimal profiling liabilities and is efficacious in several murine models of autoimmune disease.  On the basis of these findings, I appears differentiated from all other reported JAK inhibitors and has been advanced as the first pseudokinase-directed therapeutic in clin. development as an oral treatment for autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmA75TJmytlrVg90H21EOLACvtfcHk0liNbisL3nvDgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlyht7%252FP&md5=ca161c470df002b0bdd2bf6b19920ada</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00444%26sid%3Dliteratum%253Aachs%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DKempson%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DShuster%26aufirst%3DD.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DRuzanov%26aufirst%3DM.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DMulligan%26aufirst%3DD.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DChiney%26aufirst%3DM.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DLombardo%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DHighly%2520selective%2520inhibition%2520of%2520tyrosine%2520kinase%25202%2520%2528TYK2%2529%2520for%2520the%2520treatment%2520of%2520autoimmune%2520siseases%253A%2520Discovery%2520of%2520the%2520allosteric%2520inhibitor%2520BMS-986165%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8973%26epage%3D8995%26doi%3D10.1021%2Facs.jmedchem.9b00444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span>An Investigational
Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo
and a Currently Available Treatment in Participants With Moderate-to-Severe
Plaque Psoriasis. ClinicalTrials.gov. U.S. National Institutes of
Health, Bethesda, MD, 2020; NCT03611751. <a href="https://clinicaltrials.gov/ct2/show/NCT03611751" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03611751</a> (accessed Aug 2, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=An+Investigational%0AStudy+to+Evaluate+Experimental+Medication+BMS-986165+Compared+to+Placebo%0Aand+a+Currently+Available+Treatment+in+Participants+With+Moderate-to-Severe%0APlaque+Psoriasis.+ClinicalTrials.gov.+U.S.+National+Institutes+of%0AHealth%2C+Bethesda%2C+MD%2C+2020%3B+NCT03611751.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03611751+%28accessed+Aug+2%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalsamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limburg, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Z.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8597</span>– <span class="NLM_lpage">8612</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8597-8612&author=A.+Fensomeauthor=C.+M.+Amblerauthor=E.+Arnoldauthor=M.+E.+Bankerauthor=M.+F.+Brownauthor=J.+Chrencikauthor=J.+D.+Clarkauthor=M.+E.+Dowtyauthor=I.+V.+Efremovauthor=A.+Flickauthor=B.+S.+Gerstenbergerauthor=A.+Gopalsamyauthor=M.+M.+Haywardauthor=M.+Hegenauthor=B.+D.+Hollingsheadauthor=J.+Jussifauthor=J.+D.+Knafelsauthor=D.+C.+Limburgauthor=D.+Linauthor=T.+H.+Linauthor=B.+S.+Pierceauthor=E.+Saiahauthor=R.+Sharmaauthor=P.+T.+Symanowiczauthor=J.-B.+Telliezauthor=J.+I.+Trujilloauthor=F.+F.+Vajdosauthor=F.+Vincentauthor=Z.-K.+Wanauthor=L.+Xingauthor=X.+Yangauthor=X.+Yangauthor=L.+Zhang&title=Dual+inhibition+of+TYK2+and+JAK1+for+the+treatment+of+autoimmune+diseases%3A+Discovery+of+%28%28S%29-2%2C2-Difluorocyclopropyl%29%28%281R%2C5S%29-3-%282-%28%281-methyl-1H-pyrazol-4-yl%29amino%29pyrimidin-4-yl%29-3%2C8-diazabicyclo%5B3.2.1%5Doctan-8-yl%29methanone+%28PF-06700841%29&doi=10.1021%2Facs.jmedchem.8b00917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span></div><div class="casAuthors">Fensome, Andrew; Ambler, Catherine M.; Arnold, Eric; Banker, Mary Ellen; Brown, Matthew F.; Chrencik, Jill; Clark, James D.; Dowty, Martin E.; Efremov, Ivan V.; Flick, Andrew; Gerstenberger, Brian S.; Gopalsamy, Ariamala; Hayward, Matthew M.; Hegen, Martin; Hollingshead, Brett D.; Jussif, Jason; Knafels, John D.; Limburg, David C.; Lin, David; Lin, Tsung H.; Pierce, Betsy S.; Saiah, Eddine; Sharma, Raman; Symanowicz, Peter T.; Telliez, Jean-Baptiste; Trujillo, John I.; Vajdos, Felix F.; Vincent, Fabien; Wan, Zhao-Kui; Xing, Li; Yang, Xiaojing; Yang, Xin; Zhang, Liying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8597-8612</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cytokine signaling is an important characteristic of autoimmune diseases.  Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway.  JAK1 is important for the γ-common chain cytokines, interleukin (IL)-6 and type-I interferon (IFN) family, while TYK2 in addn. to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling.  Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease and rheumatoid arthritis studies, leading to multiple drug approvals.  It is hypothesized that a dual JAK1/TYK2 inhibitor will provide addnl. efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes.  Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compd. 23), which is in Phase II clin. development (NCT02969018, NCT02958865, NCT03395184, and NCT02974868).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWNhVkNWDMq7Vg90H21EOLACvtfcHk0liNbisL3nvDgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI&md5=c321512f524560cba445d070b9639e55</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00917%26sid%3Dliteratum%253Aachs%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DChrencik%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DEfremov%26aufirst%3DI.%2BV.%26aulast%3DFlick%26aufirst%3DA.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DGopalsamy%26aufirst%3DA.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHollingshead%26aufirst%3DB.%2BD.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DKnafels%26aufirst%3DJ.%2BD.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DWan%26aufirst%3DZ.-K.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDual%2520inhibition%2520of%2520TYK2%2520and%2520JAK1%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%253A%2520Discovery%2520of%2520%2528%2528S%2529-2%252C2-Difluorocyclopropyl%2529%2528%25281R%252C5S%2529-3-%25282-%2528%25281-methyl-1H-pyrazol-4-yl%2529amino%2529pyrimidin-4-yl%2529-3%252C8-diazabicyclo%255B3.2.1%255Doctan-8-yl%2529methanone%2520%2528PF-06700841%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8597%26epage%3D8612%26doi%3D10.1021%2Facs.jmedchem.8b00917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banfield, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaramozza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieras, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goteti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkle, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeva, E.</span></span> <span> </span><span class="NLM_article-title">The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2/JAK1 inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">434</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1002/jcph.1046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1002%2Fjcph.1046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=29266308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVKrurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2018&pages=434-447&author=C.+Banfieldauthor=M.+Scaramozzaauthor=W.+Zhangauthor=E.+Kierasauthor=K.+M.+Pageauthor=A.+Fensomeauthor=M.+Vincentauthor=M.+E.+Dowtyauthor=K.+Gotetiauthor=P.+J.+Winkleauthor=E.+Peeva&title=The+safety%2C+tolerability%2C+pharmacokinetics%2C+and+pharmacodynamics+of+a+TYK2%2FJAK1+inhibitor+%28PF-06700841%29+in+healthy+subjects+and+patients+with+plaque+psoriasis&doi=10.1002%2Fjcph.1046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis</span></div><div class="casAuthors">Banfield, Christopher; Scaramozza, Matthew; Zhang, Weidong; Kieras, Elizabeth; Page, Karen M.; Fensome, Andrew; Vincent, Michael; Dowty, Martin E.; Goteti, Kosalaram; Winkle, Peter J.; Peeva, Elena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">434-447</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06700841 were assessed in a randomized, double-blind, placebo-controlled, single- and multiple-dose escalation, parallel-group study in healthy subjects and patients with plaque psoriasis.  The single ascending dose (1, 3, 10, 30, 100, or 200 mg) and multiple ascending dose (MAD; PF-06700841; up to 175 mg once daily or 50 mg twice daily for 10 days) periods included 54 healthy participants.  In addn., 30 patients with psoriasis received PF-06700841 30 or 100 mg or placebo once daily for 28 days.  Single PF-06700841 doses were rapidly absorbed, with peak plasma concns. ≤ 1 h, proportional exposure up to 100 mg, and mean half-life 3.8-7.5 h.  On day 10 of MAD, plasma concns. peaked at ≤1.5 h postdose (10-175 mg once daily).  Elimination half-life was 4.9-10.7 h; steady state was reached by day 8.  In psoriasis patients on day 28, peak plasma concns. occurred at 1-2 h.  Biomarkers IP-10 and high-sensitivity C-reactive protein were reduced and returned to near baseline levels after dosing.  Maximal mean percent change from baseline in the Psoriasis Area and Severity Index scores for PF-06700841 30 mg once daily and 100 mg once daily were -67.92% and -96.31%, resp., in week 4.  All adverse events were mild/moderate.  PF-06700841 was safe and well tolerated up to 200 mg once daily in healthy subjects and 100 mg once daily in patients with psoriasis, suggesting potential therapeutic utility in plaque psoriasis and other inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHMconrLwJf7Vg90H21EOLACvtfcHk0lgnfmSg5AMGrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVKrurw%253D&md5=a907c91ff2d50db9cba930c2249ed37b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fjcph.1046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.1046%26sid%3Dliteratum%253Aachs%26aulast%3DBanfield%26aufirst%3DC.%26aulast%3DScaramozza%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DKieras%26aufirst%3DE.%26aulast%3DPage%26aufirst%3DK.%2BM.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DVincent%26aufirst%3DM.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DGoteti%26aufirst%3DK.%26aulast%3DWinkle%26aufirst%3DP.%2BJ.%26aulast%3DPeeva%26aufirst%3DE.%26atitle%3DThe%2520safety%252C%2520tolerability%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520a%2520TYK2%252FJAK1%2520inhibitor%2520%2528PF-06700841%2529%2520in%2520healthy%2520subjects%2520and%2520patients%2520with%2520plaque%2520psoriasis%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D58%26spage%3D434%26epage%3D447%26doi%3D10.1002%2Fjcph.1046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vainchenker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favale, F.</span></span> <span> </span><span class="NLM_article-title">Myelofibrosis, JAK2 inhibitors and erythropoiesis</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1219</span>– <span class="NLM_lpage">1223</span>, <span class="refDoi"> DOI: 10.1038/leu.2013.72</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1038%2Fleu.2013.72" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=23739260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFeksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=1219-1223&author=W.+Vainchenkerauthor=F.+Favale&title=Myelofibrosis%2C+JAK2+inhibitors+and+erythropoiesis&doi=10.1038%2Fleu.2013.72"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Myelofibrosis, JAK2 inhibitors and erythropoiesis</span></div><div class="casAuthors">Vainchenker, W.; Favale, F.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1219-1223</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A polemic in this issue, Pardanani et al, report the effect of a new JAK1 and JAK2 inhibitor, CYT387, in patients with high or intermediaterisk primary and secondary myelofibrosis.  In this article obsd. the contrasting effects of JAK2 on pathol. erythropoiesis, we can speculate that the effects of JAK2 inhibition Such approaches might be more efficient in PV or ET, which are essentially dependent on constitutive JAK2 inhibition, than in PMF, where several pathways are simultaneously affected in the majority of cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF51RYsD3xorVg90H21EOLACvtfcHk0lgnfmSg5AMGrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFeksbw%253D&md5=dd8eb65edf06a2af21305dcd8f866dbd</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fleu.2013.72&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2013.72%26sid%3Dliteratum%253Aachs%26aulast%3DVainchenker%26aufirst%3DW.%26aulast%3DFavale%26aufirst%3DF.%26atitle%3DMyelofibrosis%252C%2520JAK2%2520inhibitors%2520and%2520erythropoiesis%26jtitle%3DLeukemia%26date%3D2013%26volume%3D27%26spage%3D1219%26epage%3D1223%26doi%3D10.1038%2Fleu.2013.72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span>A Study
to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe
Plaque Psoriasis. ClinicalTrials.gov. U.S. National Institutes of
Health, Bethesda, MD, 2018. NCT03895372. <a href="https://clinicaltrials.gov/ct2/show/NCT03895372" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03895372</a> (accessed Mar 29, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study%0Ato+Evaluate+Safety+and+Efficacy+of+PF-06826647+For+Moderate+To+Severe%0APlaque+Psoriasis.+ClinicalTrials.gov.+U.S.+National+Institutes+of%0AHealth%2C+Bethesda%2C+MD%2C+2018.+NCT03895372.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03895372+%28accessed+Mar+29%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span>A Study
To Evaluate The Safety And Efficacy Of PF-06826647 In Participants
With Moderate To Severe Ulcerative Colitis. ClinicalTrials.gov. U.S.
National Institutes of Health, Bethesda, MD, 2020. NCT04209556. <a href="https://clinicaltrials.gov/ct2/show/NCT04209556" class="extLink">https://clinicaltrials.gov/ct2/show/NCT04209556</a> (accessed Dec 24, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study%0ATo+Evaluate+The+Safety+And+Efficacy+Of+PF-06826647+In+Participants%0AWith+Moderate+To+Severe+Ulcerative+Colitis.+ClinicalTrials.gov.+U.S.%0ANational+Institutes+of+Health%2C+Bethesda%2C+MD%2C+2020.+NCT04209556.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04209556+%28accessed+Dec+24%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span>A Study
to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and
PF 06826647 in Adults With Hidradenitis Suppurativa. ClinicalTrials.gov.
U.S. National Institutes of Health, Bethesda, MD, 2020. NCT04092452. <a href="https://clinicaltrials.gov/ct2/show/NCT04092452" class="extLink">https://clinicaltrials.gov/ct2/show/NCT04092452</a> (accessed Sep 17, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study%0Ato+Evaluate+the+Safety+and+Efficacy+of+PF-06650833%2C+PF-06700841%2C+and%0APF+06826647+in+Adults+With+Hidradenitis+Suppurativa.+ClinicalTrials.gov.%0AU.S.+National+Institutes+of+Health%2C+Bethesda%2C+MD%2C+2020.+NCT04092452.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04092452+%28accessed+Sep+17%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gifford, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalsamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limburg, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Z.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span> <span> </span><span class="NLM_article-title">Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">115481</span>– <span class="NLM_lpage">115491</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2020.115481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1016%2Fj.bmc.2020.115481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=32253095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsFOjtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115481-115491&author=A.+Fensomeauthor=C.+M.+Amblerauthor=E.+Arnoldauthor=M.+E.+Bankerauthor=J.+D.+Clarkauthor=M.+E.+Dowtyauthor=I.+V.+Efremovauthor=A.+Flickauthor=B.+S.+Gerstenbergerauthor=R.+S.+Giffordauthor=A.+Gopalsamyauthor=M.+Hegenauthor=J.+Jussifauthor=D.+C.+Limburgauthor=T.+H.+Linauthor=B.+S.+Pierceauthor=R.+Sharmaauthor=J.+I.+Trujilloauthor=F.+F.+Vajdosauthor=F.+Vincentauthor=Z.-K.+Wanauthor=L.+Xingauthor=X.+Yangauthor=X.+Yang&title=Design+and+optimization+of+a+series+of+4-%283-azabicyclo%5B3.1.0%5Dhexan-3-yl%29pyrimidin-2-amines%3A+Dual+inhibitors+of+TYK2+and+JAK1&doi=10.1016%2Fj.bmc.2020.115481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1</span></div><div class="casAuthors">Fensome, Andrew; Ambler, Catherine M.; Arnold, Eric; Banker, Mary Ellen; Clark, James D.; Dowty, Martin E.; Efremov, Ivan V.; Flick, Andrew; Gerstenberger, Brian S.; Gifford, Roger S.; Gopalsamy, Ariamala; Hegen, Martin; Jussif, Jason; Limburg, David C.; Lin, Tsung H.; Pierce, Betsy S.; Sharma, Raman; Trujillo, John I.; Vajdos, Felix F.; Vincent, Fabien; Wan, Zhao-Kui; Xing, Li; Yang, Xiaojing; Yang, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">115481</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein, we disclose a new series of TYK2/ JAK1 inhibitors based upon a 3.1.0 azabicyclic substituted pyrimidine scaffold.  We illustrate the use of structure-based drug design for the initial design and subsequent optimization of this series of compds.  One advanced example 19 met program objectives for potency, selectivity and ADME, and demonstrated oral activity in the adjuvant-induced arthritis rat model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsqcYSKJmUBrVg90H21EOLACvtfcHk0lhLtyyeiwkb0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsFOjtb4%253D&md5=333a86e0bc2d8c22cf6eb50dd3c0624a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2020.115481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2020.115481%26sid%3Dliteratum%253Aachs%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DEfremov%26aufirst%3DI.%2BV.%26aulast%3DFlick%26aufirst%3DA.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DGifford%26aufirst%3DR.%2BS.%26aulast%3DGopalsamy%26aufirst%3DA.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DWan%26aufirst%3DZ.-K.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26atitle%3DDesign%2520and%2520optimization%2520of%2520a%2520series%2520of%25204-%25283-azabicyclo%255B3.1.0%255Dhexan-3-yl%2529pyrimidin-2-amines%253A%2520Dual%2520inhibitors%2520of%2520TYK2%2520and%2520JAK1%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26spage%3D115481%26epage%3D115491%26doi%3D10.1016%2Fj.bmc.2020.115481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jesson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katkade, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span> <span> </span><span class="NLM_article-title">Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition</span>. <i>Pharmacol. Res. Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e00537-e00537</span> <span class="refDoi"> DOI: 10.1002/prp2.537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1002%2Fprp2.537" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&author=M.+E.+Dowtyauthor=T.+H.+Linauthor=M.+I.+Jessonauthor=M.+Hegenauthor=D.+A.+Martinauthor=V.+Katkadeauthor=S.+Menonauthor=J.-B.+Telliez&title=Janus+kinase+inhibitors+for+the+treatment+of+rheumatoid+arthritis+demonstrate+similar+profiles+of+in+vitro+cytokine+receptor+inhibition&doi=10.1002%2Fprp2.537"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fprp2.537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.537%26sid%3Dliteratum%253Aachs%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DD.%2BA.%26aulast%3DKatkade%26aufirst%3DV.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DJanus%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%2520demonstrate%2520similar%2520profiles%2520of%2520in%2520vitro%2520cytokine%2520receptor%2520inhibition%26jtitle%3DPharmacol.%2520Res.%2520Perspect.%26date%3D2019%26volume%3D7%26doi%3D10.1002%2Fprp2.537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5023</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.-B.+Telliez&title=Discovery+and+development+of+Janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0lhLtyyeiwkb0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DDiscovery%2520and%2520development%2520of%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klug-Mcleod, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunney, E. A.</span></span> <span> </span><span class="NLM_article-title">Kinase hinge binding scaffolds and their hydrogen bond patterns</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6520</span>– <span class="NLM_lpage">6527</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1016%2Fj.bmc.2015.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=26358279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVentr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=6520-6527&author=L.+Xingauthor=J.+Klug-Mcleodauthor=B.+Raiauthor=E.+A.+Lunney&title=Kinase+hinge+binding+scaffolds+and+their+hydrogen+bond+patterns&doi=10.1016%2Fj.bmc.2015.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase hinge binding scaffolds and their hydrogen bond patterns</span></div><div class="casAuthors">Xing, Li; Klug-Mcleod, Jacquelyn; Rai, Brajesh; Lunney, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6520-6527</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Protein kinases constitute a major class of intracellular signaling mols., and describe some of the most prominent drug targets.  Kinase inhibitors commonly employ small chem. scaffolds that form hydrogen bonds with the kinase hinge residues connecting the N- and C-terminal lobes of the catalytic domain.  In general the satisfied hydrogen bonds are required for potent inhibition, therefore constituting a conserved feature in the majority of inhibitor-kinase interactions.  From systematically analyzing the kinase scaffolds extd. from Pfizer crystal structure database (CSDb) the authors recognize that large no. of kinase inhibitors of diverse chem. structures are derived from a relatively small no. of common scaffolds.  Depending on specific substitution patterns, scaffolds may demonstrate versatile binding capacities to interact with kinase hinge.  Afforded by thousands of ligand-protein binary complexes, the hinge hydrogen bond patterns were analyzed with a focus on their three-dimensional configurations.  Most of the compds. engage H6 NH for hinge recognition.  Dual hydrogen bonds are commonly obsd. with addnl. recruitment of H4 CO upstream and/or H6 CO downstream.  Triple hydrogen bonds accounts for small no. of binary complexes.  An unusual hydrogen bond with a non-canonical H5 conformation is obsd., requiring a peptide bond flip by a glycine residue at the H6 position.  Addnl. hydrogen bonds to kinase hinge do not necessarily correlate with an increase in potency; conversely they appear to compromise kinase selectivity.  Such learnings could enhance the prospect of successful therapy design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRC-xiTiNvELVg90H21EOLACvtfcHk0lj_aIdRug16LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVentr3L&md5=048b4b99628c6e1ae273b00a47ab2377</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DL.%26aulast%3DKlug-Mcleod%26aufirst%3DJ.%26aulast%3DRai%26aufirst%3DB.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26atitle%3DKinase%2520hinge%2520binding%2520scaffolds%2520and%2520their%2520hydrogen%2520bond%2520patterns%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D6520%26epage%3D6527%26doi%3D10.1016%2Fj.bmc.2015.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, C. H.</span></span> <span> </span><span class="NLM_article-title">A molecular electrostatic potential analysis of hydrogen, halogen, and dihydrogen bonds</span>. <i>J. Phys. Chem. A</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">1697</span>– <span class="NLM_lpage">1705</span>, <span class="refDoi"> DOI: 10.1021/jp4115699</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp4115699" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVOqsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2014&pages=1697-1705&author=N.+Mohanauthor=C.+H.+Suresh&title=A+molecular+electrostatic+potential+analysis+of+hydrogen%2C+halogen%2C+and+dihydrogen+bonds&doi=10.1021%2Fjp4115699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A Molecular Electrostatic Potential Analysis of Hydrogen, Halogen, and Dihydrogen Bonds</span></div><div class="casAuthors">Mohan, Neetha; Suresh, Cherumuttathu H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry A</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1697-1705</span>CODEN:
                <span class="NLM_cas:coden">JPCAFH</span>;
        ISSN:<span class="NLM_cas:issn">1089-5639</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hydrogen, halogen, and dihydrogen bonds in weak, medium and strong regimes (<1 to ∼60 kcal/mol) have been investigated for several intermol. donor-acceptor (D-A) complexes at ab initio MP4//MP2 method coupled with atoms-in-mols. and mol. electrostatic potential (MESP) approaches.  Electron d. ρ at bond crit. point correlates well with interaction energy (Enb) for each homogeneous sample of complexes, but its applicability to the entire set of complexes is not satisfactory.  Anal. of MESP min. (Vmin) and MESP at the nuclei (Vn) shows that in all D-A complexes, MESP of A becomes more neg. and that of D becomes less neg. suggesting donation of electrons from D to A leading to electron donor-acceptor (eDA) interaction between A and D.  MESP based parameter ΔΔVn measures donor-acceptor strength of the eDA interactions as it shows a good linear correlation with Enb for all D-A complexes (R2 = 0.976) except the strongly bound bridged structures.  The bridged structures are classified as donor-acceptor-donor complexes.  MESP provides a clear evidence for hydrogen, halogen, and dihydrogen bond formation and defines them as eDA interactions in which hydrogen acts as electron acceptor in hydrogen and dihydrogen bonds while halogen acts as electron acceptor in halogen bonds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQcyQeaXvFCbVg90H21EOLACvtfcHk0lj_aIdRug16LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVOqsbk%253D&md5=2631f6ee04c2cf572d320866084720c5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjp4115699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp4115699%26sid%3Dliteratum%253Aachs%26aulast%3DMohan%26aufirst%3DN.%26aulast%3DSuresh%26aufirst%3DC.%2BH.%26atitle%3DA%2520molecular%2520electrostatic%2520potential%2520analysis%2520of%2520hydrogen%252C%2520halogen%252C%2520and%2520dihydrogen%2520bonds%26jtitle%3DJ.%2520Phys.%2520Chem.%2520A%26date%3D2014%26volume%3D118%26spage%3D1697%26epage%3D1705%26doi%3D10.1021%2Fjp4115699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Case, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainer, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seyb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glicksman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6122</span>– <span class="NLM_lpage">6126</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1016%2Fj.bmcl.2009.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=19783434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GmurrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6122-6126&author=L.+Qiaoauthor=S.+Choiauthor=A.+Caseauthor=T.+G.+Gainerauthor=K.+Seybauthor=M.+A.+Glicksmanauthor=D.+C.+Loauthor=R.+L.+Steinauthor=G.+D.+Cuny&title=Structure-activity+relationship+study+of+EphB3+receptor+tyrosine+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2009.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors</span></div><div class="casAuthors">Qiao, Lixin; Choi, Sungwoon; Case, April; Gainer, Thomas G.; Seyb, Kathleen; Glicksman, Marcie A.; Lo, Donald C.; Stein, Ross L.; Cuny, Gregory D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6122-6126</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A structure-activity relationship study for a 2-chloroanilide deriv. of pyrazolo[1,5-a]pyridine revealed that increased EphB3 kinase inhibitory activity could be accomplished by retaining the 2-chloroanilide and introducing a Ph or small electron donating substituents to the 5-position of the pyrazolo[1,5-a]pyridine.  In addn., replacement of the pyrazolo[1,5-a]pyridine with imidazo[1,2-a]pyridine was well tolerated and resulted in enhanced mouse liver microsome stability.  The structure-activity relationship for EphB3 inhibition of both heterocyclic series was similar.  Kinase inhibitory activity was also demonstrated for representative analogs in cell culture.  An analog (32, LDN-211904) was also profiled for inhibitory activity against a panel of 288 kinases and found to be quite selective for tyrosine kinases.  Overall, these studies provide useful mol. probes for examg. the in vitro, cellular and potentially in vivo kinase-dependent function of EphB3 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5VEuexFGaQrVg90H21EOLACvtfcHk0lj_aIdRug16LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GmurrP&md5=9c805701f2a2a5665d2e8bf22bb5ad5e</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DQiao%26aufirst%3DL.%26aulast%3DChoi%26aufirst%3DS.%26aulast%3DCase%26aufirst%3DA.%26aulast%3DGainer%26aufirst%3DT.%2BG.%26aulast%3DSeyb%26aufirst%3DK.%26aulast%3DGlicksman%26aufirst%3DM.%2BA.%26aulast%3DLo%26aufirst%3DD.%2BC.%26aulast%3DStein%26aufirst%3DR.%2BL.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26atitle%3DStructure-activity%2520relationship%2520study%2520of%2520EphB3%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6122%26epage%3D6126%26doi%3D10.1016%2Fj.bmcl.2009.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ninkovic, S.</span>; <span class="NLM_string-name">Braganza, J. F.</span>; <span class="NLM_string-name">Collins, M. R.</span>; <span class="NLM_string-name">Kath, J. C.</span>; <span class="NLM_string-name">Li, H.</span>; <span class="NLM_string-name">Richter, D. T.</span></span> <span> </span><span class="NLM_article-title">Preparation of Heterocyclylaminopyrazine Derivatives for Use as CHK-1 Inhibitors</span>. Patent <span class="NLM_patent">WO2010016005A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+Ninkovic&author=J.+F.+Braganza&author=M.+R.+Collins&author=J.+C.+Kath&author=H.+Li&author=D.+T.+Richter&title=Preparation+of+Heterocyclylaminopyrazine+Derivatives+for+Use+as+CHK-1+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNinkovic%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Heterocyclylaminopyrazine%2520Derivatives%2520for%2520Use%2520as%2520CHK-1%2520Inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bach Tana, J.</span>; <span class="NLM_string-name">Perez Crespo, D.</span>; <span class="NLM_string-name">Llera Soldevila, O.</span>; <span class="NLM_string-name">Esteve Trias, C.</span>; <span class="NLM_string-name">Taboada Martinez, L.</span></span> <span> </span><span class="NLM_article-title">Preparation of 2-(Pyrazolo[1,5-a]pyrazin-3-yl)pyrimidine and 2-(Pyrazolo[1,5-a]pyridin-3-yl)pyrimidine Derivatives as JAK Inhibitors for Therapy</span>. Patent <span class="NLM_patent">WO2015086693A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+Bach+Tana&author=D.+Perez+Crespo&author=O.+Llera+Soldevila&author=C.+Esteve+Trias&author=L.+Taboada+Martinez&title=Preparation+of+2-%28Pyrazolo%5B1%2C5-a%5Dpyrazin-3-yl%29pyrimidine+and+2-%28Pyrazolo%5B1%2C5-a%5Dpyridin-3-yl%29pyrimidine+Derivatives+as+JAK+Inhibitors+for+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBach%2BTana%26aufirst%3DJ.%26atitle%3DPreparation%2520of%25202-%2528Pyrazolo%255B1%252C5-a%255Dpyrazin-3-yl%2529pyrimidine%2520and%25202-%2528Pyrazolo%255B1%252C5-a%255Dpyridin-3-yl%2529pyrimidine%2520Derivatives%2520as%2520JAK%2520Inhibitors%2520for%2520Therapy%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span>; <span class="NLM_string-name">Du, Z.</span>; <span class="NLM_string-name">Farand, J.</span>; <span class="NLM_string-name">Guerrero, J. A.</span>; <span class="NLM_string-name">Katana, A. A.</span>; <span class="NLM_string-name">Kato, D.</span>; <span class="NLM_string-name">Lazerwith, S. E.</span>; <span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Link, J. O.</span>; <span class="NLM_string-name">Mai, N.</span>; <span class="NLM_string-name">Notte, G.</span>; <span class="NLM_string-name">Pyun, H.-J.</span>; <span class="NLM_string-name">Sangi, M.</span>; <span class="NLM_string-name">Schmitt, A. C.</span>; <span class="NLM_string-name">Schrier, A. J.</span>; <span class="NLM_string-name">Stevens, K. L.</span>; <span class="NLM_string-name">Venkataramani, C.</span>; <span class="NLM_string-name">Watkins, W. J.</span>; <span class="NLM_string-name">Yang, Z.-Y.</span>; <span class="NLM_string-name">Zablocki, J.</span>; <span class="NLM_string-name">Zipfel, S.</span></span> <span> </span><span class="NLM_article-title">Azabicyclyloxyalkylpyrrolidinone Derivatives as Syk Inhibitors and Their Preparation</span>. Patent <span class="NLM_patent">WO2015017610A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=K.+S.+Currie&author=Z.+Du&author=J.+Farand&author=J.+A.+Guerrero&author=A.+A.+Katana&author=D.+Kato&author=S.+E.+Lazerwith&author=J.+Li&author=J.+O.+Link&author=N.+Mai&author=G.+Notte&author=H.-J.+Pyun&author=M.+Sangi&author=A.+C.+Schmitt&author=A.+J.+Schrier&author=K.+L.+Stevens&author=C.+Venkataramani&author=W.+J.+Watkins&author=Z.-Y.+Yang&author=J.+Zablocki&author=S.+Zipfel&title=Azabicyclyloxyalkylpyrrolidinone+Derivatives+as+Syk+Inhibitors+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DAzabicyclyloxyalkylpyrrolidinone%2520Derivatives%2520as%2520Syk%2520Inhibitors%2520and%2520Their%2520Preparation%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allen, S.</span>; <span class="NLM_string-name">Boys, M. L.</span>; <span class="NLM_string-name">Chicarelli, M. J.</span>; <span class="NLM_string-name">Fell, J. B.</span>; <span class="NLM_string-name">Fischer, J. P.</span>; <span class="NLM_string-name">Gaudino, J.</span>; <span class="NLM_string-name">Hicken, E. J.</span>; <span class="NLM_string-name">Hinklin, R. J.</span>; <span class="NLM_string-name">Kraser, C. F.</span>; <span class="NLM_string-name">Laird, E.</span>; <span class="NLM_string-name">Robinson, J. E.</span>; <span class="NLM_string-name">Tang, T. P.</span>; <span class="NLM_string-name">Burgess, L. E.</span>; <span class="NLM_string-name">Rieger, R. A.</span>; <span class="NLM_string-name">Pheneger, J.</span>; <span class="NLM_string-name">Satoh, Y.</span>; <span class="NLM_string-name">Leftheris, K.</span>; <span class="NLM_string-name">Raheja, R. K.</span>; <span class="NLM_string-name">Bennett, B. L.</span></span> <span> </span><span class="NLM_article-title">4,6-Disubstituted-pyrazolo[1,5-a]pyrazines as Janus Kinase Inhibitors and Their Preparation</span>. Patent <span class="NLM_patent">WO2016090285A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Allen&author=M.+L.+Boys&author=M.+J.+Chicarelli&author=J.+B.+Fell&author=J.+P.+Fischer&author=J.+Gaudino&author=E.+J.+Hicken&author=R.+J.+Hinklin&author=C.+F.+Kraser&author=E.+Laird&author=J.+E.+Robinson&author=T.+P.+Tang&author=L.+E.+Burgess&author=R.+A.+Rieger&author=J.+Pheneger&author=Y.+Satoh&author=K.+Leftheris&author=R.+K.+Raheja&author=B.+L.+Bennett&title=4%2C6-Disubstituted-pyrazolo%5B1%2C5-a%5Dpyrazines+as+Janus+Kinase+Inhibitors+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DS.%26atitle%3D4%252C6-Disubstituted-pyrazolo%255B1%252C5-a%255Dpyrazines%2520as%2520Janus%2520Kinase%2520Inhibitors%2520and%2520Their%2520Preparation%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. W.</span>; <span class="NLM_string-name">Blake, J. F.</span>; <span class="NLM_string-name">Haas, J.</span>; <span class="NLM_string-name">Jiang, Y.</span>; <span class="NLM_string-name">Kolakowski, G. R.</span>; <span class="NLM_string-name">Moreno, D. A.</span>; <span class="NLM_string-name">Ren, L.</span>; <span class="NLM_string-name">Walls, S. M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Substituted Pyrazolo[1,5-a]pyrazine Compounds as RET Kinase Inhibitors</span>. Patent <span class="NLM_patent">WO2018136661A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+W.+Andrews&author=J.+F.+Blake&author=J.+Haas&author=Y.+Jiang&author=G.+R.+Kolakowski&author=D.+A.+Moreno&author=L.+Ren&author=S.+M.+Walls&title=Preparation+of+Substituted+Pyrazolo%5B1%2C5-a%5Dpyrazine+Compounds+as+RET+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DS.%2BW.%26atitle%3DPreparation%2520of%2520Substituted%2520Pyrazolo%255B1%252C5-a%255Dpyrazine%2520Compounds%2520as%2520RET%2520Kinase%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fradera, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Methot, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kattar, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesburg, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenblatt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. D.</span></span> <span> </span><span class="NLM_article-title">Design of selective PI3Kδ inhibitors using an iterative scaffold-hopping workflow</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2575</span>– <span class="NLM_lpage">2580</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1016%2Fj.bmcl.2019.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=31416665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2nu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=2575-2580&author=X.+Fraderaauthor=J.+L.+Methotauthor=A.+Achabauthor=M.+Christopherauthor=M.+D.+Altmanauthor=H.+Zhouauthor=M.+A.+McGowanauthor=S.+D.+Kattarauthor=K.+Wilsonauthor=Y.+Garciaauthor=M.+A.+Augustinauthor=C.+A.+Lesburgauthor=S.+Shahauthor=P.+Goldenblattauthor=J.+D.+Katz&title=Design+of+selective+PI3K%CE%B4+inhibitors+using+an+iterative+scaffold-hopping+workflow&doi=10.1016%2Fj.bmcl.2019.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Design of selective PI3Kδ inhibitors using an iterative scaffold-hopping workflow</span></div><div class="casAuthors">Fradera, Xavier; Methot, Joey L.; Achab, Abdelghani; Christopher, Matthew; Altman, Michael D.; Zhou, Hua; McGowan, Meredeth A.; Kattar, Sam D.; Wilson, Kevin; Garcia, Yudith; Augustin, Martin A.; Lesburg, Charles A.; Shah, Sanjiv; Goldenblatt, Peter; Katz, Jason D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2575-2580</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">PI3Kδ mediates key immune cell signaling pathways and is a target of interest for multiple indications in immunol. and oncol.  Here we report a structure-based scaffold-hopping strategy for the design of chem. diverse PI3Kδ inhibitors.  Using this strategy, we identified several scaffolds that can be combined to generate new PI3Kδ inhibitors with high potency and isoform selectivity.  In particular, an oxindole-based scaffold was found to impart exquisite selectivity when combined with several hinge binding motifs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqndhswHJ17ILVg90H21EOLACvtfcHk0lhSEMha93tVDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2nu7nK&md5=4c978bad05a586a3f8c762016f001ebb</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DFradera%26aufirst%3DX.%26aulast%3DMethot%26aufirst%3DJ.%2BL.%26aulast%3DAchab%26aufirst%3DA.%26aulast%3DChristopher%26aufirst%3DM.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DMcGowan%26aufirst%3DM.%2BA.%26aulast%3DKattar%26aufirst%3DS.%2BD.%26aulast%3DWilson%26aufirst%3DK.%26aulast%3DGarcia%26aufirst%3DY.%26aulast%3DAugustin%26aufirst%3DM.%2BA.%26aulast%3DLesburg%26aufirst%3DC.%2BA.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DGoldenblatt%26aufirst%3DP.%26aulast%3DKatz%26aufirst%3DJ.%2BD.%26atitle%3DDesign%2520of%2520selective%2520PI3K%25CE%25B4%2520inhibitors%2520using%2520an%2520iterative%2520scaffold-hopping%2520workflow%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D2575%26epage%3D2580%26doi%3D10.1016%2Fj.bmcl.2019.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korniski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmons, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gormley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommers, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenbrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasselli, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, T. E.</span></span> <span> </span><span class="NLM_article-title">Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>400</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2010.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1016%2Fj.jmb.2010.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=20478313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=2010&pages=413-433&author=J.+E.+Chrencikauthor=A.+Patnyauthor=I.+K.+Leungauthor=B.+Korniskiauthor=T.+L.+Emmonsauthor=T.+Hallauthor=R.+A.+Weinbergauthor=J.+A.+Gormleyauthor=J.+M.+Williamsauthor=J.+E.+Dayauthor=J.+L.+Hirschauthor=J.+R.+Kieferauthor=J.+W.+Leoneauthor=H.+D.+Fischerauthor=C.+D.+Sommersauthor=H.-C.+Huangauthor=E.+J.+Jacobsenauthor=R.+E.+Tenbrinkauthor=A.+G.+Tomasselliauthor=T.+E.+Benson&title=Structural+and+thermodynamic+characterization+of+the+TYK2+and+JAK3+kinase+domains+in+complex+with+CP-690550+and+CMP-6&doi=10.1016%2Fj.jmb.2010.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6</span></div><div class="casAuthors">Chrencik, Jill E.; Patny, Akshay; Leung, Iris K.; Korniski, Brian; Emmons, Thomas L.; Hall, Troii; Weinberg, Robin A.; Gormley, Jennifer A.; Williams, Jennifer M.; Day, Jacqueline E.; Hirsch, Jeffrey L.; Kiefer, James R.; Leone, Joseph W.; Fischer, H. David; Sommers, Cynthia D.; Huang, Horng-Chih; Jacobsen, E. J.; Tenbrink, Ruth E.; Tomasselli, Alfredo G.; Benson, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-433</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are crit. regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases.  Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clin. compd. CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.  Here, we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-JAK inhibitors CP-690550 ((3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile) and CMP-6 (tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one), both of which bind in the ATP-binding cavities of both JAK isoenzymes in orientations similar to that obsd. in crystal structures of JAK1 and JAK2.  Addnl., a complete thermodn. characterization of JAK/CP-690550 complex formation was completed by isothermal titrn. calorimetry, indicating the crit. role of the nitrile group from the CP-690550 compd.  Finally, computational anal. using WaterMap further highlights the crit. positioning of the CP-690550 nitrile group in the displacement of an unfavorable water mol. beneath the glycine-rich loop.  Taken together, the data emphasize the outstanding properties of the kinome-selective JAK inhibitor CP-690550, as well as the challenges in obtaining JAK isoenzyme-selective inhibitors due to the overall structural and sequence similarities between the TYK2, JAK1, JAK2 and JAK3 isoenzymes.  Nevertheless, subtle amino acid variations of residues lining the ligand-binding cavity of the JAK enzymes, as well as the global positioning of the glycine-rich loop, might provide the initial clues to obtaining JAK-isoenzyme selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dnGkvq0jPbVg90H21EOLACvtfcHk0lhSEMha93tVDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D&md5=1b1efc3d6f913143dc9113e4ac1c4c60</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2010.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2010.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DSommers%26aufirst%3DC.%2BD.%26aulast%3DHuang%26aufirst%3DH.-C.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DTenbrink%26aufirst%3DR.%2BE.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DBenson%26aufirst%3DT.%2BE.%26atitle%3DStructural%2520and%2520thermodynamic%2520characterization%2520of%2520the%2520TYK2%2520and%2520JAK3%2520kinase%2520domains%2520in%2520complex%2520with%2520CP-690550%2520and%2520CMP-6%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D400%26spage%3D413%26epage%3D433%26doi%3D10.1016%2Fj.jmb.2010.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allerton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A. F.</span></span> <span> </span><span class="NLM_article-title">Predicting clearance mechanism in drug discovery: Extended clearance classification system (ECCS)</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">3785</span>– <span class="NLM_lpage">3802</span>, <span class="refDoi"> DOI: 10.1007/s11095-015-1749-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1007%2Fs11095-015-1749-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=26155985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCjurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2015&pages=3785-3802&author=M.+V.+Varmaauthor=S.+J.+Steynauthor=C.+Allertonauthor=A.+F.+El-Kattan&title=Predicting+clearance+mechanism+in+drug+discovery%3A+Extended+clearance+classification+system+%28ECCS%29&doi=10.1007%2Fs11095-015-1749-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)</span></div><div class="casAuthors">Varma, Manthena V.; Steyn, Stefanus J.; Allerton, Charlotte; El-Kattan, Ayman F.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3785-3802</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Early prediction of clearance mechanisms allows for the rapid progression of drug discovery and development programs, and facilitates risk assessment of the pharmacokinetic variability assocd. with drug interactions and pharmacogenomics.  Here we propose a scientific framework - Extended Clearance Classification System (ECCS) - which can be used to predict the predominant clearance mechanism (rate-detg. process) based on physicochem. properties and passive membrane permeability.  Compds. are classified as: Class 1A - metab. as primary systemic clearance mechanism (high permeability acids/zwitterions with mol. wt. (MW) ≤400 Da), Class 1B - transporter-mediated hepatic uptake as primary systemic clearance mechanism (high permeability acids/zwitterions with MW >400 Da), Class 2 - metab. as primary clearance mechanism (high permeability bases/neutrals), Class 3A -renal clearance (low permeability acids/zwitterions with MW ≤400 Da), Class 3B - transporter mediated hepatic uptake or renal clearance (low permeability acids/zwitterions with MW >400 Da), and Class 4 - renal clearance (low permeability bases/neutrals).  The performance of the ECCS framework was validated using 307 compds. with single clearance mechanism contributing to ≥70% of systemic clearance.  The apparent permeability across clonal cell line of Madin - Darby canine kidney cells, selected for low endogenous efflux transporter expression, with a cut-off of 5 × 10-6 cm/s was used for permeability classification, and the ionization (at pH7) was assigned based on calcd. pKa.  The proposed scheme correctly predicted the rate-detg. clearance mechanism to be either metab., hepatic uptake or renal for ∼92% of total compds.  We discuss the general characteristics of each ECCS class, as well as compare and contrast the framework with the biopharmaceutics classification system (BCS) and the biopharmaceutics drug disposition classification system (BDDCS).  Collectively, the ECCS framework is valuable in early prediction of clearance mechanism and can aid in choosing the right preclin. tool kit and strategy for optimizing drug exposure and evaluating clin. risk of pharmacokinetic variability caused by drug interactions and pharmacogenomics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRANZrcZqpObVg90H21EOLACvtfcHk0lgnBfNgrwlHuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCjurfP&md5=836ba49f4fe66ceacfec6390e56bc792</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs11095-015-1749-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-015-1749-4%26sid%3Dliteratum%253Aachs%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DAllerton%26aufirst%3DC.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26atitle%3DPredicting%2520clearance%2520mechanism%2520in%2520drug%2520discovery%253A%2520Extended%2520clearance%2520classification%2520system%2520%2528ECCS%2529%26jtitle%3DPharm.%2520Res.%26date%3D2015%26volume%3D32%26spage%3D3785%26epage%3D3802%26doi%3D10.1007%2Fs11095-015-1749-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shilliday, F. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, H. V.</span></span> <span> </span><span class="NLM_article-title">Drug design structural alert: Formation of trifluoroacetaldehyde through N-dealkylation is linked to testicular lesions in rat</span>. <i>Int. J. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">546</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1177/1091581811413833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1177%2F1091581811413833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=21868768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVGktLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=546-550&author=M.+E.+Dowtyauthor=G.+Huauthor=F.+Huaauthor=F.+B.+Shillidayauthor=H.+V.+Dowty&title=Drug+design+structural+alert%3A+Formation+of+trifluoroacetaldehyde+through+N-dealkylation+is+linked+to+testicular+lesions+in+rat&doi=10.1177%2F1091581811413833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Drug design structural alert: formation of trifluoroacetaldehyde through N-dealkylation is linked to testicular lesions in rat</span></div><div class="casAuthors">Dowty, Martin E.; Hu, George; Hua, Fengmei; Shilliday, F. Barclay; Dowty, Heather V.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">546-550</span>CODEN:
                <span class="NLM_cas:coden">IJTOFN</span>;
        ISSN:<span class="NLM_cas:issn">1091-5818</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">In the process of drug design, it is important to consider potential structural alerts that may lead to toxicosis.  This work illustrates how using trifluoroethane as a part of a novel chem. entity led to cytochrome P 450 - mediated N-dealkylation and the formation of trifluoroacetaldehyde, a known testicular toxicant, in exploratory safety studies in rats.  Testicular toxicosis was noted microscopically in a dose-dependent manner as measured by testicular spermatocytic degeneration and necrosis and excessive intratubular cellular debris in the epididymis.  This apparent toxic effect correlated well with the dose-dependent formation of trifluoroacetaldehyde, identified from in vitro rat liver microsome metab. studies.  A similar safety study performed with an N-tetrazole substitution in place of the N-trifluoroethane showed no evidence of testicular injury, implicating further the role of trifluoroacetaldehyde in the testicular lesion obsd.  These results highlight the relevance of early metabolic and safety testing in assessing potential structural alerts in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFV-lzA-4PvbVg90H21EOLACvtfcHk0lgnBfNgrwlHuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVGktLfM&md5=30f0e43e80ba5d541b48eeee99b2e95b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1177%2F1091581811413833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1091581811413833%26sid%3Dliteratum%253Aachs%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DHua%26aufirst%3DF.%26aulast%3DShilliday%26aufirst%3DF.%2BB.%26aulast%3DDowty%26aufirst%3DH.%2BV.%26atitle%3DDrug%2520design%2520structural%2520alert%253A%2520Formation%2520of%2520trifluoroacetaldehyde%2520through%2520N-dealkylation%2520is%2520linked%2520to%2520testicular%2520lesions%2520in%2520rat%26jtitle%3DInt.%2520J.%2520Toxicol.%26date%3D2011%26volume%3D30%26spage%3D546%26epage%3D550%26doi%3D10.1177%2F1091581811413833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney-Pickett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umland, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebhard, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federico, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempshall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liston, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M. D.</span></span> <span> </span><span class="NLM_article-title">Development of a new permeability assay using low-efflux MDCKII cells</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">4974</span>– <span class="NLM_lpage">4985</span>, <span class="refDoi"> DOI: 10.1002/jps.22674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1002%2Fjps.22674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=21766308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=4974-4985&author=L.+Diauthor=C.+Whitney-Pickettauthor=J.+P.+Umlandauthor=H.+Zhangauthor=X.+Zhangauthor=D.+F.+Gebhardauthor=Y.+Laiauthor=J.+J.+Federicoauthor=R.+E.+Davidsonauthor=R.+Smithauthor=E.+L.+Reynerauthor=C.+Leeauthor=B.+Fengauthor=C.+Rotterauthor=M.+V.+Varmaauthor=S.+Kempshallauthor=K.+Fennerauthor=A.+F.+El-Kattanauthor=T.+E.+Listonauthor=M.+D.+Troutman&title=Development+of+a+new+permeability+assay+using+low-efflux+MDCKII+cells&doi=10.1002%2Fjps.22674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a new permeability assay using low-efflux MDCKII cells</span></div><div class="casAuthors">Di, Li; Whitney-Pickett, Carrie; Umland, John P.; Zhang, Hui; Zhang, Xun; Gebhard, David F.; Lai, Yurong; Federico, James J.; Davidson, Ralph E.; Smith, Russ; Reyner, Eric L.; Lee, Caroline; Feng, Bo; Rotter, Charles; Varma, Manthena V.; Kempshall, Sarah; Fenner, Katherine; El-kattan, Ayman F.; Liston, Theodore E.; Troutman, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4974-4985</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Permeability is an important property of drug candidates.  The Madin-Darby canine kidney cell line (MDCK) permeability assay is widely used and the primary concern of using MDCK cells is the presence of endogenous transporters of nonhuman origin.  The canine P-glycoprotein (Pgp) can interfere with permeability and transporter studies, leading to less reliable data.  A new cell line, MDCKII-LE (low efflux), has been developed by selecting a subpopulation of low-efflux cells from MDCKII-WT using an iterative fluorescence-activated cell sorting technique with calcein-AM as a Pgp and efflux substrate.  MDCKII-LE cells are a subpopulation of MDCKII cells with over 200-fold lower canine Pgp mRNA level and fivefold lower protein level than MDCKII-WT.  MDCKII-LE cells showed less functional efflux activity than MDCKII-WT based on efflux ratios.  Notably, MDCKII-MDR1 showed about 1.5-fold decreased expression of endogenous canine Pgp, suggesting that using the net flux ratio might not completely cancel out the background endogenous transporter activities.  MDCKII-LE cells offer clear advantages over the MDCKII-WT by providing less efflux transporter background signals and minimizing interference from canine Pgp.  The MDCKII-LE apparent permeability values well differentiates compds. from high to medium/low human intestinal absorption and can be used for Biopharmaceutical Classification System.  The MDCKII-LE permeability assay (4-in-1 cassette dosing) is high throughput with good precision, reproducibility, robustness, and cost-effective. © 2011 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTVtRmYnbF17Vg90H21EOLACvtfcHk0lgnBfNgrwlHuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D&md5=97f647fc215ea6d04882351ffc912a1e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fjps.22674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22674%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DUmland%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGebhard%26aufirst%3DD.%2BF.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DFederico%26aufirst%3DJ.%2BJ.%26aulast%3DDavidson%26aufirst%3DR.%2BE.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DRotter%26aufirst%3DC.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26atitle%3DDevelopment%2520of%2520a%2520new%2520permeability%2520assay%2520using%2520low-efflux%2520MDCKII%2520cells%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26spage%3D4974%26epage%3D4985%26doi%3D10.1002%2Fjps.22674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaila, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TenBrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heasley, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langille, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclos, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R.</span></span> <span> </span><span class="NLM_article-title">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A selective JAK1 clinical candidate for the treatment of autoimmune diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1130</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1130-1152&author=M.+L.+Vazquezauthor=N.+Kailaauthor=J.+W.+Strohbachauthor=J.+D.+Trzupekauthor=M.+F.+Brownauthor=M.+E.+Flanaganauthor=M.+J.+Mitton-Fryauthor=T.+A.+Johnsonauthor=R.+E.+TenBrinkauthor=E.+P.+Arnoldauthor=A.+Basakauthor=S.+E.+Heasleyauthor=S.+Kwonauthor=J.+Langilleauthor=M.+D.+Parikhauthor=S.+H.+Griffinauthor=J.+M.+Casavantauthor=B.+A.+Duclosauthor=A.+E.+Fenwickauthor=T.+M.+Harrisauthor=S.+Hanauthor=N.+Caspersauthor=M.+E.+Dowtyauthor=X.+Yangauthor=M.+E.+Bankerauthor=M.+Hegenauthor=P.+T.+Symanowiczauthor=L.+Liauthor=L.+Wangauthor=T.+H.+Linauthor=J.+Jussifauthor=J.+D.+Clarkauthor=J.-B.+Telliezauthor=R.+P.+Robinsonauthor=R.+Unwalla&title=Identification+of+N-%7Bcis-3-%5BMethyl%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%5Dcyclobutyl%7Dpropane-1-sulfonamide+%28PF-04965842%29%3A+A+selective+JAK1+clinical+candidate+for+the+treatment+of+autoimmune+diseases&doi=10.1021%2Facs.jmedchem.7b01598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases</span></div><div class="casAuthors">Vazquez, Michael L.; Kaila, Neelu; Strohbach, Joseph W.; Trzupek, John D.; Brown, Matthew F.; Flanagan, Mark E.; Mitton-Fry, Mark J.; Johnson, Timothy A.; TenBrink, Ruth E.; Arnold, Eric P.; Basak, Arindrajit; Heasley, Steven E.; Kwon, Soojin; Langille, Jonathan; Parikh, Mihir D.; Griffin, Sarah H.; Casavant, Jeffrey M.; Duclos, Brian A.; Fenwick, Ashley E.; Harris, Thomas M.; Han, Seungil; Caspers, Nicole; Dowty, Martin E.; Yang, Xin; Banker, Mary Ellen; Hegen, Martin; Symanowicz, Peter T.; Li, Li; Wang, Lu; Lin, Tsung H.; Jussif, Jason; Clark, James D.; Telliez, Jean-Baptiste; Robinson, Ralph P.; Unwalla, Ray</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1130-1152</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis.  As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling.  The authors' efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis.  Through modification of the 3-aminopiperidine linker in tofacitinib, the authors discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay.  Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by x-ray crystallog. anal.  After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (25) was nominated as a clin. candidate for the treatment of JAK1-mediated autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNdiJFIHI-YLVg90H21EOLACvtfcHk0lith6JvwkkG_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D&md5=45c6d1b0eee7ab9d5dfc8ea168607a8b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01598%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez%26aufirst%3DM.%2BL.%26aulast%3DKaila%26aufirst%3DN.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DMitton-Fry%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DTenBrink%26aufirst%3DR.%2BE.%26aulast%3DArnold%26aufirst%3DE.%2BP.%26aulast%3DBasak%26aufirst%3DA.%26aulast%3DHeasley%26aufirst%3DS.%2BE.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DLangille%26aufirst%3DJ.%26aulast%3DParikh%26aufirst%3DM.%2BD.%26aulast%3DGriffin%26aufirst%3DS.%2BH.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DDuclos%26aufirst%3DB.%2BA.%26aulast%3DFenwick%26aufirst%3DA.%2BE.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26aulast%3DUnwalla%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520N-%257Bcis-3-%255BMethyl%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%255Dcyclobutyl%257Dpropane-1-sulfonamide%2520%2528PF-04965842%2529%253A%2520A%2520selective%2520JAK1%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1130%26epage%3D1152%26doi%3D10.1021%2Facs.jmedchem.7b01598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bucher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stouten, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triballeau, N.</span></span> <span> </span><span class="NLM_article-title">Shedding light on important waters for drug design: Simulations versus grid-based methods</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">692</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.7b00642</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.7b00642" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsVylsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2018&pages=692-699&author=D.+Bucherauthor=P.+Stoutenauthor=N.+Triballeau&title=Shedding+light+on+important+waters+for+drug+design%3A+Simulations+versus+grid-based+methods&doi=10.1021%2Facs.jcim.7b00642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Shedding Light on Important Waters for Drug Design: Simulations versus Grid-Based Methods</span></div><div class="casAuthors">Bucher, Denis; Stouten, Pieter; Triballeau, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">692-699</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Water mols. play an important role in the assocn. of drugs with their pharmaceutical targets.  For this reason, calcg. the energetic contribution of water is essential to make accurate predictions of compds.' affinity and selectivity.  Water mols. can also modify the binding mode of compds. by forming water bridges, or clusters, that stabilize a particular orientation of the ligand.  Several computational methods have been developed for solvent mapping, but few studies have attempted to compare them in a drug design context.  In this paper, four com. available solvent mapping tools (SZMAP, WaterFLAP, 3D-RISM, and WaterMap) are evaluated on three different protein targets.  The methods were compared by looking at their ability to predict the structure-activity relations of lead compds.  All methods were found to be useful to some degree and to improve the predictions from docking alone.  However, the only simulation-based approach tested, WaterMap, was found in some cases to be more accurate than grid-based methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOUZ3PyrwN_LVg90H21EOLACvtfcHk0lith6JvwkkG_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsVylsLc%253D&md5=95c20e75eeafa94a3cd8e70dedcacb96</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.7b00642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.7b00642%26sid%3Dliteratum%253Aachs%26aulast%3DBucher%26aufirst%3DD.%26aulast%3DStouten%26aufirst%3DP.%26aulast%3DTriballeau%26aufirst%3DN.%26atitle%3DShedding%2520light%2520on%2520important%2520waters%2520for%2520drug%2520design%253A%2520Simulations%2520versus%2520grid-based%2520methods%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2018%26volume%3D58%26spage%3D692%26epage%3D699%26doi%3D10.1021%2Facs.jcim.7b00642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Card, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokchander, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciabola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clugston, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschantz, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wangu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moshinsky, D. J.</span></span> <span> </span><span class="NLM_article-title">High-throughput biochemical kinase selectivity assays: Panel development and screening applications</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1177/1087057108326663</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1177%2F1087057108326663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=19073965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkslGrt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=31-42&author=A.+Cardauthor=C.+Caldwellauthor=H.+Minauthor=B.+Lokchanderauthor=H.+Xiauthor=S.+Sciabolaauthor=A.+V.+Kamathauthor=S.+L.+Clugstonauthor=W.+R.+Tschantzauthor=L.+Wanguauthor=D.+J.+Moshinsky&title=High-throughput+biochemical+kinase+selectivity+assays%3A+Panel+development+and+screening+applications&doi=10.1177%2F1087057108326663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput biochemical kinase selectivity assays: panel development and screening applications</span></div><div class="casAuthors">Card, Amy; Caldwell, Chris; Min, Hyunsuk; Lokchander, Bina; Xi, Hualin; Sciabola, Simone; Kamath, Ajith V.; Clugston, Susan L.; Tschantz, William R.; Wang, Leyu; Moshinsky, Deborah J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-42</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Kinases represent attractive targets for drug discovery.  Eight small-mol. kinase inhibitors are currently marketed in the area of oncol., and numerous others are in clin. trials.  Characterization of the selectivity profiles of these compds. is important to target appropriate patient populations and to reduce the potential of toxicity due to off-target effects.  The authors describe the development, validation, and utilization of a biochem. kinase assay panel for the selectivity profiling of inhibitors.  The panel was developed as 29 radiometric Flashplate assays, and then an initial 13 were transitioned to a nonradiometric Caliper mobility shift assay format.  Generation of high-quality data from the panel is detailed along with a comparison of the assay formats.  Both assay technologies were found to be suitable for panel screening, but mobility shift assays yielded higher data quality.  The selectivity data generated here should be useful in computational modeling and help facilitate, in conjunction with sequence and structural information, the rational design of inhibitors with well-defined selectivity profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomyXhZTHNo27Vg90H21EOLACvtfcHk0liwPhZT1nOmog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkslGrt7s%253D&md5=f7091977dcac95d920a8bc292dcff78d</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1177%2F1087057108326663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057108326663%26sid%3Dliteratum%253Aachs%26aulast%3DCard%26aufirst%3DA.%26aulast%3DCaldwell%26aufirst%3DC.%26aulast%3DMin%26aufirst%3DH.%26aulast%3DLokchander%26aufirst%3DB.%26aulast%3DXi%26aufirst%3DH.%26aulast%3DSciabola%26aufirst%3DS.%26aulast%3DKamath%26aufirst%3DA.%2BV.%26aulast%3DClugston%26aufirst%3DS.%2BL.%26aulast%3DTschantz%26aufirst%3DW.%2BR.%26aulast%3DWangu%26aufirst%3DL.%26aulast%3DMoshinsky%26aufirst%3DD.%2BJ.%26atitle%3DHigh-throughput%2520biochemical%2520kinase%2520selectivity%2520assays%253A%2520Panel%2520development%2520and%2520screening%2520applications%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2009%26volume%3D14%26spage%3D31%26epage%3D42%26doi%3D10.1177%2F1087057108326663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremaine, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liras, J.</span></span> <span> </span><span class="NLM_article-title">Validation of human MDR1-MDCK and BCRP-MDCK cell lines to improve the prediction of brain penetration</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">2476</span>– <span class="NLM_lpage">2483</span>, <span class="refDoi"> DOI: 10.1016/j.xphs.2019.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1016%2Fj.xphs.2019.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=30794795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlOrurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2019&pages=2476-2483&author=B.+Fengauthor=M.+Westauthor=N.+C.+Patelauthor=T.+Wagerauthor=X.+Houauthor=J.+Johnsonauthor=L.+Tremaineauthor=J.+Liras&title=Validation+of+human+MDR1-MDCK+and+BCRP-MDCK+cell+lines+to+improve+the+prediction+of+brain+penetration&doi=10.1016%2Fj.xphs.2019.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of Human MDR1-MDCK and BCRP-MDCK Cell Lines to Improve the Prediction of Brain Penetration</span></div><div class="casAuthors">Feng, Bo; West, Mark; Patel, Nandini C.; Wager, Travis; Hou, Xinjun; Johnson, Jillian; Tremaine, Larry; Liras, Jennifer</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2476-2483</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">It is of great challenge to predict human brain penetration for substrates of multidrug resistance protein 1 (MDR1) and breast cancer resistance protein (BCRP), 2 major efflux transporters at blood-brain barrier.  Thus, a physiol. based pharmacokinetic (PBPK) model with the incorporation of in vitro MDR1 and BCRP transporter function data and transporter protein expression levels has been developed.  As such, it is crucial to generate MDR1 and BCRP substrate data with a high fidelity.  In this study, 2 widely used human MDR1 cell lines from Borst and National Institutes of Health labs. were evaluated using rodent brain penetration data, and the study suggested that the MDR1 expressed in Madin-Darby canine kidney (MDCK) cell line from National Institutes of Health lab. predicted brain penetration better, particularly for compds. with a high passive permeability.  In addn., human BCRP-MDCK cell line with 1 μM PSC833, a specific MDR1 inhibitor, demonstrated the ability to identify BCRP substrates without the confounding of endogenous canine Mdr1.  Comparison of human BCRP and mouse Bcrp transporter functions revealed that the functional differences of BCRP between the 2 species is minimal.  The incorporation of both the validated MDR1 and BCRP assays into the brain PBPK model has significantly improved the prediction for the brain penetration of MDR1 and BCRP substrates across species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJccGgmyYnkrVg90H21EOLACvtfcHk0liwPhZT1nOmog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlOrurg%253D&md5=b50738eeab75b2a1cc048372de13b1a5</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.xphs.2019.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.xphs.2019.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DWest%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DN.%2BC.%26aulast%3DWager%26aufirst%3DT.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DJohnson%26aufirst%3DJ.%26aulast%3DTremaine%26aufirst%3DL.%26aulast%3DLiras%26aufirst%3DJ.%26atitle%3DValidation%2520of%2520human%2520MDR1-MDCK%2520and%2520BCRP-MDCK%2520cell%2520lines%2520to%2520improve%2520the%2520prediction%2520of%2520brain%2520penetration%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2019%26volume%3D108%26spage%3D2476%26epage%3D2483%26doi%3D10.1016%2Fj.xphs.2019.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span> <span> </span><span class="NLM_article-title">Predicting clearance in humans from in vitro data</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.2174/156802611794480873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.2174%2F156802611794480873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=21320062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=334-339&author=R.+S.+Obach&title=Predicting+clearance+in+humans+from+in+vitro+data&doi=10.2174%2F156802611794480873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting clearance in humans from in vitro data</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">334-339</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The use of in vitro metab. in scaling to predict human clearance of new chem. entities has become a commonplace activity in the research and development of new drugs.  The measurement of in vitro lability in human liver microsomes, a rich source of drug metabolizing cytochrome P 450 enzymes, has become a high throughput screen in many research organizations which is a testament to its usefulness in drug design.  In this chapter, the methods used to scale in vitro intrinsic clearance data to predict in vivo clearance are described.  Importantly, the numerous assumptions that are required in order to use in vitro data in this manner are laid out.  These include assumptions regarding the scaling process as well as tech. aspects of the generation of the in vitro data.  Finally, some other drug clearance processes that have been emerging as important are described with regard to ongoing research efforts to develop clearance prediction methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHL7BnSTNtWbVg90H21EOLACvtfcHk0liwPhZT1nOmog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSntbk%253D&md5=38df8707bb77fdc8b6bb6ef2144a79da</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.2174%2F156802611794480873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611794480873%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPredicting%2520clearance%2520in%2520humans%2520from%2520in%2520vitro%2520data%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D334%26epage%3D339%26doi%3D10.2174%2F156802611794480873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hosea, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collard, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, R. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakar, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span> <span> </span><span class="NLM_article-title">Prediction of human pharmacokinetics from preclinical information: Comparative accuracy of quantitative prediction approaches</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1177/0091270009333209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1177%2F0091270009333209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=19299532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=513-533&author=N.+A.+Hoseaauthor=W.+T.+Collardauthor=S.+Coleauthor=T.+S.+Maurerauthor=R.+X.+Fangauthor=H.+Jonesauthor=S.+M.+Kakarauthor=Y.+Nakaiauthor=B.+J.+Smithauthor=R.+Websterauthor=K.+Beaumont&title=Prediction+of+human+pharmacokinetics+from+preclinical+information%3A+Comparative+accuracy+of+quantitative+prediction+approaches&doi=10.1177%2F0091270009333209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span></div><div class="casAuthors">Hosea, Natilie A.; Collard, Wendy T.; Cole, Susan; Maurer, Tristan S.; Fang, Rick X.; Jones, Hannah; Kakar, Shefali M.; Nakai, Yasuhiro; Smith, Bill J.; Webster, Rob; Beaumont, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">513-533</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Quant. prediction of human pharmacokinetics is crit. in assessing the viability of drug candidates and in detg. first-in-human dosing.  Numerous prediction methodologies, incorporating both in vitro and preclin. in vivo data, have been developed in recent years, each with advantages and disadvantages.  However, the lack of a comprehensive data set, both preclin. and clin., has limited efforts to evaluate the optimal strategy (or strategies) that results in quant. predictions of human pharmacokinetics.  To address this issue, the authors conducted a retrospective anal. using 50 proprietary compds. for which in vitro, preclin. pharmacokinetic data and oral single-dose human pharmacokinetic data were available.  Five predictive strategies, involving either allometry or use of unbound intrinsic clearance from microsomes or hepatocytes, were then compared for their ability to predict human oral clearance, half-life through predictions of systemic clearance, vol. of distribution, and bioavailability.  Use of a single-species scaling approach with rat, dog, or monkey was as accurate as or more accurate than using multiple-species allometry.  For those compds. cleared almost exclusively by P 450-mediated pathways, scaling from human liver microsomes was as predictive as single-species scaling of clearance based on data from rat, dog, or monkey.  These data suggest that use of predictive methods involving either single-species in vivo data or in vitro human liver microsomes can quant. predict human in vivo pharmacokinetics and suggest the possibility of streamlining the predictive methodol. through use of a single species or use only of human in vitro microsomal prepns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg67HcwS4O4LVg90H21EOLACvtfcHk0lhAEYIpdj9uiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D&md5=a0941d53fe43392f8fb1562ee546705e</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1177%2F0091270009333209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270009333209%26sid%3Dliteratum%253Aachs%26aulast%3DHosea%26aufirst%3DN.%2BA.%26aulast%3DCollard%26aufirst%3DW.%2BT.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DFang%26aufirst%3DR.%2BX.%26aulast%3DJones%26aufirst%3DH.%26aulast%3DKakar%26aufirst%3DS.%2BM.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DBeaumont%26aufirst%3DK.%26atitle%3DPrediction%2520of%2520human%2520pharmacokinetics%2520from%2520preclinical%2520information%253A%2520Comparative%2520accuracy%2520of%2520quantitative%2520prediction%2520approaches%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D49%26spage%3D513%26epage%3D533%26doi%3D10.1177%2F0091270009333209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katherine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masek, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Susan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eva, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span> <span> </span><span class="NLM_article-title">Attenuating Janus kinases (JAK) by tofacitinib effectively prevented psoriasis pathology in various mouse skin inflammation models</span>. <i>J. Clin. Cell. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1000176</span>, <span class="refDoi"> DOI: 10.4172/2155-9899.1000176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.4172%2F2155-9899.1000176" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1000176&author=L.+Hakauthor=M.+Katherineauthor=H.+Masekauthor=F.+Susanauthor=N.+Leeauthor=N.+Evaauthor=H.+Martinauthor=D.+James&title=Attenuating+Janus+kinases+%28JAK%29+by+tofacitinib+effectively+prevented+psoriasis+pathology+in+various+mouse+skin+inflammation+models&doi=10.4172%2F2155-9899.1000176"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.4172%2F2155-9899.1000176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F2155-9899.1000176%26sid%3Dliteratum%253Aachs%26aulast%3DHak%26aufirst%3DL.%26aulast%3DKatherine%26aufirst%3DM.%26aulast%3DMasek%26aufirst%3DH.%26aulast%3DSusan%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DEva%26aufirst%3DN.%26aulast%3DMartin%26aufirst%3DH.%26aulast%3DJames%26aufirst%3DD.%26atitle%3DAttenuating%2520Janus%2520kinases%2520%2528JAK%2529%2520by%2520tofacitinib%2520effectively%2520prevented%2520psoriasis%2520pathology%2520in%2520various%2520mouse%2520skin%2520inflammation%2520models%26jtitle%3DJ.%2520Clin.%2520Cell.%2520Immunol.%26date%3D2013%26volume%3D4%26spage%3D1000176%26doi%3D10.4172%2F2155-9899.1000176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gifford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffor, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span> <span> </span><span class="NLM_article-title">Demonstration of In Vitro to In Vivo translation of a TYK2 inhibitor that shows cross species potency differences</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">8974</span>, <span class="refDoi"> DOI: 10.1038/s41598-020-65762-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1038%2Fs41598-020-65762-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=32488071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtV2ku7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=8974&author=B.+S.+Gerstenbergerauthor=M.+E.+Bankerauthor=J.+D.+Clarkauthor=M.+E.+Dowtyauthor=A.+Fensomeauthor=R.+Giffordauthor=M.+C.+Grifforauthor=M.+Hegenauthor=B.+D.+Hollingsheadauthor=J.+D.+Knafelsauthor=T.+H.+Linauthor=J.+F.+Smithauthor=F.+F.+Vajdos&title=Demonstration+of+In+Vitro+to+In+Vivo+translation+of+a+TYK2+inhibitor+that+shows+cross+species+potency+differences&doi=10.1038%2Fs41598-020-65762-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences</span></div><div class="casAuthors">Gerstenberger, Brian S.; Banker, Mary Ellen; Clark, James D.; Dowty, Martin E.; Fensome, Andrew; Gifford, Roger; Griffor, Matthew C.; Hegen, Martin; Hollingshead, Brett D.; Knafels, John D.; Lin, Tsung H.; Smith, James F.; Vajdos, Felix F.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8974</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Translation of modulation of drug target activity to therapeutic effect is a crit. aspect for all drug discovery programs.  In this work we describe the profiling of a non-receptor tyrosine-protein kinase (TYK2) inhibitor which shows a functionally relevant potency shift between human and preclin. species (e.g. murine, dog, macaque) in both biochem. and cellular assays.  Comparison of the structure and sequence homol. of TYK2 between human and preclin. species within the ATP binding site highlights a single amino acid (I960 → V) responsible for the potency shift.  Through TYK2 kinase domain mutants and a TYK2 980I knock-in mouse model, we demonstrate that this single amino acid change drives a functionally relevant potency difference that exists between human and all evaluated preclin. species, for a series of TYK2 inhibitors which target the ATP binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppbgZtlCbNRLVg90H21EOLACvtfcHk0lhAEYIpdj9uiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtV2ku7jK&md5=65924cc0bdc58f0c4ea9a0a3a3955091</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fs41598-020-65762-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-020-65762-y%26sid%3Dliteratum%253Aachs%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DGifford%26aufirst%3DR.%26aulast%3DGriffor%26aufirst%3DM.%2BC.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHollingshead%26aufirst%3DB.%2BD.%26aulast%3DKnafels%26aufirst%3DJ.%2BD.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DSmith%26aufirst%3DJ.%2BF.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26atitle%3DDemonstration%2520of%2520In%2520Vitro%2520to%2520In%2520Vivo%2520translation%2520of%2520a%2520TYK2%2520inhibitor%2520that%2520shows%2520cross%2520species%2520potency%2520differences%26jtitle%3DSci.%2520Rep.%26date%3D2020%26volume%3D10%26spage%3D8974%26doi%3D10.1038%2Fs41598-020-65762-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span> <span> </span><span class="NLM_article-title">An efficient synthesis of Baricitinib</span>. <i>J. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.3184/174751916X14569294811333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.3184%2F174751916X14569294811333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVers77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2016&pages=205-208&author=J.+Xuauthor=J.+Caiauthor=J.+Chenauthor=X.+Zongauthor=X.+Wuauthor=M.+Jiauthor=P.+Wang&title=An+efficient+synthesis+of+Baricitinib&doi=10.3184%2F174751916X14569294811333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">An efficient synthesis of baricitinib</span></div><div class="casAuthors">Xu, Jiaojiao; Cai, Jin; Chen, Junding; Zong, Xi; Wu, Xuan; Ji, Min; Wang, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">205-208</span>CODEN:
                <span class="NLM_cas:coden">JCROA4</span>;
        ISSN:<span class="NLM_cas:issn">1747-5198</span>.
    
            (<span class="NLM_cas:orgname">Science Reviews 2000 Ltd.</span>)
        </div><div class="casAbstract">A highly efficient method for the synthesis of baricitinib was developed.  The starting material tert-Bu 3-oxoazetidine-1-carboxylate was converted to intermediate 2-(1-(ethylsulfonyl)azetidin-3-ylidene)acetonitrile via the Horner-Emmons reaction, deprotection of the N-Boc-group and a final sulfonamidation reaction.  Then the nucleophilic addn. reaction was carried out smoothly to afford the borate intermediate in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene under reflux.  Finally, the desired compd. baricitinib was obtained by the Suzuki coupling reaction of 4-chloro-7-H-pyrrolo[2,3-d]pyrimidine with the above borate intermediate.  All compds. were characterised by IR, MS, 1H NMR and 13C NMR.  The overall yield in this synthetic route was as high as 49%.  Moreover, this procedure was straightforward to carry out, had low cost and was suitable for industrial prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmrkAF79V4r7Vg90H21EOLACvtfcHk0lhAEYIpdj9uiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVers77F&md5=1028a8f75d586f7c99e984d187128efb</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.3184%2F174751916X14569294811333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3184%252F174751916X14569294811333%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DZong%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DJi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DP.%26atitle%3DAn%2520efficient%2520synthesis%2520of%2520Baricitinib%26jtitle%3DJ.%2520Chem.%2520Res.%26date%3D2016%26volume%3D40%26spage%3D205%26epage%3D208%26doi%3D10.3184%2F174751916X14569294811333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taydakov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasnoselskiy, S. S.</span></span> <span> </span><span class="NLM_article-title">Direct electrophilic acylation of n-substituted pyrazoles by anhydrides of carboxylic acids</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">2188</span>– <span class="NLM_lpage">2192</span>, <span class="refDoi"> DOI: 10.1055/s-0033-1338923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1055%2Fs-0033-1338923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVOls7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=2188-2192&author=I.+V.+Taydakovauthor=S.+S.+Krasnoselskiy&title=Direct+electrophilic+acylation+of+n-substituted+pyrazoles+by+anhydrides+of+carboxylic+acids&doi=10.1055%2Fs-0033-1338923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Direct electrophilic acylation of N-substituted pyrazoles by anhydrides of carboxylic acids</span></div><div class="casAuthors">Taydakov, Ilya V.; Krasnoselskiy, Sergey S.</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2188-2192</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">A simple, convenient, and scalable approach to 1-substituted 4-acylpyrazoles through direct acylation of pyrazoles by anhydrides of aliph., arom., and fluorinated carboxylic acids in the presence of concd. H2SO4 as a catalyst is described.  Target ketones were obtained in 41-86% isolated yields in high purity without laborious purifn.  The scope and limitations of the method are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2gYpeAheGD7Vg90H21EOLACvtfcHk0lgO781upckJuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVOls7nK&md5=b4c14576c7d5a1aaf446f593cbe5a46f</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1055%2Fs-0033-1338923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0033-1338923%26sid%3Dliteratum%253Aachs%26aulast%3DTaydakov%26aufirst%3DI.%2BV.%26aulast%3DKrasnoselskiy%26aufirst%3DS.%2BS.%26atitle%3DDirect%2520electrophilic%2520acylation%2520of%2520n-substituted%2520pyrazoles%2520by%2520anhydrides%2520of%2520carboxylic%2520acids%26jtitle%3DSynthesis%26date%3D2013%26volume%3D45%26spage%3D2188%26epage%3D2192%26doi%3D10.1055%2Fs-0033-1338923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span> <span> </span><span class="NLM_article-title">Steric redirection of alkylation in 1H-pyrazole-3-carboxylate esters</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">405</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2017.12.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1016%2Fj.tetlet.2017.12.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVejtr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=402-405&author=S.+W.+Wrightauthor=E.+P.+Arnoldauthor=X.+Yang&title=Steric+redirection+of+alkylation+in+1H-pyrazole-3-carboxylate+esters&doi=10.1016%2Fj.tetlet.2017.12.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Steric redirection of alkylation in 1H-pyrazole-3-carboxylate esters</span></div><div class="casAuthors">Wright, Stephen W.; Arnold, Eric P.; Yang, Xiaojing</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">402-405</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The alkylation of Et 1H-pyrazole-3-carboxylates I [R1 = H, (CH3)3Si, (CH3CH2)3Si, ((CH3)3C)(H3C)2Si, (CH3)2CHSi, etc.; R2 = H] with a variety of alkylating agents in the presence of K2CO3 was found to largely favor the formation of Et 1-substituted pyrazole-3-carboxylates I [R2 = 2-{1-[(4-methoxyphenyl)methyl]-1H-pyrazol-3-yl}-2- oxoethyl, 2-(1-methyl-1H-pyrazol-5-yl)-2-oxoethyl, benzyl, etc.].  The alkylation could be sterically redirected by the use of a triphenylsilyl group, such as Et 3-(triphenylsilyl)-1H-pyrazole-5-carboxylate to provide synthetically useful yields of Et 1-substituted-3-(triphenylsilyl)-1H-pyrazole-5-carboxylates II [R2 = 2-{1-[(4-methoxyphenyl)methyl]-1H-pyrazol-3-yl}-2-oxoethyl, 2-(1-methyl-1H-pyrazol-5-yl)-2-oxoethyl, benzyl, etc.].  The triphenylsilyl group could be removed with Bu4NF.  Other triorganosilyl groups (TMS, TES, TBDMS) failed to provide significant redirection, while TIPS proved refractory to protodesilylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcWno53KkqR7Vg90H21EOLACvtfcHk0lgO781upckJuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVejtr%252FK&md5=9cdfe1b4f0b507543fb9d9b919aa77ad</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2017.12.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2017.12.052%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DS.%2BW.%26aulast%3DArnold%26aufirst%3DE.%2BP.%26aulast%3DYang%26aufirst%3DX.%26atitle%3DSteric%2520redirection%2520of%2520alkylation%2520in%25201H-pyrazole-3-carboxylate%2520esters%26jtitle%3DTetrahedron%2520Lett.%26date%3D2018%26volume%3D59%26spage%3D402%26epage%3D405%26doi%3D10.1016%2Fj.tetlet.2017.12.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aicart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavoungou-Gomès, L.</span></span> <span> </span><span class="NLM_article-title">Conversion des furfurylalkyl et arylcetones en derives de l’isocoumarine et de l’isoquinoleine</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">925</span>, <span class="refDoi"> DOI: 10.1002/jhet.5570220361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1002%2Fjhet.5570220361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADyaL28Xht12ktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1985&pages=921-925&author=M.+Aicartauthor=L.+Mavoungou-Gom%C3%A8s&title=Conversion+des+furfurylalkyl+et+arylcetones+en+derives+de+l%E2%80%99isocoumarine+et+de+l%E2%80%99isoquinoleine&doi=10.1002%2Fjhet.5570220361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Conversion of furfuryl alkyl and aryl ketones into isocoumarin and isoquinoline derivatives</span></div><div class="casAuthors">Aicart, Michel; Mavoungou-Gomes, Louis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">921-5</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">0022-152X</span>.
    </div><div class="casAbstract">Cycloadducts I (R = Me, Ph), obtained by cycloaddn. of furfuryl ketones with Me acetylenedicarboxylate, undergo acid-catalyzed rearrangement in high yield to 6-hydroxyphthalates II.  II are useful intermediates for the synthesis of isocoumarins, e.g. III, and isoquinolines, e.g. IV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL_lt33iqz8rVg90H21EOLACvtfcHk0lgO781upckJuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xht12ktbc%253D&md5=ae0ab34b4c357c4d3ab319f05f40b2ae</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570220361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570220361%26sid%3Dliteratum%253Aachs%26aulast%3DAicart%26aufirst%3DM.%26aulast%3DMavoungou-Gom%25C3%25A8s%26aufirst%3DL.%26atitle%3DConversion%2520des%2520furfurylalkyl%2520et%2520arylcetones%2520en%2520derives%2520de%2520l%25E2%2580%2599isocoumarine%2520et%2520de%2520l%25E2%2580%2599isoquinoleine%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1985%26volume%3D22%26spage%3D921%26epage%3D925%26doi%3D10.1002%2Fjhet.5570220361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rathke, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, M.</span></span> <span> </span><span class="NLM_article-title">The Horner-Wadsworth-Emmons modification of the Wittig reaction using triethylamine and lithium or magnesium salts</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2624</span>– <span class="NLM_lpage">2626</span>, <span class="refDoi"> DOI: 10.1021/jo00215a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00215a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADyaL2MXksFelurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1985&pages=2624-2626&author=M.+W.+Rathkeauthor=M.+Nowak&title=The+Horner-Wadsworth-Emmons+modification+of+the+Wittig+reaction+using+triethylamine+and+lithium+or+magnesium+salts&doi=10.1021%2Fjo00215a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The Horner-Wadsworth-Emmons modification of the Wittig reaction using triethylamine and lithium or magnesium salts</span></div><div class="casAuthors">Rathke, Michael W.; Nowak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2624-6</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">Aldehydes were converted into the corresponding α,β-unsatd. esters using (EtO)2P(O)CH2CO2Et and Et3N in the presence of Li or Mg halides.  Under the same conditions, simple Me ketones were unreactive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSmdCP8rY7FbVg90H21EOLACvtfcHk0limBW9yjv-jPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXksFelurg%253D&md5=4ddfc256c1b9eb0ab64f40063414870f</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjo00215a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00215a004%26sid%3Dliteratum%253Aachs%26aulast%3DRathke%26aufirst%3DM.%2BW.%26aulast%3DNowak%26aufirst%3DM.%26atitle%3DThe%2520Horner-Wadsworth-Emmons%2520modification%2520of%2520the%2520Wittig%2520reaction%2520using%2520triethylamine%2520and%2520lithium%2520or%2520magnesium%2520salts%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1985%26volume%3D50%26spage%3D2624%26epage%3D2626%26doi%3D10.1021%2Fjo00215a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="note"><p class="first last">For <b>23</b> and <b>24</b>, Suzuki–Miyaura coupling was performed with <i>tert</i>-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole-1-carboxylate. For <b>25</b> and <b>26</b>, Suzuki–Miyaura coupling was performed with 1-(tetrahydropyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole. For <b>27</b> and <b>28</b>, Suzuki–Miyaura coupling was performed with 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':[]}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 10 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Chunjian Liu, James Lin, Charles Langevine, Daniel Smith, Jianqing Li, John S. Tokarski, Javed Khan, Max Ruzanov, Joann Strnad, Adriana Zupa-Fernandez, Lihong Cheng, Kathleen M. Gillooly, David Shuster, Yifan Zhang, Anil Thankappan, Kim W. McIntyre, Charu Chaudhry, Paul A. Elzinga, Manoj Chiney, Anjaneya Chimalakonda, Louis J. Lombardo, John E. Macor, Percy H. Carter, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">David S. Weinstein</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 677-694. <a href="https://doi.org/10.1021/acs.jmedchem.0c01698" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01698</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01698%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBMS-986202%25253A%252BA%252BClinical%252BTyk2%252BInhibitor%252Bthat%252BBinds%252Bto%252BTyk2%252BJH2%26aulast%3DLiu%26aufirst%3DChunjian%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D28092020%26date%3D28122020%26volume%3D64%26issue%3D1%26spage%3D677%26epage%3D694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suravi  Raychaudhuri</span>, <span class="hlFld-ContribAuthor ">Karmtej Singh  Cheema</span>, <span class="hlFld-ContribAuthor ">Smriti K.  Raychaudhuri</span>, <span class="hlFld-ContribAuthor ">Siba P.  Raychaudhuri</span>. </span><span class="cited-content_cbyCitation_article-title">Janus kinase–signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Rheumatology</span><span> <strong>2021,</strong> <em>33 </em>
                                    (4)
                                     , 348-355. <a href="https://doi.org/10.1097/BOR.0000000000000810" title="DOI URL">https://doi.org/10.1097/BOR.0000000000000810</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/BOR.0000000000000810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FBOR.0000000000000810%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Rheumatology%26atitle%3DJanus%252Bkinase%2525E2%252580%252593signal%252Btransducers%252Band%252Bactivators%252Bof%252Btranscription%252Bcell%252Bsignaling%252Bin%252BSpondyloarthritis%25253A%252Brationale%252Band%252Bevidence%252Bfor%252BJAK%252Binhibition%26aulast%3DRaychaudhuri%26aufirst%3DSuravi%26date%3D2021%26date%3D2021%26volume%3D33%26issue%3D4%26spage%3D348%26epage%3D355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvio  Danese</span>, <span class="hlFld-ContribAuthor ">Laurent  Peyrin-Biroulet</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise. </span><span class="cited-content_cbyCitation_journal-name">Inflammatory Bowel Diseases</span><span> <strong>2021,</strong> <em>8 </em><a href="https://doi.org/10.1093/ibd/izab135" title="DOI URL">https://doi.org/10.1093/ibd/izab135</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/ibd/izab135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fibd%2Fizab135%26sid%3Dliteratum%253Aachs%26jtitle%3DInflammatory%2520Bowel%2520Diseases%26atitle%3DSelective%252BTyrosine%252BKinase%252B2%252BInhibition%252Bfor%252BTreatment%252Bof%252BInflammatory%252BBowel%252BDisease%25253A%252BNew%252BHope%252Bon%252Bthe%252BRise%26aulast%3DDanese%26aufirst%3DSilvio%26date%3D2021%26date%3D2021%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesca Romana  Spinelli</span>, <span class="hlFld-ContribAuthor ">Françoise  Meylan</span>, <span class="hlFld-ContribAuthor ">John J.  O'Shea</span>, <span class="hlFld-ContribAuthor ">Massimo  Gadina</span>. </span><span class="cited-content_cbyCitation_article-title">JAK inhibitors: Ten years after. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Immunology</span><span> <strong>2021,</strong> <em> </em><a href="https://doi.org/10.1002/eji.202048922" title="DOI URL">https://doi.org/10.1002/eji.202048922</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/eji.202048922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Feji.202048922%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Immunology%26atitle%3DJAK%252Binhibitors%25253A%252BTen%252Byears%252Bafter%26aulast%3DSpinelli%26aufirst%3DFrancesca%2BRomana%26date%3D2021%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiamin  Zheng</span>, <span class="hlFld-ContribAuthor ">Jun  Wu</span>, <span class="hlFld-ContribAuthor ">Xiao  Ding</span>, <span class="hlFld-ContribAuthor ">Hong C.  Shen</span>, <span class="hlFld-ContribAuthor ">Ge  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>38 </em>, 127862. <a href="https://doi.org/10.1016/j.bmcl.2021.127862" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127862%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSmall%252Bmolecule%252Bapproaches%252Bto%252Btreat%252Bautoimmune%252Band%252Binflammatory%252Bdiseases%252B%252528Part%252BI%252529%25253A%252BKinase%252Binhibitors%26aulast%3DZheng%26aufirst%3DJiamin%26date%3D2021%26volume%3D38%26spage%3D127862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Przemysław J.  Kotyla</span>, <span class="hlFld-ContribAuthor ">Małgorzata  Engelmann</span>, <span class="hlFld-ContribAuthor ">Joanna  Giemza-Stokłosa</span>, <span class="hlFld-ContribAuthor ">Bartosz  Wnuk</span>, <span class="hlFld-ContribAuthor ">Md Asiful  Islam</span>. </span><span class="cited-content_cbyCitation_article-title">Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (5)
                                     , 2449. <a href="https://doi.org/10.3390/ijms22052449" title="DOI URL">https://doi.org/10.3390/ijms22052449</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22052449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22052449%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DThromboembolic%252BAdverse%252BDrug%252BReactions%252Bin%252BJanus%252BKinase%252B%252528JAK%252529%252BInhibitors%25253A%252BDoes%252Bthe%252BInhibitor%252BSpecificity%252BPlay%252Ba%252BRole%25253F%26aulast%3DKotyla%26aufirst%3DPrzemys%25C5%2582aw%2BJ.%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D5%26spage%3D2449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Synthesis of PF-06826647. </span><span class="cited-content_cbyCitation_journal-name">Synfacts</span><span> <strong>2021,</strong>,, 0124. <a href="https://doi.org/10.1055/s-0040-1719324" title="DOI URL">https://doi.org/10.1055/s-0040-1719324</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/s-0040-1719324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fs-0040-1719324%26sid%3Dliteratum%253Aachs%26jtitle%3DSynfacts%26atitle%3DSynthesis%252Bof%252BPF-06826647%26date%3D2021%26date%3D2021%26volume%3D17%26issue%3D02%26spage%3D0124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Georgi K  Kanev</span>, <span class="hlFld-ContribAuthor ">Chris  de Graaf</span>, <span class="hlFld-ContribAuthor ">Bart A  Westerman</span>, <span class="hlFld-ContribAuthor ">Iwan J P  de Esch</span>, <span class="hlFld-ContribAuthor ">Albert J  Kooistra</span>. </span><span class="cited-content_cbyCitation_article-title">KLIFS: an overhaul after the first 5 years of supporting kinase research. </span><span class="cited-content_cbyCitation_journal-name">Nucleic Acids Research</span><span> <strong>2021,</strong> <em>49 </em>
                                    (D1)
                                     , D562-D569. <a href="https://doi.org/10.1093/nar/gkaa895" title="DOI URL">https://doi.org/10.1093/nar/gkaa895</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/nar/gkaa895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fnar%2Fgkaa895%26sid%3Dliteratum%253Aachs%26jtitle%3DNucleic%2520Acids%2520Research%26atitle%3DKLIFS%25253A%252Ban%252Boverhaul%252Bafter%252Bthe%252Bfirst%252B5%252Byears%252Bof%252Bsupporting%252Bkinase%252Bresearch%26aulast%3DKanev%26aufirst%3DGeorgi%2BK%26date%3D2021%26date%3D2020%26volume%3D49%26issue%3DD1%26spage%3DD562%26epage%3DD569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Konstantina  Vougogiannopoulou</span>, <span class="hlFld-ContribAuthor ">Angela  Corona</span>, <span class="hlFld-ContribAuthor ">Enzo  Tramontano</span>, <span class="hlFld-ContribAuthor ">Michael N.  Alexis</span>, <span class="hlFld-ContribAuthor ">Alexios-Leandros  Skaltsounis</span>. </span><span class="cited-content_cbyCitation_article-title">Natural and Nature-Derived Products Targeting Human Coronaviruses. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (2)
                                     , 448. <a href="https://doi.org/10.3390/molecules26020448" title="DOI URL">https://doi.org/10.3390/molecules26020448</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26020448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26020448%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DNatural%252Band%252BNature-Derived%252BProducts%252BTargeting%252BHuman%252BCoronaviruses%26aulast%3DVougogiannopoulou%26aufirst%3DKonstantina%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D2%26spage%3D448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Quentin T. L.  Pasquer</span>, <span class="hlFld-ContribAuthor ">Ioannis A.  Tsakoumagkos</span>, <span class="hlFld-ContribAuthor ">Sascha  Hoogendoorn</span>. </span><span class="cited-content_cbyCitation_article-title">From Phenotypic Hit to Chemical Probe: Chemical Biology Approaches to Elucidate Small Molecule Action in Complex Biological Systems. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (23)
                                     , 5702. <a href="https://doi.org/10.3390/molecules25235702" title="DOI URL">https://doi.org/10.3390/molecules25235702</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25235702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25235702%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DFrom%252BPhenotypic%252BHit%252Bto%252BChemical%252BProbe%25253A%252BChemical%252BBiology%252BApproaches%252Bto%252BElucidate%252BSmall%252BMolecule%252BAction%252Bin%252BComplex%252BBiological%252BSystems%26aulast%3DPasquer%26aufirst%3DQuentin%2BT.%2BL.%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D23%26spage%3D5702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Approved JAK kinase inhibitors and disclosed clinical stage TYK2 kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Two different TYK2 hinge binding modes: modeled <b>2</b> (yellow) superimposed with <b>7</b> TYK2 protein X-ray structures (green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBM">6DBM</a>) with Ile960 highlighted in purple. (b) General scaffolding strategy for a [5,6]-fused ring hinge binder.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. [5,6] Fused aromatic TYK2 lead structures <b>8</b>–<b>11</b> with electrostatic potential maps calculated in Spartan ’18 with Hartree–Fock 6-31G*.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Protein X-ray structure of <b>11</b> bound to TYK2 (green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6X8F">6X8F</a>) at 2.15 Å with crystallographic waters. (b) Overlay of P-loop region of protein X-ray structure of <b>11</b> bound to TYK2 (green) at 2.15 Å with Connolly surface and JAK2 (blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6X8E">6X8E</a>) at 1.75 Å.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Protein X-ray structure of <b>22</b> in TYK2 (yellow, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6X8G">6X8G</a>)) at 2.21 Å with electrostatic potential map and modeled APO waters in the P-loop (spheres). (b) Top view of the hinge and solvent exposed region of the protein X-ray structure of <b>22</b> showing two-point interaction with Val981</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Radial plot of cytokine inhibition IC<sub>xx</sub> relative to the IL-12 IC<sub>80</sub> for compound <b>22</b>, derived from potency in human whole blood assays and predicted average daily human plasma drug concentration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>22</b> dosed at 30, 10, 3, and 1 mg/kg, po, QD inhibited ear swelling in the imiquimod-induced skin inflammation model. Compound <b>22</b> significantly inhibited ear swelling when compared to the vehicle-treated mice (<i>n</i> = 12) (30 mg/kg, 46.2%, <i>p</i> = 0.0004, 10 mg/kg, 34%, <i>p</i> = 0.0145, and 3 mg/kg, 31.3% (0.0198). The effect of the 1 mg/kg dose was not statistically significant (ns) when compared to the vehicle-treated mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>8</b>, <b>9</b>, and <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>30</b>, DBU, MeCN, 50–90 °C, 4–18 h; (b) K<sub>2</sub>CO<sub>3</sub> or Cs<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, 1,4-dioxane, H<sub>2</sub>O, 95–100 °C, 16–48 h; (c) 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, K<sub>2</sub>CO<sub>3</sub> or CsF, Pd(dppf)Cl<sub>2</sub>, 1,4-dioxane or Et(Me)<sub>2</sub>COH, 70–100 °C, 18–48 h; (d) (1) MsOH or HCl, MeCN or dioxane, 20–30 °C, 16–20 h; (2) CF<sub>3</sub>CH<sub>2</sub>OTf, DIEA, DMF or MeCN, 0–20 °C, 2–24 h; (e) (1-(<i>tert</i>-butoxycarbonyl)-1<i>H</i>-pyrazol-4-yl)boronic acid, Cs<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, 1,4-dioxane, H<sub>2</sub>O, 95 °C, 16 h; (f) <b>30</b>, DBU, MeCN, 30 °C, 16 h.</p></p></figure><figure data-id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>47</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>42</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 20 °C, 18 h; (b) NH<sub>4</sub>OAc, EtOH, 130 °C, 24 h; (c) NaOH, MeOH, H<sub>2</sub>O, 20 °C, 18 h; (d) sulfolane, 280 °C, 2 h; (e) POCl<sub>3</sub>, MeCN, 85 °C, 48 h.</p></p></figure><figure data-id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Dichloropyrazolopyrazine <b>52</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ClCH<sub>2</sub>CN, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 25 °C, 16 h; (b) H<sub>2</sub>SO<sub>4</sub>, TFA, 25 °C, 16 h; (c) NaO<i>t-</i>Bu, EtOH, THF, 70 °C, 16 h; (d) POCl<sub>3</sub>, PyHCl, 120 °C, 18 h.</p></p></figure><figure data-id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Syntheses of <i>trans</i> and <i>cis</i> Cyclobutyl-Substituted Pyrazole Boronates <b>59</b>–<b>64</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NCCH<sub>2</sub>P(O)(OEt)<sub>2</sub>, LiBr, Et<sub>3</sub>N, THF, 10–25 °C, 16–20 h. (b) For <b>59</b>, <b>60</b>, <b>62</b>, <b>63</b>: <b>29</b>, DBU, MeCN, 20–25 °C, 16–18 h. (c) For <b>61</b>, <b>64</b>: 4-bromo-1<i>H</i>-pyrazole, DBU, MeCN, 25 °C, 18 h; (d) B<sub>2</sub>Pin<sub>2</sub>, KOAc, XPhos Pd G3, 1,4-dioxane, 65 °C, 2 h.</p></p></figure><figure data-id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/medium/jm0c00948_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Test Compounds <b>11</b>—<b>28</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00948/20201120/images/large/jm0c00948_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00948&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>31</b>, K<sub>3</sub>PO<sub>4</sub>, XPhos Pd G2, 1,4-dioxane, H<sub>2</sub>O, 60 °C, 5 h; (b) (1) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 20 °C, 90 min; (2) PS-carbonate; (c) CF<sub>3</sub>CH<sub>2</sub>OTf, DIEA, DMF, 20 °C, 18 h; (d) CH<sub>3</sub>CHO, NaOAc, NaBH(OAc)<sub>3</sub>, MeOH, 25 °C, 16 h; (e) <i>c-</i>PrCHO, NaOAc, NaBH(OAc)<sub>3</sub>, MeOH, 25 °C, 16 h; (f) Ac<sub>2</sub>O, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 25 °C, 2 h; (g) BrCH<sub>2</sub>CH<sub>2</sub>OH, K<sub>2</sub>CO<sub>3</sub>, MeCN, 50 °C, 64 h; (h) BrCH<sub>2</sub>CN, DIEA, DMF, 20 °C, 22 h; (i) <b>59</b>–<b>64</b>, K<sub>3</sub>PO<sub>4</sub>, XPhos Pd G3, 1,4-dioxane, H<sub>2</sub>O, 40–55 °C, 1–18 h; (j) <b>59</b> or <b>62</b>, K<sub>3</sub>PO<sub>4</sub>, Pd(<i>t-</i>Bu<sub>3</sub>P)<sub>2</sub>, 1,4-dioxane, H<sub>2</sub>O, 25 °C, 2 h; (k) pyrazole boronate,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> K<sub>3</sub>PO<sub>4</sub>, XPhos Pd G3, 1,4-dioxane, H<sub>2</sub>O, 60 °C, 1 h; (l) TFA, TFAA, 25 °C, 0.5–2 h.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86440" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86440" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 56 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazaniga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furumoto, Y.</span></span> <span> </span><span class="NLM_article-title">Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases</span>. <i>J. Autoimmun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/j.jaut.2017.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1016%2Fj.jaut.2017.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=28676205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFantL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2017&pages=20-31&author=M.+Gadinaauthor=N.+Gazanigaauthor=L.+Vianauthor=Y.+Furumoto&title=Small+molecules+to+the+rescue%3A+Inhibition+of+cytokine+signaling+in+immune-mediated+diseases&doi=10.1016%2Fj.jaut.2017.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases</span></div><div class="casAuthors">Gadina, Massimo; Gazaniga, Nathalia; Vian, Laura; Furumoto, Yasuko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Autoimmunity</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20-31</span>CODEN:
                <span class="NLM_cas:coden">JOAUEP</span>;
        ISSN:<span class="NLM_cas:issn">0896-8411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cytokines are small, secreted proteins assocd. with the maintenance of immune homeostasis but also implicated with the pathogenesis of several autoimmune and inflammatory diseases.  Biol. agents blocking cytokines or their receptors have revolutionized the treatment of such pathologies.  Nonetheless, some patients fail to respond to these drugs or do not achieve complete remission.  The signal transduction originating from membrane-bound cytokine receptors is an intricate network of events that lead to gene expression and ultimately regulate cellular functionality.  Our understanding of the intracellular actions that mols. such as interleukins, interferons (IFNs) and tumor necrosis factor (TNF) set into motion has greatly increased in the past few years, making it possible to interfere with cytokines' signaling cascades.  The Janus kinase (JAK)/signal transducer and activator of transcription (STAT), the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), the mitogen activated protein kinase (MAPK) and the Phosphatidylinositol-3'-kinases (PI3K) pathways have all been intensively studied and key steps as well as mols. have been identified.  These research efforts have led to the development of a new generation of small mol. inhibitors.  Drugs capable of blocking JAK enzymic activity or interfering with the proteasome-mediated degrdn. of intermediates in the NF-kB pathway have already entered the clin. arena confirming the validity of this approach.  In this review, we have recapitulated the biochem. events downstream of cytokine receptors and discussed some of the drugs which have already been successfully utilized in the clinic.  Moreover, we have highlighted some of the new mols. that are currently being developed for the treatment of immune-mediated pathologies and malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDTXRNMB9IorVg90H21EOLACvtfcHk0liJdQKo9CS-cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFantL3J&md5=42c5e58da4a9d0b1e39e08bcc6875af4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.jaut.2017.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaut.2017.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DGazaniga%26aufirst%3DN.%26aulast%3DVian%26aufirst%3DL.%26aulast%3DFurumoto%26aufirst%3DY.%26atitle%3DSmall%2520molecules%2520to%2520the%2520rescue%253A%2520Inhibition%2520of%2520cytokine%2520signaling%2520in%2520immune-mediated%2520diseases%26jtitle%3DJ.%2520Autoimmun.%26date%3D2017%26volume%3D85%26spage%3D20%26epage%3D31%26doi%3D10.1016%2Fj.jaut.2017.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">843</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1038%2Fnrd.2017.201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=29104284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=843&author=D.+M.+Schwartzauthor=Y.+Kannoauthor=A.+Villarinoauthor=M.+Wardauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=JAK+inhibition+as+a+therapeutic+strategy+for+immune+and+inflammatory+diseases&doi=10.1038%2Fnrd.2017.201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Kanno, Yuka; Villarino, Alejandro; Ward, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">843-862</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts to target their assocd. signalling pathways.  Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines, and small-mol. inhibitors of JAKs (jakinibs) have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.  Building on the clin. success of first-generation jakinibs, second-generation compds. that claim to be more selective are currently undergoing development and proceeding to clin. trials.  However, important questions remain about the advantages and limitations of improved JAK selectivity, optimal routes and dosing regimens and how best to identify patients who will benefit from jakinibs.  This Review discusses the biol. of jakinibs from a translational perspective, focusing on recent insights from clin. trials, the development of novel agents and the use of jakinibs in a spectrum of immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TNpGT01l8rVg90H21EOLACvtfcHk0liJdQKo9CS-cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO&md5=4607422f83f94c0c7194935d6d460c31</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.201%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DVillarino%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJAK%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520for%2520immune%2520and%2520inflammatory%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D843%26doi%3D10.1038%2Fnrd.2017.201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solimani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreschi, K.</span></span> <span> </span><span class="NLM_article-title">Emerging topical and systemic JAK inhibitors in dermatology</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2847</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2019.02847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.3389%2Ffimmu.2019.02847" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=31849996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVeqtbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=2847&author=F.+Solimaniauthor=K.+Meierauthor=K.+Ghoreschi&title=Emerging+topical+and+systemic+JAK+inhibitors+in+dermatology&doi=10.3389%2Ffimmu.2019.02847"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging topical and systemic JAK inhibitors in dermatology</span></div><div class="casAuthors">Solimani, Farzan; Meier, Katharina; Ghoreschi, Kamran</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2847</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Accumulating data on cellular and mol. pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity.  Examples are psoriasis and atopic dermatitis, two clin. and immunol. well-defined disorders.  Here, the elucidation of key pathogenic factors such as IL-17A/IL-23 on the one hand and IL-4/IL-13 on the other hand profoundly changed our therapeutic practice.  The knowledge on intracellular pathways and governing factors is shifting our attention to new druggable mols.  Multiple cytokine receptors signal through Janus kinases (JAKs) and assocd. signal transducer and activators of transcription (STATs).  Inhibition of JAKs can simultaneously block the function of multiple cytokines.  Therefore, JAK inhibitors (JAKi) are emerging as a new class of drugs, which in dermatol. can either be used systemically as oral drugs or locally in topical formulations.  Inhibition of JAKs has been shown to be effective in various skin disorders.  The first oral JAKi have been recently approved for the treatment of rheumatoid arthritis and psoriatic arthritis.  Currently, multiple inhibitors of the JAK/STAT pathway are being investigated for skin diseases like alopecia areata, atopic dermatitis, dermatomyositis, graft-vs.-host-disease, hidradenitis suppurativa, lichen planus, lupus erythematosus, psoriasis, and vitiligo.  Here, we aim to discuss the immunol. basis and current stage of development of JAKi in dermatol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2BP8439dq-7Vg90H21EOLACvtfcHk0ljP7ArV18w1bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVeqtbfE&md5=fb32839b61c2d3d61d5deb80d5098b72</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2019.02847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2019.02847%26sid%3Dliteratum%253Aachs%26aulast%3DSolimani%26aufirst%3DF.%26aulast%3DMeier%26aufirst%3DK.%26aulast%3DGhoreschi%26aufirst%3DK.%26atitle%3DEmerging%2520topical%2520and%2520systemic%2520JAK%2520inhibitors%2520in%2520dermatology%26jtitle%3DFront.%2520Immunol.%26date%3D2019%26volume%3D10%26spage%3D2847%26doi%3D10.3389%2Ffimmu.2019.02847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jesson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katkade, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span> <span> </span><span class="NLM_article-title">Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition</span>. <i>Pharmacol. Res. Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e00537</span> <span class="refDoi"> DOI: 10.1002/prp2.537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1002%2Fprp2.537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=31832202" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&author=M.+E.+Dowtyauthor=T.+H.+Linauthor=M.+I.+Jessonauthor=M.+Hegenauthor=D.+A.+Martinauthor=V.+Katkadeauthor=S.+Menonauthor=J.-B.+Telliez&title=Janus+kinase+inhibitors+for+the+treatment+of+rheumatoid+arthritis+demonstrate+similar+profiles+of+in+vitro+cytokine+receptor+inhibition&doi=10.1002%2Fprp2.537"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fprp2.537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.537%26sid%3Dliteratum%253Aachs%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DD.%2BA.%26aulast%3DKatkade%26aufirst%3DV.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DJanus%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%2520demonstrate%2520similar%2520profiles%2520of%2520in%2520vitro%2520cytokine%2520receptor%2520inhibition%26jtitle%3DPharmacol.%2520Res.%2520Perspect.%26date%3D2019%26volume%3D7%26doi%3D10.1002%2Fprp2.537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferdinand, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Jak/STAT signaling in immunity and disease</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1401867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.4049%2Fjimmunol.1401867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=25527793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWls7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2015&pages=21-27&author=A.+V.+Villarinoauthor=Y.+Kannoauthor=J.+R.+Ferdinandauthor=J.+J.+O%E2%80%99Shea&title=Mechanisms+of+Jak%2FSTAT+signaling+in+immunity+and+disease&doi=10.4049%2Fjimmunol.1401867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Jak/STAT Signaling in Immunity and Disease</span></div><div class="casAuthors">Villarino, Alejandro V.; Kanno, Yuka; Ferdinand, John R.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-27</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">A review.  More than two decades ago, expts. on the antiviral mechanisms of IFNs led to the discovery of JAKs and their downstream effectors, the STAT proteins.  This pathway has since become a paradigm for membrane-to-nucleus signaling and explains how a broad range of sol. factors, including cytokines and hormones, mediate their diverse functions.  Jak/STAT research has not only impacted basic science, particularly in the context of intercellular communication and cell-extrinsic control of gene expression, it also has become a prototype for transition from bench to bedside, culminating in the development and clin. implementation of pathway-specific therapeutics.  This brief review synthesizes our current understanding of Jak/STAT biol. while taking stock of the lessons learned and the challenges that lie ahead.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotOsFFpF-ChLVg90H21EOLACvtfcHk0ljP7ArV18w1bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWls7rF&md5=777f0f64db038ca8a7f17554931e0655</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1401867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1401867%26sid%3Dliteratum%253Aachs%26aulast%3DVillarino%26aufirst%3DA.%2BV.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DFerdinand%26aufirst%3DJ.%2BR.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DMechanisms%2520of%2520Jak%252FSTAT%2520signaling%2520in%2520immunity%2520and%2520disease%26jtitle%3DJ.%2520Immunol.%26date%3D2015%26volume%3D194%26spage%3D21%26epage%3D27%26doi%3D10.4049%2Fjimmunol.1401867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macleod, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulagowski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin-Koh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span> <span> </span><span class="NLM_article-title">A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">2205</span>– <span class="NLM_lpage">2216</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1202859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.4049%2Fjimmunol.1202859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=23894201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=2205-2216&author=S.+J.+Sohnauthor=K.+Barrettauthor=A.+Van+Abbemaauthor=C.+Changauthor=P.+B.+Kohliauthor=H.+Kandaauthor=J.+Smithauthor=Y.+Laiauthor=A.+Zhouauthor=B.+Zhangauthor=W.+Yangauthor=K.+Williamsauthor=C.+Macleodauthor=C.+A.+Hurleyauthor=J.+J.+Kulagowskiauthor=N.+Lewin-Kohauthor=H.+S.+Denglerauthor=A.+R.+Johnsonauthor=N.+Ghilardiauthor=M.+Zakauthor=J.+Liangauthor=W.+S.+Blairauthor=S.+Magnusonauthor=L.+C.+Wu&title=A+restricted+role+for+TYK2+catalytic+activity+in+human+cytokine+responses+revealed+by+novel+TYK2-selective+inhibitors&doi=10.4049%2Fjimmunol.1202859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors</span></div><div class="casAuthors">Sohn, Sue J.; Barrett, Kathy; Van Abbema, Anne; Chang, Christine; Kohli, Pawan Bir; Kanda, Hidenobu; Smith, Janice; Lai, Yingjie; Zhou, Aihe; Zhang, Birong; Yang, Wenqian; Williams, Karen; MacLeod, Calum; Hurley, Christopher A.; Kulagowski, Janusz J.; Lewin-Koh, Nicholas; Dengler, Hart S.; Johnson, Adam R.; Ghilardi, Nico; Zak, Mark; Liang, Jun; Blair, Wade S.; Magnuson, Steven; Wu, Lawren C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2205-2216</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">TYK2 is a JAK family protein tyrosine kinase activated in response to multiple cytokines, including type I IFNs, IL-6, IL-10, IL-12, and IL-23.  Extensive studies of mice that lack TYK2 expression indicate that the IFN-α, IL-12, and IL-23 pathways, but not the IL-6 or IL-10 pathways, are compromised.  In contrast, there have been few studies of the role of TYK2 in primary human cells.  A genetic mutation at the tyk2 locus that results in a lack of TYK2 protein in a single human patient has been linked to defects in the IFN-α, IL-6, IL-10, IL-12, and IL-23 pathways, suggesting a broad role for TYK2 protein in human cytokine responses.  In this article, we have used a panel of novel potent TYK2 small-mol. inhibitors with varying degrees of selectivity against other JAK kinases to address the requirement for TYK2 catalytic activity in cytokine pathways in primary human cells.  Our results indicate that the biol. processes that require TYK2 catalytic function in humans are restricted to the IL-12 and IL-23 pathways, and suggest that inhibition of TYK2 catalytic activity may be an efficacious approach for the treatment of select autoimmune diseases without broad immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgACYZYW8b07Vg90H21EOLACvtfcHk0lhnrFwIC6dIfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtL%252FP&md5=527289e055e91fe2dfb15d3de7faa894</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1202859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1202859%26sid%3Dliteratum%253Aachs%26aulast%3DSohn%26aufirst%3DS.%2BJ.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DKanda%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DMacleod%26aufirst%3DC.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DLewin-Koh%26aufirst%3DN.%26aulast%3DDengler%26aufirst%3DH.%2BS.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DMagnuson%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DL.%2BC.%26atitle%3DA%2520restricted%2520role%2520for%2520TYK2%2520catalytic%2520activity%2520in%2520human%2520cytokine%2520responses%2520revealed%2520by%2520novel%2520TYK2-selective%2520inhibitors%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D2205%26epage%3D2216%26doi%3D10.4049%2Fjimmunol.1202859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dendrou, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attfield, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jostins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuttikkatte, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faergeman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheeseman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neville, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawcer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVean, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fugger, L.</span></span> <span> </span><span class="NLM_article-title">Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">363ra149</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aag1974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1126%2Fscitranslmed.aag1974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=27807284" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=363ra149&author=C.+A.+Dendrouauthor=A.+Cortesauthor=L.+Shipmanauthor=H.+G.+Evansauthor=K.+E.+Attfieldauthor=L.+Jostinsauthor=T.+Barberauthor=G.+Kaurauthor=S.+B.+Kuttikkatteauthor=O.+A.+Leachauthor=C.+Deselauthor=S.+L.+Faergemanauthor=J.+Cheesemanauthor=M.+J.+Nevilleauthor=S.+Sawcerauthor=A.+Compstonauthor=A.+R.+Johnsonauthor=C.+Everettauthor=J.+I.+Bellauthor=F.+Karpeauthor=M.+Ultschauthor=C.+Eigenbrotauthor=G.+McVeanauthor=L.+Fugger&title=Resolving+TYK2+locus+genotype-to-phenotype+differences+in+autoimmunity&doi=10.1126%2Fscitranslmed.aag1974"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aag1974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aag1974%26sid%3Dliteratum%253Aachs%26aulast%3DDendrou%26aufirst%3DC.%2BA.%26aulast%3DCortes%26aufirst%3DA.%26aulast%3DShipman%26aufirst%3DL.%26aulast%3DEvans%26aufirst%3DH.%2BG.%26aulast%3DAttfield%26aufirst%3DK.%2BE.%26aulast%3DJostins%26aufirst%3DL.%26aulast%3DBarber%26aufirst%3DT.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DKuttikkatte%26aufirst%3DS.%2BB.%26aulast%3DLeach%26aufirst%3DO.%2BA.%26aulast%3DDesel%26aufirst%3DC.%26aulast%3DFaergeman%26aufirst%3DS.%2BL.%26aulast%3DCheeseman%26aufirst%3DJ.%26aulast%3DNeville%26aufirst%3DM.%2BJ.%26aulast%3DSawcer%26aufirst%3DS.%26aulast%3DCompston%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DBell%26aufirst%3DJ.%2BI.%26aulast%3DKarpe%26aufirst%3DF.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DMcVean%26aufirst%3DG.%26aulast%3DFugger%26aufirst%3DL.%26atitle%3DResolving%2520TYK2%2520locus%2520genotype-to-phenotype%2520differences%2520in%2520autoimmunity%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26spage%3D363ra149%26doi%3D10.1126%2Fscitranslmed.aag1974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hundhausen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinsman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkatkar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allenspach, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clough, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eken, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oukka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerosaletti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckner, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlings, D. J.</span></span> <span> </span><span class="NLM_article-title">The TYK2-P1104A autoimmune protective variant limits coordinate signals required to generate specialized T cell subsets</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">44</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2019.00044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.3389%2Ffimmu.2019.00044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=30740104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlWktLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=44&author=J.+A.+Gormanauthor=C.+Hundhausenauthor=M.+Kinsmanauthor=T.+Arkatkarauthor=E.+J.+Allenspachauthor=C.+Cloughauthor=S.+E.+Westauthor=K.+Thomasauthor=A.+Ekenauthor=S.+Khimauthor=M.+Haleauthor=M.+Oukkaauthor=S.+W.+Jacksonauthor=K.+Cerosalettiauthor=J.+H.+Bucknerauthor=D.+J.+Rawlings&title=The+TYK2-P1104A+autoimmune+protective+variant+limits+coordinate+signals+required+to+generate+specialized+T+cell+subsets&doi=10.3389%2Ffimmu.2019.00044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The TYK2-P1104A autoimmune protective variant limits coordinate signals required to generate specialized T cell subsets</span></div><div class="casAuthors">Gorman, Jacquelyn A.; Hundhausen, Christian; Kinsman, Mackenzie; Arkatkar, Tanvi; Allenspach, Eric J.; Clough, Courtnee; West, Samuel E.; Thomas, Kerri; Eken, Ahmet; Khim, Socheath; Hale, Malika; Oukka, Mohamed; Jackson, Shaun W.; Cerosaletti, Karen; Buckner, Jane H.; Rawlings, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">44</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">TYK2 is a JAK family member that functions downstream of multiple cytokine receptors.  Genome wide assocn. studies have linked a SNP (rs34536443) within TYK2 encoding a Proline to Alanine substitution at amino acid 1104, to protection from multiple autoimmune diseases including systemic lupus erythematosus (SLE) and multiple sclerosis (MS).  The protective role of this SNP in autoimmune pathogenesis, however, remains incompletely understood.  Here we found that T follicular helper (Tfh) cells, switched memory B cells, and IFNAR signaling were decreased in healthy individuals that expressed the protective variant TYK2A1104 (TYK2P).  To study this variant in vivo, we developed a knock-in murine model of this allele.  Murine Tyk2P expressing T cells homozygous for the protective allele, but not cells heterozygous for this change, manifest decreased IL-12 receptor signaling, important for Tfh lineage commitment.  Further, homozygous Tyk2P T cells exhibited diminished in vitro Th1 skewing.  Surprisingly, despite these signaling changes, in vivo formation of Tfh and GC B cells was unaffected in two models of T cell dependent immune responses and in two alternative SLE models.  TYK2 is also activated downstream of IL-23 receptor engagement.  Here, we found that Tyk2P expressing T cells had reduced IL-23 dependent signaling as well as a diminished ability to skew toward Th17 in vitro.  Consistent with these findings, homozygous, but not heterozygous, Tyk2P mice were fully protected in a murine model of MS.  Homozygous Tyk2P mice had fewer infiltrating CD4+ T cells within the CNS.  Most strikingly, homozygous mice had a decreased proportion of IL-17+/IFNg+, double pos., pathogenic CD4+ T cells in both the draining lymph nodes (LN) and CNS.  Thus, in an autoimmunemodel, such as EAE, impacted by both altered Th1 and Th17 signaling, the Tyk2P allele can effectively shield animals from disease.  Taken together, our findings suggest that TYK2P diminishes IL-12, IL-23, and IFN I signaling and that its protective effect is most likely manifest in the setting of autoimmune triggers that concurrently dysregulate at least two of these important signaling cascades.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNTbSApKHwTrVg90H21EOLACvtfcHk0lhnrFwIC6dIfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlWktLnK&md5=ec37d6c20f9eac5eba980e5078da862a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2019.00044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2019.00044%26sid%3Dliteratum%253Aachs%26aulast%3DGorman%26aufirst%3DJ.%2BA.%26aulast%3DHundhausen%26aufirst%3DC.%26aulast%3DKinsman%26aufirst%3DM.%26aulast%3DArkatkar%26aufirst%3DT.%26aulast%3DAllenspach%26aufirst%3DE.%2BJ.%26aulast%3DClough%26aufirst%3DC.%26aulast%3DWest%26aufirst%3DS.%2BE.%26aulast%3DThomas%26aufirst%3DK.%26aulast%3DEken%26aufirst%3DA.%26aulast%3DKhim%26aufirst%3DS.%26aulast%3DHale%26aufirst%3DM.%26aulast%3DOukka%26aufirst%3DM.%26aulast%3DJackson%26aufirst%3DS.%2BW.%26aulast%3DCerosaletti%26aufirst%3DK.%26aulast%3DBuckner%26aufirst%3DJ.%2BH.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520TYK2-P1104A%2520autoimmune%2520protective%2520variant%2520limits%2520coordinate%2520signals%2520required%2520to%2520generate%2520specialized%2520T%2520cell%2520subsets%26jtitle%3DFront.%2520Immunol.%26date%3D2019%26volume%3D10%26spage%3D44%26doi%3D10.3389%2Ffimmu.2019.00044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaghi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callis, K. D.</span></span> <span> </span><span class="NLM_article-title">Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis</span>. <i>J. Drugs Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">160</span>– <span class="NLM_lpage">167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=22270196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVGisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=160-167&author=D.+Zaghiauthor=G.+G.+Kruegerauthor=K.+D.+Callis&title=Ustekinumab%3A+a+review+in+the+treatment+of+plaque+psoriasis+and+psoriatic+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis</span></div><div class="casAuthors">Zaghi, Daniel; Krueger, Gerald G.; Duffin, Kristina Callis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drugs in Dermatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">160-167</span>CODEN:
                <span class="NLM_cas:coden">JDDOBA</span>;
        ISSN:<span class="NLM_cas:issn">1545-9616</span>.
    
            (<span class="NLM_cas:orgname">Journal of Drugs in Dermatology</span>)
        </div><div class="casAbstract">A review.  Psoriasis is a complex, multigenic immune/inflammatory-mediated disorder that variably affects the skin, nails, and joints.  In Sept. 2009, ustekinumab (Stelara), a monoclonal antibody that targets interleukin 12 (IL-12) and 23 (IL-23), was approved in the United States for treatment of moderate-to-severe plaque psoriasis.  The drug's mechanism of action is derived from extensive immunol. and genomic research identifying IL-12 and IL-23 of the Th1 and Th17 inflammatory pathways, resp., as key mediators of psoriasis.  Ustekinumab is a completely human monoclonal antibody to the shared p40 subunit of IL-12 and IL-23.  The drug has demonstrated efficacy, short-term safety, and convenience of use in the treatment of plaque psoriasis and psoriatic arthritis.  Though long-term safety concerns remain, ustekinumab adds to the current treatment armamentarium and holds promise to improve quality of life.  This is a concise and current review of ustekinumab in the treatment of plaque psoriasis and psoriatic arthritis, with focus on data from the seven published clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryI6jNhNzbaLVg90H21EOLACvtfcHk0ljV51l57Seqzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVGisb4%253D&md5=0a7bc928380d0ef2ce2d0340e6d9a86f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZaghi%26aufirst%3DD.%26aulast%3DKrueger%26aufirst%3DG.%2BG.%26aulast%3DCallis%26aufirst%3DK.%2BD.%26atitle%3DUstekinumab%253A%2520a%2520review%2520in%2520the%2520treatment%2520of%2520plaque%2520psoriasis%2520and%2520psoriatic%2520arthritis%26jtitle%3DJ.%2520Drugs%2520Dermatol.%26date%3D2012%26volume%3D11%26spage%3D160%26epage%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, S. T.</span></span> <span> </span><span class="NLM_article-title">Ustekinumab: A review in moderate to severe Crohn’s disease</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1105</span>– <span class="NLM_lpage">1114</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0765-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1007%2Fs40265-017-0765-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=28528528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVOktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1105-1114&author=Y.+N.+Lambauthor=S.+T.+Duggan&title=Ustekinumab%3A+A+review+in+moderate+to+severe+Crohn%E2%80%99s+disease&doi=10.1007%2Fs40265-017-0765-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Ustekinumab: A Review in Moderate to Severe Crohn's Disease</span></div><div class="casAuthors">Lamb, Yvette N.; Duggan, Sean T.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1105-1114</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Ustekinumab (Stelara) has been recently approved in the EU and the USA as i.v. induction and s.c. maintenance therapy for adult patients with moderately to severely active Crohn's disease who have failed or were intolerant to treatment with immunomodulators, corticosteroids or at least one tumor necrosis factor (TNF) antagonist.  Ustekinumab, a monoclonal antibody to the shared p40 subunit of the proinflammatory interleukin (IL)-12 and IL-23 cytokines, has a unique mechanism of action distinct from that of TNF antagonists.  In pivotal phase III trials, compared with placebo, ustekinumab induction therapy improved clin. response and remission rates in patients who had previously failed or were intolerant to conventional therapies or at least one TNF antagonist.  When administered as s.c. maintenance therapy, ustekinumab continued to offer benefits over placebo for clin. response and remission in patients who had clin. responded to the induction therapy.  Ustekinumab was generally well tolerated as both induction and maintenance therapy; serious infections and malignancies were rare.  Thus, ustekinumab presents a promising alternative treatment option in patients with moderately to severely active Crohn's disease who have failed or are intolerant to treatment with conventional therapies or TNF antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4ftg-dQNuBbVg90H21EOLACvtfcHk0ljV51l57Seqzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVOktb8%253D&md5=eb377509b791b9b9e182a73d2a85f395</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0765-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0765-6%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DY.%2BN.%26aulast%3DDuggan%26aufirst%3DS.%2BT.%26atitle%3DUstekinumab%253A%2520A%2520review%2520in%2520moderate%2520to%2520severe%2520Crohn%25E2%2580%2599s%2520disease%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1105%26epage%3D1114%26doi%3D10.1007%2Fs40265-017-0765-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sands, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandborn, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panaccione, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johanns, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adedokun, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyrin-Biroulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Assche, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danese, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Targan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abreu, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hisamatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szapary, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marano, C.</span></span> <span> </span><span class="NLM_article-title">Ustekinumab as induction and maintenance therapy for ulcerative colitis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>381</i></span>,  <span class="NLM_fpage">1201</span>– <span class="NLM_lpage">1214</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1900750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1056%2FNEJMoa1900750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=31553833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFWnsbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2019&pages=1201-1214&author=B.+E.+Sandsauthor=W.+J.+Sandbornauthor=R.+Panaccioneauthor=C.+D.+O%E2%80%99Brienauthor=H.+Zhangauthor=J.+Johannsauthor=O.+J.+Adedokunauthor=K.+Liauthor=L.+Peyrin-Birouletauthor=G.+Van+Asscheauthor=S.+Daneseauthor=S.+Targanauthor=M.+T.+Abreuauthor=T.+Hisamatsuauthor=P.+Szaparyauthor=C.+Marano&title=Ustekinumab+as+induction+and+maintenance+therapy+for+ulcerative+colitis&doi=10.1056%2FNEJMoa1900750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Ustekinumab as induction and maintenance therapy for ulcerative colitis</span></div><div class="casAuthors">Sands, B. E.; Sandborn, W. J.; Panaccione, R.; O'Brien, C. D.; Zhang, H.; Johanns, J.; Adedokun, O. J.; Li, K.; Peyrin-Biroulet, L.; Van Assche, G.; Danese, S.; Targan, S.; Abreu, M. T.; Hisamatsu, T.; Szapary, P.; Marano, C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1201-1214</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The efficacy of ustekinumab, an antagonist of the p40 subunit of interleukin-12 and interleukin-23, as induction and maintenance therapy in patients with ulcerative colitis is unknown.  We evaluated ustekinumab as 8-wk induction therapy and 44-wk maintenance therapy in patients with moderate-to-severe ulcerative colitis.  A total of 961 patients were randomly assigned to receive an i.v. induction dose of ustekinumab (either 130 mg [320 patients] or a wt.-range-based dose that approximated 6 mg per kg of body wt. [322]) or placebo (319).  Patients who had a response to induction therapy 8 wk after administration of i.v. ustekinumab were randomly assigned again to receive s.c. maintenance injections of 90 mg of ustekinumab (either every 12 wk [172 patients] or every 8 wk [176]) or placebo (175).  The primary end point in the induction trial (week 8) and the maintenance trial (week 44) was clin. remission (defined as a total score of ≤2 on the Mayo scale [range, 0 to 12, with higher scores indicating more severe disease] and no subscore >1 [range, 0 to 3] on any of the four Mayo scale components).  The percentage of patients who had clin. remission at week 8 among patients who received i.v. ustekinumab at a dose of 130 mg (15.6%) or 6 mg per kg (15.5%) was significantly higher than that among patients who received placebo (5.3%) (P lesser than 0.001 for both comparisons).  Among patients who had a response to induction therapy with ustekinumab and underwent a second randomization, the percentage of patients who had clin. remission at week 44 was significantly higher among patients assigned to 90 mg of s.c. ustekinumab every 12 wk (38.4%) or every 8 wk (43.8%) than among those assigned to placebo (24.0%) (P = 0.002 and P lesser than 0.001, resp.).  The incidence of serious adverse events with ustekinumab was similar to that with placebo.  Through 52 wk of exposure, there were two deaths (one each from acute respiratory distress syndrome and hemorrhage from esophageal varices) and seven cases of cancer (one each of prostate, colon, renal papillary, and rectal cancer and three nonmelanoma skin cancers) among 825 patients who received ustekinumab and no deaths and one case of cancer (testicular cancer) among 319 patients who received placebo.  Ustekinumab was more effective than placebo for inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzZGJKBq2nqbVg90H21EOLACvtfcHk0ljV51l57Seqzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFWnsbbE&md5=389d274cfa9d808851957367c4900db2</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1900750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1900750%26sid%3Dliteratum%253Aachs%26aulast%3DSands%26aufirst%3DB.%2BE.%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DPanaccione%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%2BD.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DJohanns%26aufirst%3DJ.%26aulast%3DAdedokun%26aufirst%3DO.%2BJ.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DPeyrin-Biroulet%26aufirst%3DL.%26aulast%3DVan%2BAssche%26aufirst%3DG.%26aulast%3DDanese%26aufirst%3DS.%26aulast%3DTargan%26aufirst%3DS.%26aulast%3DAbreu%26aufirst%3DM.%2BT.%26aulast%3DHisamatsu%26aufirst%3DT.%26aulast%3DSzapary%26aufirst%3DP.%26aulast%3DMarano%26aufirst%3DC.%26atitle%3DUstekinumab%2520as%2520induction%2520and%2520maintenance%2520therapy%2520for%2520ulcerative%2520colitis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D381%26spage%3D1201%26epage%3D1214%26doi%3D10.1056%2FNEJMoa1900750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhutani, T.</span></span> <span> </span><span class="NLM_article-title">Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1993</span>– <span class="NLM_lpage">2000</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S137588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.2147%2FDDDT.S137588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=31354244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVykurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=1993-2000&author=E.+J.+Yangauthor=M.+P.+Smithauthor=K.+Lyauthor=T.+Bhutani&title=Evaluating+guselkumab%3A+an+anti-IL-23+antibody+for+the+treatment+of+plaque+psoriasis&doi=10.2147%2FDDDT.S137588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis</span></div><div class="casAuthors">Yang, Eric J.; Smith, Mary Patricia; Ly, Karen; Bhutani, Tina</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1993-2000</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">The approval of guselkumab marks the entry of the IL-23 inhibitor class into the therapeutic armamentarium for patients with moderate-to-severe plaque psoriasis.  This class specifically targets the upstream portion of the type 17 helper T (Th17) axis, which has been implicated as a key driver of the abnormal inflammatory state obsd. in psoriasis.  Guselkumab is highly efficacious, with over 85% of the patients achieving ≥ 75% redn. in Psoriasis Area and Severity Index from baseline (PASI 75) and over 70% of the patients achieving PASI 90 response in its Phase III clin. trials.  Addnl., this medication is well-tolerated, with non-serious infections such as nasopharyngitis and upper respiratory infections (URIs) being the most common adverse events (AEs) reported in its clin. trials.  Guselkumab offers yet another effective treatment option in the rapidly growing list of available biol. therapies for moderate-to-severe plaque psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor83KSz_qbTLVg90H21EOLACvtfcHk0lj2-DuFQvjU6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVykurk%253D&md5=48634c9b116dfd58ba54e8d290e1054a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S137588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S137588%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DE.%2BJ.%26aulast%3DSmith%26aufirst%3DM.%2BP.%26aulast%3DLy%26aufirst%3DK.%26aulast%3DBhutani%26aufirst%3DT.%26atitle%3DEvaluating%2520guselkumab%253A%2520an%2520anti-IL-23%2520antibody%2520for%2520the%2520treatment%2520of%2520plaque%2520psoriasis%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2019%26volume%3D13%26spage%3D1993%26epage%3D2000%26doi%3D10.2147%2FDDDT.S137588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blauvelt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukhalo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooderham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacour, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philipp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyring, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berner, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visvanathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pamulapati, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flack, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padula, S. J.</span></span> <span> </span><span class="NLM_article-title">Risankizumab versus Ustekinumab for moderate-to-severe plaque psoriasis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">1551</span>– <span class="NLM_lpage">1560</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1607017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1056%2FNEJMoa1607017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=28423301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOnsb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2017&pages=1551-1560&author=K.+A.+Pappauthor=A.+Blauveltauthor=M.+Bukhaloauthor=M.+Gooderhamauthor=J.+G.+Kruegerauthor=J.-P.+Lacourauthor=A.+Menterauthor=S.+Philippauthor=H.+Sofenauthor=S.+Tyringauthor=B.+R.+Bernerauthor=S.+Visvanathanauthor=C.+Pamulapatiauthor=N.+Bennettauthor=M.+Flackauthor=P.+Schollauthor=S.+J.+Padula&title=Risankizumab+versus+Ustekinumab+for+moderate-to-severe+plaque+psoriasis&doi=10.1056%2FNEJMoa1607017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis</span></div><div class="casAuthors">Papp, Kim A.; Blauvelt, Andrew; Bukhalo, Michael; Gooderham, Melinda; Krueger, James; Lacour, Jean-Philippe; Menter, Alan; Philipp, Sandra; Sofen, Howard; Tyring, Stephen; Berner, Beate R.; Visvanathan, Sudha; Pamulapati, Chandrasena; Bennett, Nathan; Flack, Mary; Scholl, Paul; Padula, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1551-1560</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Interleukin-23 is thought to be crit. to the pathogenesis of psoriasis.  We compared risankizumab (BI 655066), a humanized IgG1 monoclonal antibody that inhibits interleukin-23 by specifically targeting the p19 subunit and thus prevents interleukin-23 signaling, and ustekinumab, an interleukin-12 and interleukin-23 inhibitor, in patients with moderate-to-severe plaque psoriasis.  METHODS We randomly assigned a total of 166 patients to receive s.c. injections of risankizumab (a single 18-mg dose at week 0 or 90-mg or 180-mg doses at weeks 0, 4, and 16) or ustekinumab (45 or 90 mg, according to body wt., at weeks 0, 4, and 16).  The primary end point was a 90% or greater redn. from baseline in the Psoriasis Area and Severity Index (PASI) score at week 12.  RESULTS At week 12, the percentage of patients with a 90% or greater redn. in the PASI score was 77% (64 of 83 patients) for risankizumab (90-mg and 180-mg groups, pooled), as compared with 40% (16 of 40 patients) for ustekinumab (P<0.001); the percentage of patients with a 100% redn. in the PASI score was 45% in the pooled 90-mg and 180-mg risankizumab groups, as compared with 18% in the ustekinumab group.  Efficacy was generally maintained up to 20 wk after the final dose of 90 or 180 mg of risankizumab.  In the 18-mg and 90-mg risankizumab groups and the ustekinumab group, 5 patients (12%), 6 patients (15%), and 3 patients (8%), resp., had serious adverse events, including two basal-cell carcinomas and one major cardiovascular adverse event; there were no serious adverse events in the 180-mg risankizumab group.  CONCLUSIONS In this phase 2 trial, selective blockade of interleukin-23 with risankizumab was assocd. with clin. responses superior to those assocd. with ustekinumab.  This trial was not large enough or of long enough duration to draw conclusions about safety. (Funded by Boehringer Ingelheim; ClinicalTrials.gov no., NCT02054481).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9P87OIwFs5rVg90H21EOLACvtfcHk0lh_XhrQQXoFRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOnsb%252FI&md5=fa36a543b578ddc52d8c9ac7983f996c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1607017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1607017%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DBlauvelt%26aufirst%3DA.%26aulast%3DBukhalo%26aufirst%3DM.%26aulast%3DGooderham%26aufirst%3DM.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26aulast%3DLacour%26aufirst%3DJ.-P.%26aulast%3DMenter%26aufirst%3DA.%26aulast%3DPhilipp%26aufirst%3DS.%26aulast%3DSofen%26aufirst%3DH.%26aulast%3DTyring%26aufirst%3DS.%26aulast%3DBerner%26aufirst%3DB.%2BR.%26aulast%3DVisvanathan%26aufirst%3DS.%26aulast%3DPamulapati%26aufirst%3DC.%26aulast%3DBennett%26aufirst%3DN.%26aulast%3DFlack%26aufirst%3DM.%26aulast%3DScholl%26aufirst%3DP.%26aulast%3DPadula%26aufirst%3DS.%2BJ.%26atitle%3DRisankizumab%2520versus%2520Ustekinumab%2520for%2520moderate-to-severe%2520plaque%2520psoriasis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D376%26spage%3D1551%26epage%3D1560%26doi%3D10.1056%2FNEJMoa1607017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X.-Y.</span></span> <span> </span><span class="NLM_article-title">Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1080/13543776.2019.1567713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1080%2F13543776.2019.1567713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=30621465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2kuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=137-149&author=X.+Heauthor=X.+Chenauthor=H.+Zhangauthor=T.+Xieauthor=X.-Y.+Ye&title=Selective+Tyk2+inhibitors+as+potential+therapeutic+agents%3A+a+patent+review+%282015%E2%80%932018%29&doi=10.1080%2F13543776.2019.1567713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018)</span></div><div class="casAuthors">He, Xingrui; Chen, Xiabin; Zhang, Hancheng; Xie, Tian; Ye, Xiang-Yang</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-149</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Tyrosine kinase 2 (Tyk2) is a non-receptor tyrosine-protein kinase, an enzyme that in humans is encoded by the TYK2 gene.  Tyk2, together with three other family subtypes, namely, Jak1, Jak2, and Jak3, belong to the JAK family.  Before 2014, far more publications and patents appeared in public domain attributing to the development of selective Jak2 and Jak3 inhibitors than those for selective Tyk2 and Jak1 inhibitors.  This review sought to give an overview of patents related to small mol. selective Tyk2 inhibitors published from 2015 to 2018.  The article also covers clin. activities of small mol. selective Tyk2 inhibitors in recent years.  As a key component of the JAK-STAT signaling pathway, Tyk2 regulates INFα, IL12, and IL23.  Selective inhibition of Tyk2 can provide pharmacol. benefits in the treatment of many diseases such as psoriasis, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), cancer, and diabetes.  The selectivity against other Jak family subtypes (such as Jak2) is crucial in order to minimize the potential side effects and to maximize the desired pharmacol. effects.  In this context, this review of recent selective Tyk2 inhibitor patents may prove valid, interesting, and promising within the therapeutic paradigm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrer4xPnKRtvrVg90H21EOLACvtfcHk0lh_XhrQQXoFRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2kuro%253D&md5=cf7fa5e5f7a92eb951886f7951f7da4b</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1080%2F13543776.2019.1567713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2019.1567713%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DYe%26aufirst%3DX.-Y.%26atitle%3DSelective%2520Tyk2%2520inhibitors%2520as%2520potential%2520therapeutic%2520agents%253A%2520a%2520patent%2520review%2520%25282015%25E2%2580%25932018%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2019%26volume%3D29%26spage%3D137%26epage%3D149%26doi%3D10.1080%2F13543776.2019.1567713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thaçi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooderham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girgis, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span> <span> </span><span class="NLM_article-title">Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">1313</span>– <span class="NLM_lpage">1321</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1806382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1056%2FNEJMoa1806382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=30205746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFWlsrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=1313-1321&author=K.+Pappauthor=K.+Gordonauthor=D.+Tha%C3%A7iauthor=A.+Moritaauthor=M.+Gooderhamauthor=P.+Foleyauthor=I.+G.+Girgisauthor=S.+Kunduauthor=S.+Banerjee&title=Phase+2+trial+of+selective+tyrosine+kinase+2+inhibition+in+psoriasis&doi=10.1056%2FNEJMoa1806382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis</span></div><div class="casAuthors">Papp, Kim; Gordon, Kenneth; Thaci, Diamant; Morita, Akimichi; Gooderham, Melinda; Foley, Peter; Girgis, Ihab G.; Kundu, Sudeep; Banerjee, Subhashis</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1313-1321</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Tyrosine kinase 2 (TYK2) signaling pathways, which mediate cytokine signaling, are implicated in the pathophysiol. of psoriasis.  Selective inhibitors of TYK2 may be effective in treating psoriasis. methods We conducted a phase 2, double-blind trial of a TYK2 inhibitor, BMS-986165, in adults with moderate-to-severe psoriasis, excluding patients with a previous lack of response to agents targeting cytokine signaling through the same tyrosine kinase pathway.  Patients were randomly assigned to receive the drug orally at a dose of 3 mg every other day, 3 mg daily, 3 mg twice daily, 6 mg twice daily, or 12 mg daily or to receive placebo.  The primary end point was a 75% or greater redn. from baseline in the Psoriasis Area and Severity Index (PASI) score at week 12 (higher scores indicate greater severity of psoriasis). results A total of 267 patients received at least one dose in an intervention group of the trial.  At week 12, the percentage of patients with a 75% or greater redn. in the PASI score was 7% (3 of 45 patients) with placebo, 9% (4 of 44 patients) with 3 mg of BMS-986165 every other day (P = 0.49 vs. placebo), 39% (17 of 44 patients) with 3 mg daily (P<0.001 vs. placebo), 69% (31 of 45 patients) with 3 mg twice daily (P<0.001 vs. placebo), 67% (30 of 45 patients) with 6 mg twice daily (P<0.001 vs. placebo), and 75% (33 of 44 patients) with 12 mg daily (P<0.001 vs. placebo).  There were three serious adverse events in patients receiving the active drug, as well as one case of malignant melanoma 96 days after the start of treatment. conclusions Selective inhibition of TYK2 with the oral agent BMS-986165 at doses of 3 mg daily and higher resulted in greater clearing of psoriasis than did placebo over a period of 12 wk.  Larger and longer-duration trials of this drug are required to det. its safety and durability of effect in patients with psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhqWANKhDdt7Vg90H21EOLACvtfcHk0lh_XhrQQXoFRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFWlsrbE&md5=ededd5d925dd557cceacc472839a966a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1806382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1806382%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%26aulast%3DGordon%26aufirst%3DK.%26aulast%3DTha%25C3%25A7i%26aufirst%3DD.%26aulast%3DMorita%26aufirst%3DA.%26aulast%3DGooderham%26aufirst%3DM.%26aulast%3DFoley%26aufirst%3DP.%26aulast%3DGirgis%26aufirst%3DI.%2BG.%26aulast%3DKundu%26aufirst%3DS.%26aulast%3DBanerjee%26aufirst%3DS.%26atitle%3DPhase%25202%2520trial%2520of%2520selective%2520tyrosine%2520kinase%25202%2520inhibition%2520in%2520psoriasis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D1313%26epage%3D1321%26doi%3D10.1056%2FNEJMoa1806382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catlett, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimalakonda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L. M.</span></span> <span> </span><span class="NLM_article-title">Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">eaaw1736</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aaw1736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1126%2Fscitranslmed.aaw1736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=31341059" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&author=J.+R.+Burkeauthor=L.+Chengauthor=K.+M.+Gilloolyauthor=J.+Strnadauthor=A.+Zupa-Fernandezauthor=I.+M.+Catlettauthor=Y.+Zhangauthor=E.+M.+Heimrichauthor=K.+W.+McIntyreauthor=M.+D.+Cunninghamauthor=J.+A.+Carmanauthor=X.+Zhouauthor=D.+Banasauthor=C.+Chaudhryauthor=S.+Liauthor=C.+D%E2%80%99Arienzoauthor=A.+Chimalakondaauthor=X.+Yangauthor=J.+H.+Xieauthor=J.+Pangauthor=Q.+Zhaoauthor=S.+M.+Roseauthor=J.+Huangauthor=R.+M.+Moslinauthor=S.+T.+Wrobleskiauthor=D.+S.+Weinsteinauthor=L.+M.+Salter-Cid&title=Autoimmune+pathways+in+mice+and+humans+are+blocked+by+pharmacological+stabilization+of+the+TYK2+pseudokinase+domain&doi=10.1126%2Fscitranslmed.aaw1736"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaw1736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaw1736%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCatlett%26aufirst%3DI.%2BM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%2BM.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DCunningham%26aufirst%3DM.%2BD.%26aulast%3DCarman%26aufirst%3DJ.%2BA.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DBanas%26aufirst%3DD.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DJ.%2BH.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DRose%26aufirst%3DS.%2BM.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DMoslin%26aufirst%3DR.%2BM.%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26aulast%3DSalter-Cid%26aufirst%3DL.%2BM.%26atitle%3DAutoimmune%2520pathways%2520in%2520mice%2520and%2520humans%2520are%2520blocked%2520by%2520pharmacological%2520stabilization%2520of%2520the%2520TYK2%2520pseudokinase%2520domain%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26doi%3D10.1126%2Fscitranslmed.aaw1736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span> <span> </span><span class="NLM_article-title">Selective Janus kinase inhibitors come of age</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1038/s41584-018-0155-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1038%2Fs41584-018-0155-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=30622297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A280%3ADC%252BB3cnptlegtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=74-75&author=J.+J.+O%E2%80%99Sheaauthor=M.+Gadina&title=Selective+Janus+kinase+inhibitors+come+of+age&doi=10.1038%2Fs41584-018-0155-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Janus kinase inhibitors come of age</span></div><div class="casAuthors">O'Shea John J; Gadina Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Rheumatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">74-75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQ5b1SiSXp96_dlEzl_fBafW6udTcc2eazRUYSpjrUQLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnptlegtg%253D%253D&md5=3bd9525750aa0109f8eaafd4adfe34dc</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fs41584-018-0155-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41584-018-0155-9%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DGadina%26aufirst%3DM.%26atitle%3DSelective%2520Janus%2520kinase%2520inhibitors%2520come%2520of%2520age%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2019%26volume%3D15%26spage%3D74%26epage%3D75%26doi%3D10.1038%2Fs41584-018-0155-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hosseini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharibi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marofi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javadian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babaloo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baradaran, B.</span></span> <span> </span><span class="NLM_article-title">Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>235</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">5903</span>– <span class="NLM_lpage">5924</span>, <span class="refDoi"> DOI: 10.1002/jcp.29593</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1002%2Fjcp.29593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=32072644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtF2nsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=2020&pages=5903-5924&issue=9&author=A.+Hosseiniauthor=T.+Gharibiauthor=F.+Marofiauthor=M.+Javadianauthor=Z.+Babalooauthor=B.+Baradaran&title=Janus+kinase+inhibitors%3A+A+therapeutic+strategy+for+cancer+and+autoimmune+diseases&doi=10.1002%2Fjcp.29593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases</span></div><div class="casAuthors">Hosseini, Arezoo; Gharibi, Tohid; Marofi, Faroogh; Javadian, Mahsa; Babaloo, Zohreh; Baradaran, Behzad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">235</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5903-5924</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Many cytokines are crucial drivers of cancers and autoimmune conditions.  These proteins bind to receptors and signal their responses through Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways.  Genetic variations in the JAK-STAT pathway are correlated with the increased risk of cancers, autoimmunity as well as inflammatory diseases.  Targeting JAKs and STATs can be a safe and efficacious strategy for treating these diseases.  Tofacitinib, as the first JAK inhibitor, is approved for rheumatoid arthritis therapy.  Also, many other JAK inhibitors have been proven or are in various phases of clin. trials for various diseases.  At present, small-mol. JAK inhibitors are considered as a novel category of drugs in the treatment of cancer and immune-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAwlkagGvd-rVg90H21EOLACvtfcHk0lgZQbj4KTQENA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtF2nsbg%253D&md5=8b4a5345f83894bc751e5e1d5d4b317f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fjcp.29593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.29593%26sid%3Dliteratum%253Aachs%26aulast%3DHosseini%26aufirst%3DA.%26aulast%3DGharibi%26aufirst%3DT.%26aulast%3DMarofi%26aufirst%3DF.%26aulast%3DJavadian%26aufirst%3DM.%26aulast%3DBabaloo%26aufirst%3DZ.%26aulast%3DBaradaran%26aufirst%3DB.%26atitle%3DJanus%2520kinase%2520inhibitors%253A%2520A%2520therapeutic%2520strategy%2520for%2520cancer%2520and%2520autoimmune%2520diseases%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2020%26volume%3D235%26issue%3D9%26spage%3D5903%26epage%3D5924%26doi%3D10.1002%2Fjcp.29593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimalakonda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune siseases: Discovery of the allosteric inhibitor BMS-986165</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8973</span>– <span class="NLM_lpage">8995</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00444</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00444" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlyht7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8973-8995&author=S.+T.+Wrobleskiauthor=R.+Moslinauthor=S.+Linauthor=Y.+Zhangauthor=S.+Spergelauthor=J.+Kempsonauthor=J.+S.+Tokarskiauthor=J.+Strnadauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=D.+Shusterauthor=K.+Gilloolyauthor=X.+Yangauthor=E.+Heimrichauthor=K.+W.+McIntyreauthor=C.+Chaudhryauthor=J.+Khanauthor=M.+Ruzanovauthor=J.+Tredupauthor=D.+Mulliganauthor=D.+Xieauthor=H.+Sunauthor=C.+Huangauthor=C.+D%E2%80%99Arienzoauthor=N.+Aranibarauthor=M.+Chineyauthor=A.+Chimalakondaauthor=W.+J.+Pittsauthor=L.+Lombardoauthor=P.+H.+Carterauthor=J.+R.+Burkeauthor=D.+S.+Weinstein&title=Highly+selective+inhibition+of+tyrosine+kinase+2+%28TYK2%29+for+the+treatment+of+autoimmune+siseases%3A+Discovery+of+the+allosteric+inhibitor+BMS-986165&doi=10.1021%2Facs.jmedchem.9b00444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165</span></div><div class="casAuthors">Wrobleski, Stephen T.; Moslin, Ryan; Lin, Shuqun; Zhang, Yanlei; Spergel, Steven; Kempson, James; Tokarski, John S.; Strnad, Joann; Zupa-Fernandez, Adriana; Cheng, Lihong; Shuster, David; Gillooly, Kathleen; Yang, Xiaoxia; Heimrich, Elizabeth; McIntyre, Kim W.; Chaudhry, Charu; Khan, Javed; Ruzanov, Max; Tredup, Jeffrey; Mulligan, Dawn; Xie, Dianlin; Sun, Huadong; Huang, Christine; D'Arienzo, Celia; Aranibar, Nelly; Chiney, Manoj; Chimalakonda, Anjaneya; Pitts, William J.; Lombardo, Louis; Carter, Percy H.; Burke, James R.; Weinstein, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8973-8995</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases.  The discovery of isoform selective JAK inhibitors that traditionally target the catalytically active site of this kinase family has been a formidable challenge.  Our strategy to achieve high selectivity for TYK2 relies on targeting the TYK2 pseudokinase (JH2) domain.  Herein we report the late stage optimization efforts including a structure-guided design and water displacement strategy that led to the discovery of BMS-986165 (11, I) as a high affinity JH2 ligand and potent allosteric inhibitor of TYK2.  In addn. to unprecedented JAK isoform and kinome selectivity, I shows excellent pharmacokinetic properties with minimal profiling liabilities and is efficacious in several murine models of autoimmune disease.  On the basis of these findings, I appears differentiated from all other reported JAK inhibitors and has been advanced as the first pseudokinase-directed therapeutic in clin. development as an oral treatment for autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmA75TJmytlrVg90H21EOLACvtfcHk0ljNMW-NnNDl0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlyht7%252FP&md5=ca161c470df002b0bdd2bf6b19920ada</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00444%26sid%3Dliteratum%253Aachs%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DKempson%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DShuster%26aufirst%3DD.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DRuzanov%26aufirst%3DM.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DMulligan%26aufirst%3DD.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DChiney%26aufirst%3DM.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DLombardo%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DHighly%2520selective%2520inhibition%2520of%2520tyrosine%2520kinase%25202%2520%2528TYK2%2529%2520for%2520the%2520treatment%2520of%2520autoimmune%2520siseases%253A%2520Discovery%2520of%2520the%2520allosteric%2520inhibitor%2520BMS-986165%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8973%26epage%3D8995%26doi%3D10.1021%2Facs.jmedchem.9b00444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span>An Investigational
Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo
and a Currently Available Treatment in Participants With Moderate-to-Severe
Plaque Psoriasis. ClinicalTrials.gov. U.S. National Institutes of
Health, Bethesda, MD, 2020; NCT03611751. <a href="https://clinicaltrials.gov/ct2/show/NCT03611751" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03611751</a> (accessed Aug 2, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=An+Investigational%0AStudy+to+Evaluate+Experimental+Medication+BMS-986165+Compared+to+Placebo%0Aand+a+Currently+Available+Treatment+in+Participants+With+Moderate-to-Severe%0APlaque+Psoriasis.+ClinicalTrials.gov.+U.S.+National+Institutes+of%0AHealth%2C+Bethesda%2C+MD%2C+2020%3B+NCT03611751.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03611751+%28accessed+Aug+2%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalsamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limburg, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Z.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8597</span>– <span class="NLM_lpage">8612</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8597-8612&author=A.+Fensomeauthor=C.+M.+Amblerauthor=E.+Arnoldauthor=M.+E.+Bankerauthor=M.+F.+Brownauthor=J.+Chrencikauthor=J.+D.+Clarkauthor=M.+E.+Dowtyauthor=I.+V.+Efremovauthor=A.+Flickauthor=B.+S.+Gerstenbergerauthor=A.+Gopalsamyauthor=M.+M.+Haywardauthor=M.+Hegenauthor=B.+D.+Hollingsheadauthor=J.+Jussifauthor=J.+D.+Knafelsauthor=D.+C.+Limburgauthor=D.+Linauthor=T.+H.+Linauthor=B.+S.+Pierceauthor=E.+Saiahauthor=R.+Sharmaauthor=P.+T.+Symanowiczauthor=J.-B.+Telliezauthor=J.+I.+Trujilloauthor=F.+F.+Vajdosauthor=F.+Vincentauthor=Z.-K.+Wanauthor=L.+Xingauthor=X.+Yangauthor=X.+Yangauthor=L.+Zhang&title=Dual+inhibition+of+TYK2+and+JAK1+for+the+treatment+of+autoimmune+diseases%3A+Discovery+of+%28%28S%29-2%2C2-Difluorocyclopropyl%29%28%281R%2C5S%29-3-%282-%28%281-methyl-1H-pyrazol-4-yl%29amino%29pyrimidin-4-yl%29-3%2C8-diazabicyclo%5B3.2.1%5Doctan-8-yl%29methanone+%28PF-06700841%29&doi=10.1021%2Facs.jmedchem.8b00917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span></div><div class="casAuthors">Fensome, Andrew; Ambler, Catherine M.; Arnold, Eric; Banker, Mary Ellen; Brown, Matthew F.; Chrencik, Jill; Clark, James D.; Dowty, Martin E.; Efremov, Ivan V.; Flick, Andrew; Gerstenberger, Brian S.; Gopalsamy, Ariamala; Hayward, Matthew M.; Hegen, Martin; Hollingshead, Brett D.; Jussif, Jason; Knafels, John D.; Limburg, David C.; Lin, David; Lin, Tsung H.; Pierce, Betsy S.; Saiah, Eddine; Sharma, Raman; Symanowicz, Peter T.; Telliez, Jean-Baptiste; Trujillo, John I.; Vajdos, Felix F.; Vincent, Fabien; Wan, Zhao-Kui; Xing, Li; Yang, Xiaojing; Yang, Xin; Zhang, Liying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8597-8612</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cytokine signaling is an important characteristic of autoimmune diseases.  Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway.  JAK1 is important for the γ-common chain cytokines, interleukin (IL)-6 and type-I interferon (IFN) family, while TYK2 in addn. to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling.  Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease and rheumatoid arthritis studies, leading to multiple drug approvals.  It is hypothesized that a dual JAK1/TYK2 inhibitor will provide addnl. efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes.  Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compd. 23), which is in Phase II clin. development (NCT02969018, NCT02958865, NCT03395184, and NCT02974868).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWNhVkNWDMq7Vg90H21EOLACvtfcHk0ljNMW-NnNDl0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI&md5=c321512f524560cba445d070b9639e55</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00917%26sid%3Dliteratum%253Aachs%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DChrencik%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DEfremov%26aufirst%3DI.%2BV.%26aulast%3DFlick%26aufirst%3DA.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DGopalsamy%26aufirst%3DA.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHollingshead%26aufirst%3DB.%2BD.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DKnafels%26aufirst%3DJ.%2BD.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DWan%26aufirst%3DZ.-K.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDual%2520inhibition%2520of%2520TYK2%2520and%2520JAK1%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%253A%2520Discovery%2520of%2520%2528%2528S%2529-2%252C2-Difluorocyclopropyl%2529%2528%25281R%252C5S%2529-3-%25282-%2528%25281-methyl-1H-pyrazol-4-yl%2529amino%2529pyrimidin-4-yl%2529-3%252C8-diazabicyclo%255B3.2.1%255Doctan-8-yl%2529methanone%2520%2528PF-06700841%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8597%26epage%3D8612%26doi%3D10.1021%2Facs.jmedchem.8b00917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banfield, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaramozza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieras, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goteti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkle, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeva, E.</span></span> <span> </span><span class="NLM_article-title">The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2/JAK1 inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">434</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1002/jcph.1046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1002%2Fjcph.1046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=29266308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVKrurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2018&pages=434-447&author=C.+Banfieldauthor=M.+Scaramozzaauthor=W.+Zhangauthor=E.+Kierasauthor=K.+M.+Pageauthor=A.+Fensomeauthor=M.+Vincentauthor=M.+E.+Dowtyauthor=K.+Gotetiauthor=P.+J.+Winkleauthor=E.+Peeva&title=The+safety%2C+tolerability%2C+pharmacokinetics%2C+and+pharmacodynamics+of+a+TYK2%2FJAK1+inhibitor+%28PF-06700841%29+in+healthy+subjects+and+patients+with+plaque+psoriasis&doi=10.1002%2Fjcph.1046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis</span></div><div class="casAuthors">Banfield, Christopher; Scaramozza, Matthew; Zhang, Weidong; Kieras, Elizabeth; Page, Karen M.; Fensome, Andrew; Vincent, Michael; Dowty, Martin E.; Goteti, Kosalaram; Winkle, Peter J.; Peeva, Elena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">434-447</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06700841 were assessed in a randomized, double-blind, placebo-controlled, single- and multiple-dose escalation, parallel-group study in healthy subjects and patients with plaque psoriasis.  The single ascending dose (1, 3, 10, 30, 100, or 200 mg) and multiple ascending dose (MAD; PF-06700841; up to 175 mg once daily or 50 mg twice daily for 10 days) periods included 54 healthy participants.  In addn., 30 patients with psoriasis received PF-06700841 30 or 100 mg or placebo once daily for 28 days.  Single PF-06700841 doses were rapidly absorbed, with peak plasma concns. ≤ 1 h, proportional exposure up to 100 mg, and mean half-life 3.8-7.5 h.  On day 10 of MAD, plasma concns. peaked at ≤1.5 h postdose (10-175 mg once daily).  Elimination half-life was 4.9-10.7 h; steady state was reached by day 8.  In psoriasis patients on day 28, peak plasma concns. occurred at 1-2 h.  Biomarkers IP-10 and high-sensitivity C-reactive protein were reduced and returned to near baseline levels after dosing.  Maximal mean percent change from baseline in the Psoriasis Area and Severity Index scores for PF-06700841 30 mg once daily and 100 mg once daily were -67.92% and -96.31%, resp., in week 4.  All adverse events were mild/moderate.  PF-06700841 was safe and well tolerated up to 200 mg once daily in healthy subjects and 100 mg once daily in patients with psoriasis, suggesting potential therapeutic utility in plaque psoriasis and other inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHMconrLwJf7Vg90H21EOLACvtfcHk0lhghNrn0PFz2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVKrurw%253D&md5=a907c91ff2d50db9cba930c2249ed37b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fjcph.1046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.1046%26sid%3Dliteratum%253Aachs%26aulast%3DBanfield%26aufirst%3DC.%26aulast%3DScaramozza%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DKieras%26aufirst%3DE.%26aulast%3DPage%26aufirst%3DK.%2BM.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DVincent%26aufirst%3DM.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DGoteti%26aufirst%3DK.%26aulast%3DWinkle%26aufirst%3DP.%2BJ.%26aulast%3DPeeva%26aufirst%3DE.%26atitle%3DThe%2520safety%252C%2520tolerability%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520a%2520TYK2%252FJAK1%2520inhibitor%2520%2528PF-06700841%2529%2520in%2520healthy%2520subjects%2520and%2520patients%2520with%2520plaque%2520psoriasis%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D58%26spage%3D434%26epage%3D447%26doi%3D10.1002%2Fjcph.1046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vainchenker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favale, F.</span></span> <span> </span><span class="NLM_article-title">Myelofibrosis, JAK2 inhibitors and erythropoiesis</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1219</span>– <span class="NLM_lpage">1223</span>, <span class="refDoi"> DOI: 10.1038/leu.2013.72</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1038%2Fleu.2013.72" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=23739260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFeksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=1219-1223&author=W.+Vainchenkerauthor=F.+Favale&title=Myelofibrosis%2C+JAK2+inhibitors+and+erythropoiesis&doi=10.1038%2Fleu.2013.72"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Myelofibrosis, JAK2 inhibitors and erythropoiesis</span></div><div class="casAuthors">Vainchenker, W.; Favale, F.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1219-1223</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A polemic in this issue, Pardanani et al, report the effect of a new JAK1 and JAK2 inhibitor, CYT387, in patients with high or intermediaterisk primary and secondary myelofibrosis.  In this article obsd. the contrasting effects of JAK2 on pathol. erythropoiesis, we can speculate that the effects of JAK2 inhibition Such approaches might be more efficient in PV or ET, which are essentially dependent on constitutive JAK2 inhibition, than in PMF, where several pathways are simultaneously affected in the majority of cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF51RYsD3xorVg90H21EOLACvtfcHk0lhghNrn0PFz2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFeksbw%253D&md5=dd8eb65edf06a2af21305dcd8f866dbd</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fleu.2013.72&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2013.72%26sid%3Dliteratum%253Aachs%26aulast%3DVainchenker%26aufirst%3DW.%26aulast%3DFavale%26aufirst%3DF.%26atitle%3DMyelofibrosis%252C%2520JAK2%2520inhibitors%2520and%2520erythropoiesis%26jtitle%3DLeukemia%26date%3D2013%26volume%3D27%26spage%3D1219%26epage%3D1223%26doi%3D10.1038%2Fleu.2013.72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span>A Study
to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe
Plaque Psoriasis. ClinicalTrials.gov. U.S. National Institutes of
Health, Bethesda, MD, 2018. NCT03895372. <a href="https://clinicaltrials.gov/ct2/show/NCT03895372" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03895372</a> (accessed Mar 29, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study%0Ato+Evaluate+Safety+and+Efficacy+of+PF-06826647+For+Moderate+To+Severe%0APlaque+Psoriasis.+ClinicalTrials.gov.+U.S.+National+Institutes+of%0AHealth%2C+Bethesda%2C+MD%2C+2018.+NCT03895372.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03895372+%28accessed+Mar+29%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span>A Study
To Evaluate The Safety And Efficacy Of PF-06826647 In Participants
With Moderate To Severe Ulcerative Colitis. ClinicalTrials.gov. U.S.
National Institutes of Health, Bethesda, MD, 2020. NCT04209556. <a href="https://clinicaltrials.gov/ct2/show/NCT04209556" class="extLink">https://clinicaltrials.gov/ct2/show/NCT04209556</a> (accessed Dec 24, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study%0ATo+Evaluate+The+Safety+And+Efficacy+Of+PF-06826647+In+Participants%0AWith+Moderate+To+Severe+Ulcerative+Colitis.+ClinicalTrials.gov.+U.S.%0ANational+Institutes+of+Health%2C+Bethesda%2C+MD%2C+2020.+NCT04209556.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04209556+%28accessed+Dec+24%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span>A Study
to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and
PF 06826647 in Adults With Hidradenitis Suppurativa. ClinicalTrials.gov.
U.S. National Institutes of Health, Bethesda, MD, 2020. NCT04092452. <a href="https://clinicaltrials.gov/ct2/show/NCT04092452" class="extLink">https://clinicaltrials.gov/ct2/show/NCT04092452</a> (accessed Sep 17, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study%0Ato+Evaluate+the+Safety+and+Efficacy+of+PF-06650833%2C+PF-06700841%2C+and%0APF+06826647+in+Adults+With+Hidradenitis+Suppurativa.+ClinicalTrials.gov.%0AU.S.+National+Institutes+of+Health%2C+Bethesda%2C+MD%2C+2020.+NCT04092452.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04092452+%28accessed+Sep+17%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gifford, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalsamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limburg, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Z.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span> <span> </span><span class="NLM_article-title">Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">115481</span>– <span class="NLM_lpage">115491</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2020.115481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1016%2Fj.bmc.2020.115481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=32253095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsFOjtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115481-115491&author=A.+Fensomeauthor=C.+M.+Amblerauthor=E.+Arnoldauthor=M.+E.+Bankerauthor=J.+D.+Clarkauthor=M.+E.+Dowtyauthor=I.+V.+Efremovauthor=A.+Flickauthor=B.+S.+Gerstenbergerauthor=R.+S.+Giffordauthor=A.+Gopalsamyauthor=M.+Hegenauthor=J.+Jussifauthor=D.+C.+Limburgauthor=T.+H.+Linauthor=B.+S.+Pierceauthor=R.+Sharmaauthor=J.+I.+Trujilloauthor=F.+F.+Vajdosauthor=F.+Vincentauthor=Z.-K.+Wanauthor=L.+Xingauthor=X.+Yangauthor=X.+Yang&title=Design+and+optimization+of+a+series+of+4-%283-azabicyclo%5B3.1.0%5Dhexan-3-yl%29pyrimidin-2-amines%3A+Dual+inhibitors+of+TYK2+and+JAK1&doi=10.1016%2Fj.bmc.2020.115481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1</span></div><div class="casAuthors">Fensome, Andrew; Ambler, Catherine M.; Arnold, Eric; Banker, Mary Ellen; Clark, James D.; Dowty, Martin E.; Efremov, Ivan V.; Flick, Andrew; Gerstenberger, Brian S.; Gifford, Roger S.; Gopalsamy, Ariamala; Hegen, Martin; Jussif, Jason; Limburg, David C.; Lin, Tsung H.; Pierce, Betsy S.; Sharma, Raman; Trujillo, John I.; Vajdos, Felix F.; Vincent, Fabien; Wan, Zhao-Kui; Xing, Li; Yang, Xiaojing; Yang, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">115481</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein, we disclose a new series of TYK2/ JAK1 inhibitors based upon a 3.1.0 azabicyclic substituted pyrimidine scaffold.  We illustrate the use of structure-based drug design for the initial design and subsequent optimization of this series of compds.  One advanced example 19 met program objectives for potency, selectivity and ADME, and demonstrated oral activity in the adjuvant-induced arthritis rat model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsqcYSKJmUBrVg90H21EOLACvtfcHk0lgTHfa2bqkNFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsFOjtb4%253D&md5=333a86e0bc2d8c22cf6eb50dd3c0624a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2020.115481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2020.115481%26sid%3Dliteratum%253Aachs%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DEfremov%26aufirst%3DI.%2BV.%26aulast%3DFlick%26aufirst%3DA.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DGifford%26aufirst%3DR.%2BS.%26aulast%3DGopalsamy%26aufirst%3DA.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DWan%26aufirst%3DZ.-K.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26atitle%3DDesign%2520and%2520optimization%2520of%2520a%2520series%2520of%25204-%25283-azabicyclo%255B3.1.0%255Dhexan-3-yl%2529pyrimidin-2-amines%253A%2520Dual%2520inhibitors%2520of%2520TYK2%2520and%2520JAK1%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26spage%3D115481%26epage%3D115491%26doi%3D10.1016%2Fj.bmc.2020.115481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jesson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katkade, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span> <span> </span><span class="NLM_article-title">Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition</span>. <i>Pharmacol. Res. Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e00537-e00537</span> <span class="refDoi"> DOI: 10.1002/prp2.537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1002%2Fprp2.537" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&author=M.+E.+Dowtyauthor=T.+H.+Linauthor=M.+I.+Jessonauthor=M.+Hegenauthor=D.+A.+Martinauthor=V.+Katkadeauthor=S.+Menonauthor=J.-B.+Telliez&title=Janus+kinase+inhibitors+for+the+treatment+of+rheumatoid+arthritis+demonstrate+similar+profiles+of+in+vitro+cytokine+receptor+inhibition&doi=10.1002%2Fprp2.537"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fprp2.537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.537%26sid%3Dliteratum%253Aachs%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DD.%2BA.%26aulast%3DKatkade%26aufirst%3DV.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DJanus%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%2520demonstrate%2520similar%2520profiles%2520of%2520in%2520vitro%2520cytokine%2520receptor%2520inhibition%26jtitle%3DPharmacol.%2520Res.%2520Perspect.%26date%3D2019%26volume%3D7%26doi%3D10.1002%2Fprp2.537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5023</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.-B.+Telliez&title=Discovery+and+development+of+Janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0lgTHfa2bqkNFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DDiscovery%2520and%2520development%2520of%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klug-Mcleod, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunney, E. A.</span></span> <span> </span><span class="NLM_article-title">Kinase hinge binding scaffolds and their hydrogen bond patterns</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6520</span>– <span class="NLM_lpage">6527</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1016%2Fj.bmc.2015.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=26358279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVentr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=6520-6527&author=L.+Xingauthor=J.+Klug-Mcleodauthor=B.+Raiauthor=E.+A.+Lunney&title=Kinase+hinge+binding+scaffolds+and+their+hydrogen+bond+patterns&doi=10.1016%2Fj.bmc.2015.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase hinge binding scaffolds and their hydrogen bond patterns</span></div><div class="casAuthors">Xing, Li; Klug-Mcleod, Jacquelyn; Rai, Brajesh; Lunney, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6520-6527</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Protein kinases constitute a major class of intracellular signaling mols., and describe some of the most prominent drug targets.  Kinase inhibitors commonly employ small chem. scaffolds that form hydrogen bonds with the kinase hinge residues connecting the N- and C-terminal lobes of the catalytic domain.  In general the satisfied hydrogen bonds are required for potent inhibition, therefore constituting a conserved feature in the majority of inhibitor-kinase interactions.  From systematically analyzing the kinase scaffolds extd. from Pfizer crystal structure database (CSDb) the authors recognize that large no. of kinase inhibitors of diverse chem. structures are derived from a relatively small no. of common scaffolds.  Depending on specific substitution patterns, scaffolds may demonstrate versatile binding capacities to interact with kinase hinge.  Afforded by thousands of ligand-protein binary complexes, the hinge hydrogen bond patterns were analyzed with a focus on their three-dimensional configurations.  Most of the compds. engage H6 NH for hinge recognition.  Dual hydrogen bonds are commonly obsd. with addnl. recruitment of H4 CO upstream and/or H6 CO downstream.  Triple hydrogen bonds accounts for small no. of binary complexes.  An unusual hydrogen bond with a non-canonical H5 conformation is obsd., requiring a peptide bond flip by a glycine residue at the H6 position.  Addnl. hydrogen bonds to kinase hinge do not necessarily correlate with an increase in potency; conversely they appear to compromise kinase selectivity.  Such learnings could enhance the prospect of successful therapy design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRC-xiTiNvELVg90H21EOLACvtfcHk0liuBhR7dvFs3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVentr3L&md5=048b4b99628c6e1ae273b00a47ab2377</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DL.%26aulast%3DKlug-Mcleod%26aufirst%3DJ.%26aulast%3DRai%26aufirst%3DB.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26atitle%3DKinase%2520hinge%2520binding%2520scaffolds%2520and%2520their%2520hydrogen%2520bond%2520patterns%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D6520%26epage%3D6527%26doi%3D10.1016%2Fj.bmc.2015.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, C. H.</span></span> <span> </span><span class="NLM_article-title">A molecular electrostatic potential analysis of hydrogen, halogen, and dihydrogen bonds</span>. <i>J. Phys. Chem. A</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">1697</span>– <span class="NLM_lpage">1705</span>, <span class="refDoi"> DOI: 10.1021/jp4115699</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp4115699" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVOqsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2014&pages=1697-1705&author=N.+Mohanauthor=C.+H.+Suresh&title=A+molecular+electrostatic+potential+analysis+of+hydrogen%2C+halogen%2C+and+dihydrogen+bonds&doi=10.1021%2Fjp4115699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A Molecular Electrostatic Potential Analysis of Hydrogen, Halogen, and Dihydrogen Bonds</span></div><div class="casAuthors">Mohan, Neetha; Suresh, Cherumuttathu H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry A</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1697-1705</span>CODEN:
                <span class="NLM_cas:coden">JPCAFH</span>;
        ISSN:<span class="NLM_cas:issn">1089-5639</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hydrogen, halogen, and dihydrogen bonds in weak, medium and strong regimes (<1 to ∼60 kcal/mol) have been investigated for several intermol. donor-acceptor (D-A) complexes at ab initio MP4//MP2 method coupled with atoms-in-mols. and mol. electrostatic potential (MESP) approaches.  Electron d. ρ at bond crit. point correlates well with interaction energy (Enb) for each homogeneous sample of complexes, but its applicability to the entire set of complexes is not satisfactory.  Anal. of MESP min. (Vmin) and MESP at the nuclei (Vn) shows that in all D-A complexes, MESP of A becomes more neg. and that of D becomes less neg. suggesting donation of electrons from D to A leading to electron donor-acceptor (eDA) interaction between A and D.  MESP based parameter ΔΔVn measures donor-acceptor strength of the eDA interactions as it shows a good linear correlation with Enb for all D-A complexes (R2 = 0.976) except the strongly bound bridged structures.  The bridged structures are classified as donor-acceptor-donor complexes.  MESP provides a clear evidence for hydrogen, halogen, and dihydrogen bond formation and defines them as eDA interactions in which hydrogen acts as electron acceptor in hydrogen and dihydrogen bonds while halogen acts as electron acceptor in halogen bonds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQcyQeaXvFCbVg90H21EOLACvtfcHk0liuBhR7dvFs3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVOqsbk%253D&md5=2631f6ee04c2cf572d320866084720c5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjp4115699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp4115699%26sid%3Dliteratum%253Aachs%26aulast%3DMohan%26aufirst%3DN.%26aulast%3DSuresh%26aufirst%3DC.%2BH.%26atitle%3DA%2520molecular%2520electrostatic%2520potential%2520analysis%2520of%2520hydrogen%252C%2520halogen%252C%2520and%2520dihydrogen%2520bonds%26jtitle%3DJ.%2520Phys.%2520Chem.%2520A%26date%3D2014%26volume%3D118%26spage%3D1697%26epage%3D1705%26doi%3D10.1021%2Fjp4115699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Case, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainer, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seyb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glicksman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6122</span>– <span class="NLM_lpage">6126</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1016%2Fj.bmcl.2009.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=19783434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GmurrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6122-6126&author=L.+Qiaoauthor=S.+Choiauthor=A.+Caseauthor=T.+G.+Gainerauthor=K.+Seybauthor=M.+A.+Glicksmanauthor=D.+C.+Loauthor=R.+L.+Steinauthor=G.+D.+Cuny&title=Structure-activity+relationship+study+of+EphB3+receptor+tyrosine+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2009.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors</span></div><div class="casAuthors">Qiao, Lixin; Choi, Sungwoon; Case, April; Gainer, Thomas G.; Seyb, Kathleen; Glicksman, Marcie A.; Lo, Donald C.; Stein, Ross L.; Cuny, Gregory D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6122-6126</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A structure-activity relationship study for a 2-chloroanilide deriv. of pyrazolo[1,5-a]pyridine revealed that increased EphB3 kinase inhibitory activity could be accomplished by retaining the 2-chloroanilide and introducing a Ph or small electron donating substituents to the 5-position of the pyrazolo[1,5-a]pyridine.  In addn., replacement of the pyrazolo[1,5-a]pyridine with imidazo[1,2-a]pyridine was well tolerated and resulted in enhanced mouse liver microsome stability.  The structure-activity relationship for EphB3 inhibition of both heterocyclic series was similar.  Kinase inhibitory activity was also demonstrated for representative analogs in cell culture.  An analog (32, LDN-211904) was also profiled for inhibitory activity against a panel of 288 kinases and found to be quite selective for tyrosine kinases.  Overall, these studies provide useful mol. probes for examg. the in vitro, cellular and potentially in vivo kinase-dependent function of EphB3 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5VEuexFGaQrVg90H21EOLACvtfcHk0li9RZ52pztI8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GmurrP&md5=9c805701f2a2a5665d2e8bf22bb5ad5e</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DQiao%26aufirst%3DL.%26aulast%3DChoi%26aufirst%3DS.%26aulast%3DCase%26aufirst%3DA.%26aulast%3DGainer%26aufirst%3DT.%2BG.%26aulast%3DSeyb%26aufirst%3DK.%26aulast%3DGlicksman%26aufirst%3DM.%2BA.%26aulast%3DLo%26aufirst%3DD.%2BC.%26aulast%3DStein%26aufirst%3DR.%2BL.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26atitle%3DStructure-activity%2520relationship%2520study%2520of%2520EphB3%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6122%26epage%3D6126%26doi%3D10.1016%2Fj.bmcl.2009.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ninkovic, S.</span>; <span class="NLM_string-name">Braganza, J. F.</span>; <span class="NLM_string-name">Collins, M. R.</span>; <span class="NLM_string-name">Kath, J. C.</span>; <span class="NLM_string-name">Li, H.</span>; <span class="NLM_string-name">Richter, D. T.</span></span> <span> </span><span class="NLM_article-title">Preparation of Heterocyclylaminopyrazine Derivatives for Use as CHK-1 Inhibitors</span>. Patent <span class="NLM_patent">WO2010016005A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+Ninkovic&author=J.+F.+Braganza&author=M.+R.+Collins&author=J.+C.+Kath&author=H.+Li&author=D.+T.+Richter&title=Preparation+of+Heterocyclylaminopyrazine+Derivatives+for+Use+as+CHK-1+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNinkovic%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Heterocyclylaminopyrazine%2520Derivatives%2520for%2520Use%2520as%2520CHK-1%2520Inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bach Tana, J.</span>; <span class="NLM_string-name">Perez Crespo, D.</span>; <span class="NLM_string-name">Llera Soldevila, O.</span>; <span class="NLM_string-name">Esteve Trias, C.</span>; <span class="NLM_string-name">Taboada Martinez, L.</span></span> <span> </span><span class="NLM_article-title">Preparation of 2-(Pyrazolo[1,5-a]pyrazin-3-yl)pyrimidine and 2-(Pyrazolo[1,5-a]pyridin-3-yl)pyrimidine Derivatives as JAK Inhibitors for Therapy</span>. Patent <span class="NLM_patent">WO2015086693A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+Bach+Tana&author=D.+Perez+Crespo&author=O.+Llera+Soldevila&author=C.+Esteve+Trias&author=L.+Taboada+Martinez&title=Preparation+of+2-%28Pyrazolo%5B1%2C5-a%5Dpyrazin-3-yl%29pyrimidine+and+2-%28Pyrazolo%5B1%2C5-a%5Dpyridin-3-yl%29pyrimidine+Derivatives+as+JAK+Inhibitors+for+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBach%2BTana%26aufirst%3DJ.%26atitle%3DPreparation%2520of%25202-%2528Pyrazolo%255B1%252C5-a%255Dpyrazin-3-yl%2529pyrimidine%2520and%25202-%2528Pyrazolo%255B1%252C5-a%255Dpyridin-3-yl%2529pyrimidine%2520Derivatives%2520as%2520JAK%2520Inhibitors%2520for%2520Therapy%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span>; <span class="NLM_string-name">Du, Z.</span>; <span class="NLM_string-name">Farand, J.</span>; <span class="NLM_string-name">Guerrero, J. A.</span>; <span class="NLM_string-name">Katana, A. A.</span>; <span class="NLM_string-name">Kato, D.</span>; <span class="NLM_string-name">Lazerwith, S. E.</span>; <span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Link, J. O.</span>; <span class="NLM_string-name">Mai, N.</span>; <span class="NLM_string-name">Notte, G.</span>; <span class="NLM_string-name">Pyun, H.-J.</span>; <span class="NLM_string-name">Sangi, M.</span>; <span class="NLM_string-name">Schmitt, A. C.</span>; <span class="NLM_string-name">Schrier, A. J.</span>; <span class="NLM_string-name">Stevens, K. L.</span>; <span class="NLM_string-name">Venkataramani, C.</span>; <span class="NLM_string-name">Watkins, W. J.</span>; <span class="NLM_string-name">Yang, Z.-Y.</span>; <span class="NLM_string-name">Zablocki, J.</span>; <span class="NLM_string-name">Zipfel, S.</span></span> <span> </span><span class="NLM_article-title">Azabicyclyloxyalkylpyrrolidinone Derivatives as Syk Inhibitors and Their Preparation</span>. Patent <span class="NLM_patent">WO2015017610A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=K.+S.+Currie&author=Z.+Du&author=J.+Farand&author=J.+A.+Guerrero&author=A.+A.+Katana&author=D.+Kato&author=S.+E.+Lazerwith&author=J.+Li&author=J.+O.+Link&author=N.+Mai&author=G.+Notte&author=H.-J.+Pyun&author=M.+Sangi&author=A.+C.+Schmitt&author=A.+J.+Schrier&author=K.+L.+Stevens&author=C.+Venkataramani&author=W.+J.+Watkins&author=Z.-Y.+Yang&author=J.+Zablocki&author=S.+Zipfel&title=Azabicyclyloxyalkylpyrrolidinone+Derivatives+as+Syk+Inhibitors+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DAzabicyclyloxyalkylpyrrolidinone%2520Derivatives%2520as%2520Syk%2520Inhibitors%2520and%2520Their%2520Preparation%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allen, S.</span>; <span class="NLM_string-name">Boys, M. L.</span>; <span class="NLM_string-name">Chicarelli, M. J.</span>; <span class="NLM_string-name">Fell, J. B.</span>; <span class="NLM_string-name">Fischer, J. P.</span>; <span class="NLM_string-name">Gaudino, J.</span>; <span class="NLM_string-name">Hicken, E. J.</span>; <span class="NLM_string-name">Hinklin, R. J.</span>; <span class="NLM_string-name">Kraser, C. F.</span>; <span class="NLM_string-name">Laird, E.</span>; <span class="NLM_string-name">Robinson, J. E.</span>; <span class="NLM_string-name">Tang, T. P.</span>; <span class="NLM_string-name">Burgess, L. E.</span>; <span class="NLM_string-name">Rieger, R. A.</span>; <span class="NLM_string-name">Pheneger, J.</span>; <span class="NLM_string-name">Satoh, Y.</span>; <span class="NLM_string-name">Leftheris, K.</span>; <span class="NLM_string-name">Raheja, R. K.</span>; <span class="NLM_string-name">Bennett, B. L.</span></span> <span> </span><span class="NLM_article-title">4,6-Disubstituted-pyrazolo[1,5-a]pyrazines as Janus Kinase Inhibitors and Their Preparation</span>. Patent <span class="NLM_patent">WO2016090285A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Allen&author=M.+L.+Boys&author=M.+J.+Chicarelli&author=J.+B.+Fell&author=J.+P.+Fischer&author=J.+Gaudino&author=E.+J.+Hicken&author=R.+J.+Hinklin&author=C.+F.+Kraser&author=E.+Laird&author=J.+E.+Robinson&author=T.+P.+Tang&author=L.+E.+Burgess&author=R.+A.+Rieger&author=J.+Pheneger&author=Y.+Satoh&author=K.+Leftheris&author=R.+K.+Raheja&author=B.+L.+Bennett&title=4%2C6-Disubstituted-pyrazolo%5B1%2C5-a%5Dpyrazines+as+Janus+Kinase+Inhibitors+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DS.%26atitle%3D4%252C6-Disubstituted-pyrazolo%255B1%252C5-a%255Dpyrazines%2520as%2520Janus%2520Kinase%2520Inhibitors%2520and%2520Their%2520Preparation%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. W.</span>; <span class="NLM_string-name">Blake, J. F.</span>; <span class="NLM_string-name">Haas, J.</span>; <span class="NLM_string-name">Jiang, Y.</span>; <span class="NLM_string-name">Kolakowski, G. R.</span>; <span class="NLM_string-name">Moreno, D. A.</span>; <span class="NLM_string-name">Ren, L.</span>; <span class="NLM_string-name">Walls, S. M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Substituted Pyrazolo[1,5-a]pyrazine Compounds as RET Kinase Inhibitors</span>. Patent <span class="NLM_patent">WO2018136661A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+W.+Andrews&author=J.+F.+Blake&author=J.+Haas&author=Y.+Jiang&author=G.+R.+Kolakowski&author=D.+A.+Moreno&author=L.+Ren&author=S.+M.+Walls&title=Preparation+of+Substituted+Pyrazolo%5B1%2C5-a%5Dpyrazine+Compounds+as+RET+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DS.%2BW.%26atitle%3DPreparation%2520of%2520Substituted%2520Pyrazolo%255B1%252C5-a%255Dpyrazine%2520Compounds%2520as%2520RET%2520Kinase%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fradera, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Methot, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kattar, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesburg, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenblatt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. D.</span></span> <span> </span><span class="NLM_article-title">Design of selective PI3Kδ inhibitors using an iterative scaffold-hopping workflow</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2575</span>– <span class="NLM_lpage">2580</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1016%2Fj.bmcl.2019.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=31416665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2nu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=2575-2580&author=X.+Fraderaauthor=J.+L.+Methotauthor=A.+Achabauthor=M.+Christopherauthor=M.+D.+Altmanauthor=H.+Zhouauthor=M.+A.+McGowanauthor=S.+D.+Kattarauthor=K.+Wilsonauthor=Y.+Garciaauthor=M.+A.+Augustinauthor=C.+A.+Lesburgauthor=S.+Shahauthor=P.+Goldenblattauthor=J.+D.+Katz&title=Design+of+selective+PI3K%CE%B4+inhibitors+using+an+iterative+scaffold-hopping+workflow&doi=10.1016%2Fj.bmcl.2019.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Design of selective PI3Kδ inhibitors using an iterative scaffold-hopping workflow</span></div><div class="casAuthors">Fradera, Xavier; Methot, Joey L.; Achab, Abdelghani; Christopher, Matthew; Altman, Michael D.; Zhou, Hua; McGowan, Meredeth A.; Kattar, Sam D.; Wilson, Kevin; Garcia, Yudith; Augustin, Martin A.; Lesburg, Charles A.; Shah, Sanjiv; Goldenblatt, Peter; Katz, Jason D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2575-2580</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">PI3Kδ mediates key immune cell signaling pathways and is a target of interest for multiple indications in immunol. and oncol.  Here we report a structure-based scaffold-hopping strategy for the design of chem. diverse PI3Kδ inhibitors.  Using this strategy, we identified several scaffolds that can be combined to generate new PI3Kδ inhibitors with high potency and isoform selectivity.  In particular, an oxindole-based scaffold was found to impart exquisite selectivity when combined with several hinge binding motifs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqndhswHJ17ILVg90H21EOLACvtfcHk0lgOKFLaU79eHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2nu7nK&md5=4c978bad05a586a3f8c762016f001ebb</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DFradera%26aufirst%3DX.%26aulast%3DMethot%26aufirst%3DJ.%2BL.%26aulast%3DAchab%26aufirst%3DA.%26aulast%3DChristopher%26aufirst%3DM.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DMcGowan%26aufirst%3DM.%2BA.%26aulast%3DKattar%26aufirst%3DS.%2BD.%26aulast%3DWilson%26aufirst%3DK.%26aulast%3DGarcia%26aufirst%3DY.%26aulast%3DAugustin%26aufirst%3DM.%2BA.%26aulast%3DLesburg%26aufirst%3DC.%2BA.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DGoldenblatt%26aufirst%3DP.%26aulast%3DKatz%26aufirst%3DJ.%2BD.%26atitle%3DDesign%2520of%2520selective%2520PI3K%25CE%25B4%2520inhibitors%2520using%2520an%2520iterative%2520scaffold-hopping%2520workflow%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D2575%26epage%3D2580%26doi%3D10.1016%2Fj.bmcl.2019.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korniski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmons, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gormley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommers, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenbrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasselli, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, T. E.</span></span> <span> </span><span class="NLM_article-title">Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>400</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2010.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1016%2Fj.jmb.2010.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=20478313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=2010&pages=413-433&author=J.+E.+Chrencikauthor=A.+Patnyauthor=I.+K.+Leungauthor=B.+Korniskiauthor=T.+L.+Emmonsauthor=T.+Hallauthor=R.+A.+Weinbergauthor=J.+A.+Gormleyauthor=J.+M.+Williamsauthor=J.+E.+Dayauthor=J.+L.+Hirschauthor=J.+R.+Kieferauthor=J.+W.+Leoneauthor=H.+D.+Fischerauthor=C.+D.+Sommersauthor=H.-C.+Huangauthor=E.+J.+Jacobsenauthor=R.+E.+Tenbrinkauthor=A.+G.+Tomasselliauthor=T.+E.+Benson&title=Structural+and+thermodynamic+characterization+of+the+TYK2+and+JAK3+kinase+domains+in+complex+with+CP-690550+and+CMP-6&doi=10.1016%2Fj.jmb.2010.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6</span></div><div class="casAuthors">Chrencik, Jill E.; Patny, Akshay; Leung, Iris K.; Korniski, Brian; Emmons, Thomas L.; Hall, Troii; Weinberg, Robin A.; Gormley, Jennifer A.; Williams, Jennifer M.; Day, Jacqueline E.; Hirsch, Jeffrey L.; Kiefer, James R.; Leone, Joseph W.; Fischer, H. David; Sommers, Cynthia D.; Huang, Horng-Chih; Jacobsen, E. J.; Tenbrink, Ruth E.; Tomasselli, Alfredo G.; Benson, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-433</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are crit. regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases.  Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clin. compd. CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.  Here, we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-JAK inhibitors CP-690550 ((3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile) and CMP-6 (tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one), both of which bind in the ATP-binding cavities of both JAK isoenzymes in orientations similar to that obsd. in crystal structures of JAK1 and JAK2.  Addnl., a complete thermodn. characterization of JAK/CP-690550 complex formation was completed by isothermal titrn. calorimetry, indicating the crit. role of the nitrile group from the CP-690550 compd.  Finally, computational anal. using WaterMap further highlights the crit. positioning of the CP-690550 nitrile group in the displacement of an unfavorable water mol. beneath the glycine-rich loop.  Taken together, the data emphasize the outstanding properties of the kinome-selective JAK inhibitor CP-690550, as well as the challenges in obtaining JAK isoenzyme-selective inhibitors due to the overall structural and sequence similarities between the TYK2, JAK1, JAK2 and JAK3 isoenzymes.  Nevertheless, subtle amino acid variations of residues lining the ligand-binding cavity of the JAK enzymes, as well as the global positioning of the glycine-rich loop, might provide the initial clues to obtaining JAK-isoenzyme selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dnGkvq0jPbVg90H21EOLACvtfcHk0lgOKFLaU79eHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D&md5=1b1efc3d6f913143dc9113e4ac1c4c60</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2010.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2010.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DSommers%26aufirst%3DC.%2BD.%26aulast%3DHuang%26aufirst%3DH.-C.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DTenbrink%26aufirst%3DR.%2BE.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DBenson%26aufirst%3DT.%2BE.%26atitle%3DStructural%2520and%2520thermodynamic%2520characterization%2520of%2520the%2520TYK2%2520and%2520JAK3%2520kinase%2520domains%2520in%2520complex%2520with%2520CP-690550%2520and%2520CMP-6%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D400%26spage%3D413%26epage%3D433%26doi%3D10.1016%2Fj.jmb.2010.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allerton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A. F.</span></span> <span> </span><span class="NLM_article-title">Predicting clearance mechanism in drug discovery: Extended clearance classification system (ECCS)</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">3785</span>– <span class="NLM_lpage">3802</span>, <span class="refDoi"> DOI: 10.1007/s11095-015-1749-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1007%2Fs11095-015-1749-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=26155985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCjurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2015&pages=3785-3802&author=M.+V.+Varmaauthor=S.+J.+Steynauthor=C.+Allertonauthor=A.+F.+El-Kattan&title=Predicting+clearance+mechanism+in+drug+discovery%3A+Extended+clearance+classification+system+%28ECCS%29&doi=10.1007%2Fs11095-015-1749-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)</span></div><div class="casAuthors">Varma, Manthena V.; Steyn, Stefanus J.; Allerton, Charlotte; El-Kattan, Ayman F.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3785-3802</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Early prediction of clearance mechanisms allows for the rapid progression of drug discovery and development programs, and facilitates risk assessment of the pharmacokinetic variability assocd. with drug interactions and pharmacogenomics.  Here we propose a scientific framework - Extended Clearance Classification System (ECCS) - which can be used to predict the predominant clearance mechanism (rate-detg. process) based on physicochem. properties and passive membrane permeability.  Compds. are classified as: Class 1A - metab. as primary systemic clearance mechanism (high permeability acids/zwitterions with mol. wt. (MW) ≤400 Da), Class 1B - transporter-mediated hepatic uptake as primary systemic clearance mechanism (high permeability acids/zwitterions with MW >400 Da), Class 2 - metab. as primary clearance mechanism (high permeability bases/neutrals), Class 3A -renal clearance (low permeability acids/zwitterions with MW ≤400 Da), Class 3B - transporter mediated hepatic uptake or renal clearance (low permeability acids/zwitterions with MW >400 Da), and Class 4 - renal clearance (low permeability bases/neutrals).  The performance of the ECCS framework was validated using 307 compds. with single clearance mechanism contributing to ≥70% of systemic clearance.  The apparent permeability across clonal cell line of Madin - Darby canine kidney cells, selected for low endogenous efflux transporter expression, with a cut-off of 5 × 10-6 cm/s was used for permeability classification, and the ionization (at pH7) was assigned based on calcd. pKa.  The proposed scheme correctly predicted the rate-detg. clearance mechanism to be either metab., hepatic uptake or renal for ∼92% of total compds.  We discuss the general characteristics of each ECCS class, as well as compare and contrast the framework with the biopharmaceutics classification system (BCS) and the biopharmaceutics drug disposition classification system (BDDCS).  Collectively, the ECCS framework is valuable in early prediction of clearance mechanism and can aid in choosing the right preclin. tool kit and strategy for optimizing drug exposure and evaluating clin. risk of pharmacokinetic variability caused by drug interactions and pharmacogenomics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRANZrcZqpObVg90H21EOLACvtfcHk0lj6qSeKlDnq1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCjurfP&md5=836ba49f4fe66ceacfec6390e56bc792</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs11095-015-1749-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-015-1749-4%26sid%3Dliteratum%253Aachs%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DAllerton%26aufirst%3DC.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26atitle%3DPredicting%2520clearance%2520mechanism%2520in%2520drug%2520discovery%253A%2520Extended%2520clearance%2520classification%2520system%2520%2528ECCS%2529%26jtitle%3DPharm.%2520Res.%26date%3D2015%26volume%3D32%26spage%3D3785%26epage%3D3802%26doi%3D10.1007%2Fs11095-015-1749-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shilliday, F. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, H. V.</span></span> <span> </span><span class="NLM_article-title">Drug design structural alert: Formation of trifluoroacetaldehyde through N-dealkylation is linked to testicular lesions in rat</span>. <i>Int. J. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">546</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1177/1091581811413833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1177%2F1091581811413833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=21868768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVGktLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=546-550&author=M.+E.+Dowtyauthor=G.+Huauthor=F.+Huaauthor=F.+B.+Shillidayauthor=H.+V.+Dowty&title=Drug+design+structural+alert%3A+Formation+of+trifluoroacetaldehyde+through+N-dealkylation+is+linked+to+testicular+lesions+in+rat&doi=10.1177%2F1091581811413833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Drug design structural alert: formation of trifluoroacetaldehyde through N-dealkylation is linked to testicular lesions in rat</span></div><div class="casAuthors">Dowty, Martin E.; Hu, George; Hua, Fengmei; Shilliday, F. Barclay; Dowty, Heather V.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">546-550</span>CODEN:
                <span class="NLM_cas:coden">IJTOFN</span>;
        ISSN:<span class="NLM_cas:issn">1091-5818</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">In the process of drug design, it is important to consider potential structural alerts that may lead to toxicosis.  This work illustrates how using trifluoroethane as a part of a novel chem. entity led to cytochrome P 450 - mediated N-dealkylation and the formation of trifluoroacetaldehyde, a known testicular toxicant, in exploratory safety studies in rats.  Testicular toxicosis was noted microscopically in a dose-dependent manner as measured by testicular spermatocytic degeneration and necrosis and excessive intratubular cellular debris in the epididymis.  This apparent toxic effect correlated well with the dose-dependent formation of trifluoroacetaldehyde, identified from in vitro rat liver microsome metab. studies.  A similar safety study performed with an N-tetrazole substitution in place of the N-trifluoroethane showed no evidence of testicular injury, implicating further the role of trifluoroacetaldehyde in the testicular lesion obsd.  These results highlight the relevance of early metabolic and safety testing in assessing potential structural alerts in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFV-lzA-4PvbVg90H21EOLACvtfcHk0lhDnCk4Wbn98g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVGktLfM&md5=30f0e43e80ba5d541b48eeee99b2e95b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1177%2F1091581811413833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1091581811413833%26sid%3Dliteratum%253Aachs%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DHua%26aufirst%3DF.%26aulast%3DShilliday%26aufirst%3DF.%2BB.%26aulast%3DDowty%26aufirst%3DH.%2BV.%26atitle%3DDrug%2520design%2520structural%2520alert%253A%2520Formation%2520of%2520trifluoroacetaldehyde%2520through%2520N-dealkylation%2520is%2520linked%2520to%2520testicular%2520lesions%2520in%2520rat%26jtitle%3DInt.%2520J.%2520Toxicol.%26date%3D2011%26volume%3D30%26spage%3D546%26epage%3D550%26doi%3D10.1177%2F1091581811413833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney-Pickett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umland, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebhard, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federico, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempshall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liston, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M. D.</span></span> <span> </span><span class="NLM_article-title">Development of a new permeability assay using low-efflux MDCKII cells</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">4974</span>– <span class="NLM_lpage">4985</span>, <span class="refDoi"> DOI: 10.1002/jps.22674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1002%2Fjps.22674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=21766308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=4974-4985&author=L.+Diauthor=C.+Whitney-Pickettauthor=J.+P.+Umlandauthor=H.+Zhangauthor=X.+Zhangauthor=D.+F.+Gebhardauthor=Y.+Laiauthor=J.+J.+Federicoauthor=R.+E.+Davidsonauthor=R.+Smithauthor=E.+L.+Reynerauthor=C.+Leeauthor=B.+Fengauthor=C.+Rotterauthor=M.+V.+Varmaauthor=S.+Kempshallauthor=K.+Fennerauthor=A.+F.+El-Kattanauthor=T.+E.+Listonauthor=M.+D.+Troutman&title=Development+of+a+new+permeability+assay+using+low-efflux+MDCKII+cells&doi=10.1002%2Fjps.22674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a new permeability assay using low-efflux MDCKII cells</span></div><div class="casAuthors">Di, Li; Whitney-Pickett, Carrie; Umland, John P.; Zhang, Hui; Zhang, Xun; Gebhard, David F.; Lai, Yurong; Federico, James J.; Davidson, Ralph E.; Smith, Russ; Reyner, Eric L.; Lee, Caroline; Feng, Bo; Rotter, Charles; Varma, Manthena V.; Kempshall, Sarah; Fenner, Katherine; El-kattan, Ayman F.; Liston, Theodore E.; Troutman, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4974-4985</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Permeability is an important property of drug candidates.  The Madin-Darby canine kidney cell line (MDCK) permeability assay is widely used and the primary concern of using MDCK cells is the presence of endogenous transporters of nonhuman origin.  The canine P-glycoprotein (Pgp) can interfere with permeability and transporter studies, leading to less reliable data.  A new cell line, MDCKII-LE (low efflux), has been developed by selecting a subpopulation of low-efflux cells from MDCKII-WT using an iterative fluorescence-activated cell sorting technique with calcein-AM as a Pgp and efflux substrate.  MDCKII-LE cells are a subpopulation of MDCKII cells with over 200-fold lower canine Pgp mRNA level and fivefold lower protein level than MDCKII-WT.  MDCKII-LE cells showed less functional efflux activity than MDCKII-WT based on efflux ratios.  Notably, MDCKII-MDR1 showed about 1.5-fold decreased expression of endogenous canine Pgp, suggesting that using the net flux ratio might not completely cancel out the background endogenous transporter activities.  MDCKII-LE cells offer clear advantages over the MDCKII-WT by providing less efflux transporter background signals and minimizing interference from canine Pgp.  The MDCKII-LE apparent permeability values well differentiates compds. from high to medium/low human intestinal absorption and can be used for Biopharmaceutical Classification System.  The MDCKII-LE permeability assay (4-in-1 cassette dosing) is high throughput with good precision, reproducibility, robustness, and cost-effective. © 2011 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTVtRmYnbF17Vg90H21EOLACvtfcHk0lhDnCk4Wbn98g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D&md5=97f647fc215ea6d04882351ffc912a1e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fjps.22674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22674%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DUmland%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGebhard%26aufirst%3DD.%2BF.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DFederico%26aufirst%3DJ.%2BJ.%26aulast%3DDavidson%26aufirst%3DR.%2BE.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DRotter%26aufirst%3DC.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26atitle%3DDevelopment%2520of%2520a%2520new%2520permeability%2520assay%2520using%2520low-efflux%2520MDCKII%2520cells%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26spage%3D4974%26epage%3D4985%26doi%3D10.1002%2Fjps.22674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaila, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TenBrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heasley, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langille, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclos, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R.</span></span> <span> </span><span class="NLM_article-title">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A selective JAK1 clinical candidate for the treatment of autoimmune diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1130</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1130-1152&author=M.+L.+Vazquezauthor=N.+Kailaauthor=J.+W.+Strohbachauthor=J.+D.+Trzupekauthor=M.+F.+Brownauthor=M.+E.+Flanaganauthor=M.+J.+Mitton-Fryauthor=T.+A.+Johnsonauthor=R.+E.+TenBrinkauthor=E.+P.+Arnoldauthor=A.+Basakauthor=S.+E.+Heasleyauthor=S.+Kwonauthor=J.+Langilleauthor=M.+D.+Parikhauthor=S.+H.+Griffinauthor=J.+M.+Casavantauthor=B.+A.+Duclosauthor=A.+E.+Fenwickauthor=T.+M.+Harrisauthor=S.+Hanauthor=N.+Caspersauthor=M.+E.+Dowtyauthor=X.+Yangauthor=M.+E.+Bankerauthor=M.+Hegenauthor=P.+T.+Symanowiczauthor=L.+Liauthor=L.+Wangauthor=T.+H.+Linauthor=J.+Jussifauthor=J.+D.+Clarkauthor=J.-B.+Telliezauthor=R.+P.+Robinsonauthor=R.+Unwalla&title=Identification+of+N-%7Bcis-3-%5BMethyl%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%5Dcyclobutyl%7Dpropane-1-sulfonamide+%28PF-04965842%29%3A+A+selective+JAK1+clinical+candidate+for+the+treatment+of+autoimmune+diseases&doi=10.1021%2Facs.jmedchem.7b01598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases</span></div><div class="casAuthors">Vazquez, Michael L.; Kaila, Neelu; Strohbach, Joseph W.; Trzupek, John D.; Brown, Matthew F.; Flanagan, Mark E.; Mitton-Fry, Mark J.; Johnson, Timothy A.; TenBrink, Ruth E.; Arnold, Eric P.; Basak, Arindrajit; Heasley, Steven E.; Kwon, Soojin; Langille, Jonathan; Parikh, Mihir D.; Griffin, Sarah H.; Casavant, Jeffrey M.; Duclos, Brian A.; Fenwick, Ashley E.; Harris, Thomas M.; Han, Seungil; Caspers, Nicole; Dowty, Martin E.; Yang, Xin; Banker, Mary Ellen; Hegen, Martin; Symanowicz, Peter T.; Li, Li; Wang, Lu; Lin, Tsung H.; Jussif, Jason; Clark, James D.; Telliez, Jean-Baptiste; Robinson, Ralph P.; Unwalla, Ray</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1130-1152</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis.  As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling.  The authors' efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis.  Through modification of the 3-aminopiperidine linker in tofacitinib, the authors discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay.  Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by x-ray crystallog. anal.  After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (25) was nominated as a clin. candidate for the treatment of JAK1-mediated autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNdiJFIHI-YLVg90H21EOLACvtfcHk0ljFqSdRQSwtpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D&md5=45c6d1b0eee7ab9d5dfc8ea168607a8b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01598%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez%26aufirst%3DM.%2BL.%26aulast%3DKaila%26aufirst%3DN.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DMitton-Fry%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DTenBrink%26aufirst%3DR.%2BE.%26aulast%3DArnold%26aufirst%3DE.%2BP.%26aulast%3DBasak%26aufirst%3DA.%26aulast%3DHeasley%26aufirst%3DS.%2BE.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DLangille%26aufirst%3DJ.%26aulast%3DParikh%26aufirst%3DM.%2BD.%26aulast%3DGriffin%26aufirst%3DS.%2BH.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DDuclos%26aufirst%3DB.%2BA.%26aulast%3DFenwick%26aufirst%3DA.%2BE.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26aulast%3DUnwalla%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520N-%257Bcis-3-%255BMethyl%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%255Dcyclobutyl%257Dpropane-1-sulfonamide%2520%2528PF-04965842%2529%253A%2520A%2520selective%2520JAK1%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1130%26epage%3D1152%26doi%3D10.1021%2Facs.jmedchem.7b01598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bucher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stouten, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triballeau, N.</span></span> <span> </span><span class="NLM_article-title">Shedding light on important waters for drug design: Simulations versus grid-based methods</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">692</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.7b00642</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.7b00642" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsVylsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2018&pages=692-699&author=D.+Bucherauthor=P.+Stoutenauthor=N.+Triballeau&title=Shedding+light+on+important+waters+for+drug+design%3A+Simulations+versus+grid-based+methods&doi=10.1021%2Facs.jcim.7b00642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Shedding Light on Important Waters for Drug Design: Simulations versus Grid-Based Methods</span></div><div class="casAuthors">Bucher, Denis; Stouten, Pieter; Triballeau, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">692-699</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Water mols. play an important role in the assocn. of drugs with their pharmaceutical targets.  For this reason, calcg. the energetic contribution of water is essential to make accurate predictions of compds.' affinity and selectivity.  Water mols. can also modify the binding mode of compds. by forming water bridges, or clusters, that stabilize a particular orientation of the ligand.  Several computational methods have been developed for solvent mapping, but few studies have attempted to compare them in a drug design context.  In this paper, four com. available solvent mapping tools (SZMAP, WaterFLAP, 3D-RISM, and WaterMap) are evaluated on three different protein targets.  The methods were compared by looking at their ability to predict the structure-activity relations of lead compds.  All methods were found to be useful to some degree and to improve the predictions from docking alone.  However, the only simulation-based approach tested, WaterMap, was found in some cases to be more accurate than grid-based methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOUZ3PyrwN_LVg90H21EOLACvtfcHk0li9sM5-bsfQNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsVylsLc%253D&md5=95c20e75eeafa94a3cd8e70dedcacb96</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.7b00642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.7b00642%26sid%3Dliteratum%253Aachs%26aulast%3DBucher%26aufirst%3DD.%26aulast%3DStouten%26aufirst%3DP.%26aulast%3DTriballeau%26aufirst%3DN.%26atitle%3DShedding%2520light%2520on%2520important%2520waters%2520for%2520drug%2520design%253A%2520Simulations%2520versus%2520grid-based%2520methods%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2018%26volume%3D58%26spage%3D692%26epage%3D699%26doi%3D10.1021%2Facs.jcim.7b00642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Card, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokchander, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciabola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clugston, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschantz, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wangu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moshinsky, D. J.</span></span> <span> </span><span class="NLM_article-title">High-throughput biochemical kinase selectivity assays: Panel development and screening applications</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1177/1087057108326663</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1177%2F1087057108326663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=19073965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkslGrt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=31-42&author=A.+Cardauthor=C.+Caldwellauthor=H.+Minauthor=B.+Lokchanderauthor=H.+Xiauthor=S.+Sciabolaauthor=A.+V.+Kamathauthor=S.+L.+Clugstonauthor=W.+R.+Tschantzauthor=L.+Wanguauthor=D.+J.+Moshinsky&title=High-throughput+biochemical+kinase+selectivity+assays%3A+Panel+development+and+screening+applications&doi=10.1177%2F1087057108326663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput biochemical kinase selectivity assays: panel development and screening applications</span></div><div class="casAuthors">Card, Amy; Caldwell, Chris; Min, Hyunsuk; Lokchander, Bina; Xi, Hualin; Sciabola, Simone; Kamath, Ajith V.; Clugston, Susan L.; Tschantz, William R.; Wang, Leyu; Moshinsky, Deborah J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-42</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Kinases represent attractive targets for drug discovery.  Eight small-mol. kinase inhibitors are currently marketed in the area of oncol., and numerous others are in clin. trials.  Characterization of the selectivity profiles of these compds. is important to target appropriate patient populations and to reduce the potential of toxicity due to off-target effects.  The authors describe the development, validation, and utilization of a biochem. kinase assay panel for the selectivity profiling of inhibitors.  The panel was developed as 29 radiometric Flashplate assays, and then an initial 13 were transitioned to a nonradiometric Caliper mobility shift assay format.  Generation of high-quality data from the panel is detailed along with a comparison of the assay formats.  Both assay technologies were found to be suitable for panel screening, but mobility shift assays yielded higher data quality.  The selectivity data generated here should be useful in computational modeling and help facilitate, in conjunction with sequence and structural information, the rational design of inhibitors with well-defined selectivity profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomyXhZTHNo27Vg90H21EOLACvtfcHk0ljXqMdArhBRCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkslGrt7s%253D&md5=f7091977dcac95d920a8bc292dcff78d</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1177%2F1087057108326663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057108326663%26sid%3Dliteratum%253Aachs%26aulast%3DCard%26aufirst%3DA.%26aulast%3DCaldwell%26aufirst%3DC.%26aulast%3DMin%26aufirst%3DH.%26aulast%3DLokchander%26aufirst%3DB.%26aulast%3DXi%26aufirst%3DH.%26aulast%3DSciabola%26aufirst%3DS.%26aulast%3DKamath%26aufirst%3DA.%2BV.%26aulast%3DClugston%26aufirst%3DS.%2BL.%26aulast%3DTschantz%26aufirst%3DW.%2BR.%26aulast%3DWangu%26aufirst%3DL.%26aulast%3DMoshinsky%26aufirst%3DD.%2BJ.%26atitle%3DHigh-throughput%2520biochemical%2520kinase%2520selectivity%2520assays%253A%2520Panel%2520development%2520and%2520screening%2520applications%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2009%26volume%3D14%26spage%3D31%26epage%3D42%26doi%3D10.1177%2F1087057108326663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremaine, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liras, J.</span></span> <span> </span><span class="NLM_article-title">Validation of human MDR1-MDCK and BCRP-MDCK cell lines to improve the prediction of brain penetration</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">2476</span>– <span class="NLM_lpage">2483</span>, <span class="refDoi"> DOI: 10.1016/j.xphs.2019.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1016%2Fj.xphs.2019.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=30794795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlOrurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2019&pages=2476-2483&author=B.+Fengauthor=M.+Westauthor=N.+C.+Patelauthor=T.+Wagerauthor=X.+Houauthor=J.+Johnsonauthor=L.+Tremaineauthor=J.+Liras&title=Validation+of+human+MDR1-MDCK+and+BCRP-MDCK+cell+lines+to+improve+the+prediction+of+brain+penetration&doi=10.1016%2Fj.xphs.2019.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of Human MDR1-MDCK and BCRP-MDCK Cell Lines to Improve the Prediction of Brain Penetration</span></div><div class="casAuthors">Feng, Bo; West, Mark; Patel, Nandini C.; Wager, Travis; Hou, Xinjun; Johnson, Jillian; Tremaine, Larry; Liras, Jennifer</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2476-2483</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">It is of great challenge to predict human brain penetration for substrates of multidrug resistance protein 1 (MDR1) and breast cancer resistance protein (BCRP), 2 major efflux transporters at blood-brain barrier.  Thus, a physiol. based pharmacokinetic (PBPK) model with the incorporation of in vitro MDR1 and BCRP transporter function data and transporter protein expression levels has been developed.  As such, it is crucial to generate MDR1 and BCRP substrate data with a high fidelity.  In this study, 2 widely used human MDR1 cell lines from Borst and National Institutes of Health labs. were evaluated using rodent brain penetration data, and the study suggested that the MDR1 expressed in Madin-Darby canine kidney (MDCK) cell line from National Institutes of Health lab. predicted brain penetration better, particularly for compds. with a high passive permeability.  In addn., human BCRP-MDCK cell line with 1 μM PSC833, a specific MDR1 inhibitor, demonstrated the ability to identify BCRP substrates without the confounding of endogenous canine Mdr1.  Comparison of human BCRP and mouse Bcrp transporter functions revealed that the functional differences of BCRP between the 2 species is minimal.  The incorporation of both the validated MDR1 and BCRP assays into the brain PBPK model has significantly improved the prediction for the brain penetration of MDR1 and BCRP substrates across species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJccGgmyYnkrVg90H21EOLACvtfcHk0ljXqMdArhBRCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlOrurg%253D&md5=b50738eeab75b2a1cc048372de13b1a5</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.xphs.2019.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.xphs.2019.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DWest%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DN.%2BC.%26aulast%3DWager%26aufirst%3DT.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DJohnson%26aufirst%3DJ.%26aulast%3DTremaine%26aufirst%3DL.%26aulast%3DLiras%26aufirst%3DJ.%26atitle%3DValidation%2520of%2520human%2520MDR1-MDCK%2520and%2520BCRP-MDCK%2520cell%2520lines%2520to%2520improve%2520the%2520prediction%2520of%2520brain%2520penetration%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2019%26volume%3D108%26spage%3D2476%26epage%3D2483%26doi%3D10.1016%2Fj.xphs.2019.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span> <span> </span><span class="NLM_article-title">Predicting clearance in humans from in vitro data</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.2174/156802611794480873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.2174%2F156802611794480873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=21320062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=334-339&author=R.+S.+Obach&title=Predicting+clearance+in+humans+from+in+vitro+data&doi=10.2174%2F156802611794480873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting clearance in humans from in vitro data</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">334-339</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The use of in vitro metab. in scaling to predict human clearance of new chem. entities has become a commonplace activity in the research and development of new drugs.  The measurement of in vitro lability in human liver microsomes, a rich source of drug metabolizing cytochrome P 450 enzymes, has become a high throughput screen in many research organizations which is a testament to its usefulness in drug design.  In this chapter, the methods used to scale in vitro intrinsic clearance data to predict in vivo clearance are described.  Importantly, the numerous assumptions that are required in order to use in vitro data in this manner are laid out.  These include assumptions regarding the scaling process as well as tech. aspects of the generation of the in vitro data.  Finally, some other drug clearance processes that have been emerging as important are described with regard to ongoing research efforts to develop clearance prediction methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHL7BnSTNtWbVg90H21EOLACvtfcHk0lib6eiiD2-W9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSntbk%253D&md5=38df8707bb77fdc8b6bb6ef2144a79da</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.2174%2F156802611794480873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611794480873%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPredicting%2520clearance%2520in%2520humans%2520from%2520in%2520vitro%2520data%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D334%26epage%3D339%26doi%3D10.2174%2F156802611794480873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hosea, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collard, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, R. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakar, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span> <span> </span><span class="NLM_article-title">Prediction of human pharmacokinetics from preclinical information: Comparative accuracy of quantitative prediction approaches</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1177/0091270009333209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1177%2F0091270009333209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=19299532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=513-533&author=N.+A.+Hoseaauthor=W.+T.+Collardauthor=S.+Coleauthor=T.+S.+Maurerauthor=R.+X.+Fangauthor=H.+Jonesauthor=S.+M.+Kakarauthor=Y.+Nakaiauthor=B.+J.+Smithauthor=R.+Websterauthor=K.+Beaumont&title=Prediction+of+human+pharmacokinetics+from+preclinical+information%3A+Comparative+accuracy+of+quantitative+prediction+approaches&doi=10.1177%2F0091270009333209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span></div><div class="casAuthors">Hosea, Natilie A.; Collard, Wendy T.; Cole, Susan; Maurer, Tristan S.; Fang, Rick X.; Jones, Hannah; Kakar, Shefali M.; Nakai, Yasuhiro; Smith, Bill J.; Webster, Rob; Beaumont, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">513-533</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Quant. prediction of human pharmacokinetics is crit. in assessing the viability of drug candidates and in detg. first-in-human dosing.  Numerous prediction methodologies, incorporating both in vitro and preclin. in vivo data, have been developed in recent years, each with advantages and disadvantages.  However, the lack of a comprehensive data set, both preclin. and clin., has limited efforts to evaluate the optimal strategy (or strategies) that results in quant. predictions of human pharmacokinetics.  To address this issue, the authors conducted a retrospective anal. using 50 proprietary compds. for which in vitro, preclin. pharmacokinetic data and oral single-dose human pharmacokinetic data were available.  Five predictive strategies, involving either allometry or use of unbound intrinsic clearance from microsomes or hepatocytes, were then compared for their ability to predict human oral clearance, half-life through predictions of systemic clearance, vol. of distribution, and bioavailability.  Use of a single-species scaling approach with rat, dog, or monkey was as accurate as or more accurate than using multiple-species allometry.  For those compds. cleared almost exclusively by P 450-mediated pathways, scaling from human liver microsomes was as predictive as single-species scaling of clearance based on data from rat, dog, or monkey.  These data suggest that use of predictive methods involving either single-species in vivo data or in vitro human liver microsomes can quant. predict human in vivo pharmacokinetics and suggest the possibility of streamlining the predictive methodol. through use of a single species or use only of human in vitro microsomal prepns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg67HcwS4O4LVg90H21EOLACvtfcHk0lib6eiiD2-W9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D&md5=a0941d53fe43392f8fb1562ee546705e</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1177%2F0091270009333209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270009333209%26sid%3Dliteratum%253Aachs%26aulast%3DHosea%26aufirst%3DN.%2BA.%26aulast%3DCollard%26aufirst%3DW.%2BT.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DFang%26aufirst%3DR.%2BX.%26aulast%3DJones%26aufirst%3DH.%26aulast%3DKakar%26aufirst%3DS.%2BM.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DBeaumont%26aufirst%3DK.%26atitle%3DPrediction%2520of%2520human%2520pharmacokinetics%2520from%2520preclinical%2520information%253A%2520Comparative%2520accuracy%2520of%2520quantitative%2520prediction%2520approaches%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D49%26spage%3D513%26epage%3D533%26doi%3D10.1177%2F0091270009333209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katherine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masek, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Susan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eva, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span> <span> </span><span class="NLM_article-title">Attenuating Janus kinases (JAK) by tofacitinib effectively prevented psoriasis pathology in various mouse skin inflammation models</span>. <i>J. Clin. Cell. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1000176</span>, <span class="refDoi"> DOI: 10.4172/2155-9899.1000176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.4172%2F2155-9899.1000176" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1000176&author=L.+Hakauthor=M.+Katherineauthor=H.+Masekauthor=F.+Susanauthor=N.+Leeauthor=N.+Evaauthor=H.+Martinauthor=D.+James&title=Attenuating+Janus+kinases+%28JAK%29+by+tofacitinib+effectively+prevented+psoriasis+pathology+in+various+mouse+skin+inflammation+models&doi=10.4172%2F2155-9899.1000176"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.4172%2F2155-9899.1000176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F2155-9899.1000176%26sid%3Dliteratum%253Aachs%26aulast%3DHak%26aufirst%3DL.%26aulast%3DKatherine%26aufirst%3DM.%26aulast%3DMasek%26aufirst%3DH.%26aulast%3DSusan%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DEva%26aufirst%3DN.%26aulast%3DMartin%26aufirst%3DH.%26aulast%3DJames%26aufirst%3DD.%26atitle%3DAttenuating%2520Janus%2520kinases%2520%2528JAK%2529%2520by%2520tofacitinib%2520effectively%2520prevented%2520psoriasis%2520pathology%2520in%2520various%2520mouse%2520skin%2520inflammation%2520models%26jtitle%3DJ.%2520Clin.%2520Cell.%2520Immunol.%26date%3D2013%26volume%3D4%26spage%3D1000176%26doi%3D10.4172%2F2155-9899.1000176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gifford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffor, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span> <span> </span><span class="NLM_article-title">Demonstration of In Vitro to In Vivo translation of a TYK2 inhibitor that shows cross species potency differences</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">8974</span>, <span class="refDoi"> DOI: 10.1038/s41598-020-65762-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1038%2Fs41598-020-65762-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=32488071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtV2ku7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=8974&author=B.+S.+Gerstenbergerauthor=M.+E.+Bankerauthor=J.+D.+Clarkauthor=M.+E.+Dowtyauthor=A.+Fensomeauthor=R.+Giffordauthor=M.+C.+Grifforauthor=M.+Hegenauthor=B.+D.+Hollingsheadauthor=J.+D.+Knafelsauthor=T.+H.+Linauthor=J.+F.+Smithauthor=F.+F.+Vajdos&title=Demonstration+of+In+Vitro+to+In+Vivo+translation+of+a+TYK2+inhibitor+that+shows+cross+species+potency+differences&doi=10.1038%2Fs41598-020-65762-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences</span></div><div class="casAuthors">Gerstenberger, Brian S.; Banker, Mary Ellen; Clark, James D.; Dowty, Martin E.; Fensome, Andrew; Gifford, Roger; Griffor, Matthew C.; Hegen, Martin; Hollingshead, Brett D.; Knafels, John D.; Lin, Tsung H.; Smith, James F.; Vajdos, Felix F.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8974</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Translation of modulation of drug target activity to therapeutic effect is a crit. aspect for all drug discovery programs.  In this work we describe the profiling of a non-receptor tyrosine-protein kinase (TYK2) inhibitor which shows a functionally relevant potency shift between human and preclin. species (e.g. murine, dog, macaque) in both biochem. and cellular assays.  Comparison of the structure and sequence homol. of TYK2 between human and preclin. species within the ATP binding site highlights a single amino acid (I960 → V) responsible for the potency shift.  Through TYK2 kinase domain mutants and a TYK2 980I knock-in mouse model, we demonstrate that this single amino acid change drives a functionally relevant potency difference that exists between human and all evaluated preclin. species, for a series of TYK2 inhibitors which target the ATP binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppbgZtlCbNRLVg90H21EOLACvtfcHk0lj-FYhnALIV6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtV2ku7jK&md5=65924cc0bdc58f0c4ea9a0a3a3955091</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fs41598-020-65762-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-020-65762-y%26sid%3Dliteratum%253Aachs%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DGifford%26aufirst%3DR.%26aulast%3DGriffor%26aufirst%3DM.%2BC.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHollingshead%26aufirst%3DB.%2BD.%26aulast%3DKnafels%26aufirst%3DJ.%2BD.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DSmith%26aufirst%3DJ.%2BF.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26atitle%3DDemonstration%2520of%2520In%2520Vitro%2520to%2520In%2520Vivo%2520translation%2520of%2520a%2520TYK2%2520inhibitor%2520that%2520shows%2520cross%2520species%2520potency%2520differences%26jtitle%3DSci.%2520Rep.%26date%3D2020%26volume%3D10%26spage%3D8974%26doi%3D10.1038%2Fs41598-020-65762-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span> <span> </span><span class="NLM_article-title">An efficient synthesis of Baricitinib</span>. <i>J. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.3184/174751916X14569294811333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.3184%2F174751916X14569294811333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVers77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2016&pages=205-208&author=J.+Xuauthor=J.+Caiauthor=J.+Chenauthor=X.+Zongauthor=X.+Wuauthor=M.+Jiauthor=P.+Wang&title=An+efficient+synthesis+of+Baricitinib&doi=10.3184%2F174751916X14569294811333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">An efficient synthesis of baricitinib</span></div><div class="casAuthors">Xu, Jiaojiao; Cai, Jin; Chen, Junding; Zong, Xi; Wu, Xuan; Ji, Min; Wang, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">205-208</span>CODEN:
                <span class="NLM_cas:coden">JCROA4</span>;
        ISSN:<span class="NLM_cas:issn">1747-5198</span>.
    
            (<span class="NLM_cas:orgname">Science Reviews 2000 Ltd.</span>)
        </div><div class="casAbstract">A highly efficient method for the synthesis of baricitinib was developed.  The starting material tert-Bu 3-oxoazetidine-1-carboxylate was converted to intermediate 2-(1-(ethylsulfonyl)azetidin-3-ylidene)acetonitrile via the Horner-Emmons reaction, deprotection of the N-Boc-group and a final sulfonamidation reaction.  Then the nucleophilic addn. reaction was carried out smoothly to afford the borate intermediate in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene under reflux.  Finally, the desired compd. baricitinib was obtained by the Suzuki coupling reaction of 4-chloro-7-H-pyrrolo[2,3-d]pyrimidine with the above borate intermediate.  All compds. were characterised by IR, MS, 1H NMR and 13C NMR.  The overall yield in this synthetic route was as high as 49%.  Moreover, this procedure was straightforward to carry out, had low cost and was suitable for industrial prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmrkAF79V4r7Vg90H21EOLACvtfcHk0lj-FYhnALIV6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVers77F&md5=1028a8f75d586f7c99e984d187128efb</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.3184%2F174751916X14569294811333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3184%252F174751916X14569294811333%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DZong%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DJi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DP.%26atitle%3DAn%2520efficient%2520synthesis%2520of%2520Baricitinib%26jtitle%3DJ.%2520Chem.%2520Res.%26date%3D2016%26volume%3D40%26spage%3D205%26epage%3D208%26doi%3D10.3184%2F174751916X14569294811333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taydakov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasnoselskiy, S. S.</span></span> <span> </span><span class="NLM_article-title">Direct electrophilic acylation of n-substituted pyrazoles by anhydrides of carboxylic acids</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">2188</span>– <span class="NLM_lpage">2192</span>, <span class="refDoi"> DOI: 10.1055/s-0033-1338923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1055%2Fs-0033-1338923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVOls7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=2188-2192&author=I.+V.+Taydakovauthor=S.+S.+Krasnoselskiy&title=Direct+electrophilic+acylation+of+n-substituted+pyrazoles+by+anhydrides+of+carboxylic+acids&doi=10.1055%2Fs-0033-1338923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Direct electrophilic acylation of N-substituted pyrazoles by anhydrides of carboxylic acids</span></div><div class="casAuthors">Taydakov, Ilya V.; Krasnoselskiy, Sergey S.</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2188-2192</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">A simple, convenient, and scalable approach to 1-substituted 4-acylpyrazoles through direct acylation of pyrazoles by anhydrides of aliph., arom., and fluorinated carboxylic acids in the presence of concd. H2SO4 as a catalyst is described.  Target ketones were obtained in 41-86% isolated yields in high purity without laborious purifn.  The scope and limitations of the method are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2gYpeAheGD7Vg90H21EOLACvtfcHk0ljnDDWAzz-g8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVOls7nK&md5=b4c14576c7d5a1aaf446f593cbe5a46f</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1055%2Fs-0033-1338923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0033-1338923%26sid%3Dliteratum%253Aachs%26aulast%3DTaydakov%26aufirst%3DI.%2BV.%26aulast%3DKrasnoselskiy%26aufirst%3DS.%2BS.%26atitle%3DDirect%2520electrophilic%2520acylation%2520of%2520n-substituted%2520pyrazoles%2520by%2520anhydrides%2520of%2520carboxylic%2520acids%26jtitle%3DSynthesis%26date%3D2013%26volume%3D45%26spage%3D2188%26epage%3D2192%26doi%3D10.1055%2Fs-0033-1338923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span> <span> </span><span class="NLM_article-title">Steric redirection of alkylation in 1H-pyrazole-3-carboxylate esters</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">405</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2017.12.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1016%2Fj.tetlet.2017.12.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVejtr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=402-405&author=S.+W.+Wrightauthor=E.+P.+Arnoldauthor=X.+Yang&title=Steric+redirection+of+alkylation+in+1H-pyrazole-3-carboxylate+esters&doi=10.1016%2Fj.tetlet.2017.12.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Steric redirection of alkylation in 1H-pyrazole-3-carboxylate esters</span></div><div class="casAuthors">Wright, Stephen W.; Arnold, Eric P.; Yang, Xiaojing</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">402-405</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The alkylation of Et 1H-pyrazole-3-carboxylates I [R1 = H, (CH3)3Si, (CH3CH2)3Si, ((CH3)3C)(H3C)2Si, (CH3)2CHSi, etc.; R2 = H] with a variety of alkylating agents in the presence of K2CO3 was found to largely favor the formation of Et 1-substituted pyrazole-3-carboxylates I [R2 = 2-{1-[(4-methoxyphenyl)methyl]-1H-pyrazol-3-yl}-2- oxoethyl, 2-(1-methyl-1H-pyrazol-5-yl)-2-oxoethyl, benzyl, etc.].  The alkylation could be sterically redirected by the use of a triphenylsilyl group, such as Et 3-(triphenylsilyl)-1H-pyrazole-5-carboxylate to provide synthetically useful yields of Et 1-substituted-3-(triphenylsilyl)-1H-pyrazole-5-carboxylates II [R2 = 2-{1-[(4-methoxyphenyl)methyl]-1H-pyrazol-3-yl}-2-oxoethyl, 2-(1-methyl-1H-pyrazol-5-yl)-2-oxoethyl, benzyl, etc.].  The triphenylsilyl group could be removed with Bu4NF.  Other triorganosilyl groups (TMS, TES, TBDMS) failed to provide significant redirection, while TIPS proved refractory to protodesilylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcWno53KkqR7Vg90H21EOLACvtfcHk0ljnDDWAzz-g8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVejtr%252FK&md5=9cdfe1b4f0b507543fb9d9b919aa77ad</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2017.12.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2017.12.052%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DS.%2BW.%26aulast%3DArnold%26aufirst%3DE.%2BP.%26aulast%3DYang%26aufirst%3DX.%26atitle%3DSteric%2520redirection%2520of%2520alkylation%2520in%25201H-pyrazole-3-carboxylate%2520esters%26jtitle%3DTetrahedron%2520Lett.%26date%3D2018%26volume%3D59%26spage%3D402%26epage%3D405%26doi%3D10.1016%2Fj.tetlet.2017.12.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aicart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavoungou-Gomès, L.</span></span> <span> </span><span class="NLM_article-title">Conversion des furfurylalkyl et arylcetones en derives de l’isocoumarine et de l’isoquinoleine</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">925</span>, <span class="refDoi"> DOI: 10.1002/jhet.5570220361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=10.1002%2Fjhet.5570220361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADyaL28Xht12ktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1985&pages=921-925&author=M.+Aicartauthor=L.+Mavoungou-Gom%C3%A8s&title=Conversion+des+furfurylalkyl+et+arylcetones+en+derives+de+l%E2%80%99isocoumarine+et+de+l%E2%80%99isoquinoleine&doi=10.1002%2Fjhet.5570220361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Conversion of furfuryl alkyl and aryl ketones into isocoumarin and isoquinoline derivatives</span></div><div class="casAuthors">Aicart, Michel; Mavoungou-Gomes, Louis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">921-5</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">0022-152X</span>.
    </div><div class="casAbstract">Cycloadducts I (R = Me, Ph), obtained by cycloaddn. of furfuryl ketones with Me acetylenedicarboxylate, undergo acid-catalyzed rearrangement in high yield to 6-hydroxyphthalates II.  II are useful intermediates for the synthesis of isocoumarins, e.g. III, and isoquinolines, e.g. IV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL_lt33iqz8rVg90H21EOLACvtfcHk0ljnDDWAzz-g8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xht12ktbc%253D&md5=ae0ab34b4c357c4d3ab319f05f40b2ae</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570220361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570220361%26sid%3Dliteratum%253Aachs%26aulast%3DAicart%26aufirst%3DM.%26aulast%3DMavoungou-Gom%25C3%25A8s%26aufirst%3DL.%26atitle%3DConversion%2520des%2520furfurylalkyl%2520et%2520arylcetones%2520en%2520derives%2520de%2520l%25E2%2580%2599isocoumarine%2520et%2520de%2520l%25E2%2580%2599isoquinoleine%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1985%26volume%3D22%26spage%3D921%26epage%3D925%26doi%3D10.1002%2Fjhet.5570220361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rathke, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, M.</span></span> <span> </span><span class="NLM_article-title">The Horner-Wadsworth-Emmons modification of the Wittig reaction using triethylamine and lithium or magnesium salts</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2624</span>– <span class="NLM_lpage">2626</span>, <span class="refDoi"> DOI: 10.1021/jo00215a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00215a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;key=1%3ACAS%3A528%3ADyaL2MXksFelurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1985&pages=2624-2626&author=M.+W.+Rathkeauthor=M.+Nowak&title=The+Horner-Wadsworth-Emmons+modification+of+the+Wittig+reaction+using+triethylamine+and+lithium+or+magnesium+salts&doi=10.1021%2Fjo00215a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The Horner-Wadsworth-Emmons modification of the Wittig reaction using triethylamine and lithium or magnesium salts</span></div><div class="casAuthors">Rathke, Michael W.; Nowak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2624-6</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">Aldehydes were converted into the corresponding α,β-unsatd. esters using (EtO)2P(O)CH2CO2Et and Et3N in the presence of Li or Mg halides.  Under the same conditions, simple Me ketones were unreactive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSmdCP8rY7FbVg90H21EOLACvtfcHk0liKFQutbwndZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXksFelurg%253D&md5=4ddfc256c1b9eb0ab64f40063414870f</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjo00215a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00215a004%26sid%3Dliteratum%253Aachs%26aulast%3DRathke%26aufirst%3DM.%2BW.%26aulast%3DNowak%26aufirst%3DM.%26atitle%3DThe%2520Horner-Wadsworth-Emmons%2520modification%2520of%2520the%2520Wittig%2520reaction%2520using%2520triethylamine%2520and%2520lithium%2520or%2520magnesium%2520salts%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1985%26volume%3D50%26spage%3D2624%26epage%3D2626%26doi%3D10.1021%2Fjo00215a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="note"><p class="first last">For <b>23</b> and <b>24</b>, Suzuki–Miyaura coupling was performed with <i>tert</i>-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole-1-carboxylate. For <b>25</b> and <b>26</b>, Suzuki–Miyaura coupling was performed with 1-(tetrahydropyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole. For <b>27</b> and <b>28</b>, Suzuki–Miyaura coupling was performed with 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBM','PDB','6DBM'); return false;">PDB: 6DBM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6X8F" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6X8F','PDB','6X8F'); return false;">PDB: 6X8F</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6X8E" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6X8E','PDB','6X8E'); return false;">PDB: 6X8E</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6X8G" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6X8G','PDB','6X8G'); return false;">PDB: 6X8G</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i30"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00948">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_71474"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00948?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00948</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00948/suppl_file/jm0c00948_si_001.csv">CSV</a>)</p></li><li><p class="inline">Synthesis of <b>8</b>–<b>10</b>, <b>17</b>–<b>20</b>, and <b>23</b>–<b>28</b>; (2) kinase profiling for compound <b>22</b> at 1 μM; (3) X-ray crystallography methods; (4) <sup>1</sup>H and <sup>13</sup>C NMR spectra and HPLC traces of compounds <b>8</b>–<b>28</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00948/suppl_file/jm0c00948_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00948/suppl_file/jm0c00948_si_001.csv">jm0c00948_si_001.csv (1.91 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00948/suppl_file/jm0c00948_si_002.pdf">jm0c00948_si_002.pdf (4.03 MB)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for the X-ray structure of compound <b>11</b> in TYK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6X8F">6X8F</a>) and JAK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6X8E">6X8E</a>) and compound <b>22</b> in TYK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6X8G">6X8G</a>) are available from the RCSB Protein Data Bank (<a href="http://www.rcsb.org" class="extLink">www.rcsb.org</a>).</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00948%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-22" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00948" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797bd2cde52428","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
